



(86) Date de dépôt PCT/PCT Filing Date: 2005/07/27

(87) Date publication PCT/PCT Publication Date: 2006/02/02

(85) Entrée phase nationale/National Entry: 2007/01/26

(86) N° demande PCT/PCT Application No.: JP 2005/014136

(87) N° publication PCT/PCT Publication No.: 2006/011631

(30) Priorité/Priority: 2004/07/27 (AU2004904196)

(51) Cl.Int./Int.Cl. *C07D 277/46* (2006.01),
A61K 31/426 (2006.01)





(71) Demandeur/Applicant:
ASTELLAS PHARMA INC., JP

(72) Inventeurs/Inventors:
INOUE, TAKAYUKI, JP;
TOJO, TAKASHI, JP;
MORITA, MASATAKA, JP

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : DERIVES DE THIAZOLE PRESENTANT UNE ACTIVITE D'INHIBITION DE LA VAP-1

(54) Title: THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY



(57) Abrégé/Abstract:

A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 February 2006 (02.02.2006)

PCT

(10) International Publication Number
WO 2006/011631 A3

(51) International Patent Classification:

C07D 277/46 (2006.01) A61K 31/426 (2006.01)

(21) International Application Number:

PCT/JP2005/014136

(22) International Filing Date: 27 July 2005 (27.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2004904196 27 July 2004 (27.07.2004) AU

(71) Applicant (for all designated States except US): **ASTELLAS PHARMA INC.** [JP/JP]; 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 1038411 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **INOUE, Takayuki** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411 (JP). **TOJO, Takashi** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411 (JP). **MORITA, Masataka** [JP/JP]; c/o Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411 (JP).(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Odaka Midotsuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0044 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.





(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY



(57) Abstract: A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

WO 2006/011631 A3

WO 2006/011631 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

20 April 2006

DESCRIPTION**THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY****TECHNICAL FIELD**

The present invention relates to a compound or a
5 pharmaceutically acceptable salt thereof useful as a vascular
adhesion protein-1 inhibitor, a pharmaceutical composition
comprising the compound or salt thereof as an active
ingredient, a method for preventing or treating a vascular
adhesion protein-1 associated disease, especially macular
10 edema, use of the compound, salt thereof or composition, and
the like.

BACKGROUND ART

Vascular adhesion protein-1 (hereinafter to be
abbreviated as VAP-1) is an amine oxidase (semicarbazide
15 sensitive amine oxidase, SSAO) which is abundant in human
plasma, and shows remarkably increased expression in
vascular endothelium and vascular smooth muscle of the
inflammatory region. While the physiological role of VAP-1
has not been clarified until recently, VAP-1 gene was cloned
20 in 1998, and VAP-1 has been reported to be a membrane
protein that regulates rolling and migration of lymphocyte
and NK cell as an adhesion molecule under regulation of
expression by inflammatory cytokine. Although the amine to
be a substrate is unknown, it is considered to be
25 methylamine generated in any part of living organisms. It is
also known that hydrogen peroxide and aldehydes produced due
to the amine oxidase activity in the molecule are important
factors of adhesion activity.

A recent report has documented that VAP-1 enzyme
30 activity in plasma increases in diabetic patients, whether
type I or type II, and the increase is particularly
remarkable in diabetic patients suffering from retinopathy
complications (Diabetologia, 42 (1999) 233-237 and Diabetic

Medicine, 16 (1999) 514-521).

In addition, it has been reported that VAP-1 is associated with the following diseases:

- (1) cirrhosis, essential stabilized hypertension, diabetes, arthrosis (see JP-A-61-239891 and USP 4,888,283);
- (2) endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients) (see WO 93/23023);
- (3) an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjögren's syndrome, Behçet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis); a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphthous stomatitis]; a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke); a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease); a (chronic) skin inflammatory disease or condition (psoriasis, allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris); a disease related to carbohydrate metabolism (diabetes and complications from diabetes)

including microvascular and macrovascular disease
(atherosclerosis, vascular retinopathies, retinopathy,
nephropathy, nephrotic syndrome and neuropathy (polyneuropathy,
mononeuropathies and autonomic neuropathy), foot ulcers, joint
5 problems, and increased risk of infection); a disease related
to aberrations in adipocyte differentiation or function or
smooth muscle cell function (atherosclerosis and obesity); a
vascular disease [atheromatous atherosclerosis,
nonatheromatous atherosclerosis, ischemic heart disease
10 including myocardial infarction and peripheral arterial
occlusion, Raynaud's disease and phenomenon, and
thromboangiitis obliterans (Buerger's disease)]; chronic
arthritis; inflammatory bowel diseases; skin dermatoses (see
WO 02/02090, WO 02/02541 and US patent application publication
15 No. 2002/0173521 A1);
(4) diabetes mellitus (see WO 02/38152);
(5) SSAO-mediated complication [diabetes (insulin dependent
diabetes mellitus (IDDM) and non-insulin dependent diabetes
mellitus (NIDDM)) and vascular complication (heart attack,
20 angina, strokes, amputations, blindness and renal failure)]
(see WO 02/38153);
(6) hepatitis, transplantation, and the like.

Under the present circumstances, a drug treatment or
prophylaxis of the above diseases has been demanded.

25 In addition, macular edema is a common ocular
abnormality resulting from a vast etiology and characterized
by perturbation of the integrity of the blood-retinal
barrier of the perifoveal capillaries and the optic nerve
head. Macular edema is known to include diabetic and non-
30 diabetic macular edema. Macular edema as a diabetic
complication is a disease state that can occur in any stage
of diabetic retinopathy, emerges before the onset of
neovascularization and causes serious visual disorders.


Macular area is a highly evolved part in retina and plays a key role in controlling the eyesight. Once the macular area suffers from edema, how mild the change may be, it causes a significant failure of eyesight, and when left unattended, the edema causes irreversible changes of macular tissue, and it is considered to encourage progress of retinopathy.

At present, for macular edema, laser beam photocoagulation and vitreous surgery have been tried as a symptomatic therapy. However, irradiation of laser on the macular area is not easy and unnecessary laser treatments may produce side effects (e.g., possible encouragement of edema by causing inflammation). The vitreous surgery is considered to provide efficacy in 70 percent of macular edema, but physical and economical burden on patients is high, and the incidence of recurrence is also high. These treatment methods are not usually employed in the initial stage of macular edema, particularly so in the stages when the decrease of vision is comparatively small. Accordingly, a drug treatment comparatively easily applicable from the early stages of the disease has been also demanded under the present circumstances.

DISCLOSURE OF INVENTION

The present inventors have intensively worked on the problem of the drug treatment of a VAP-1 associated disease and found that a VAP-1 inhibitor is useful for the prophylaxis or treatment of the disease, particularly macular edema, and completed the present invention. Thus, the present invention provides the following.

[1] A compound of the formula (I), (II), (III) or (IV) [hereinafter sometimes referred to as Compound (I), (II), (III) or (IV), or VAP-1 inhibitor]:



wherein

R¹ is alkylcarbonyl;

X₁ is a bond or lower alkylene;

5 Y₁ is a bond, lower alkylene, -CH₂-CO-, -CH₂-CH₂-CO-,
-CH₂-CH₂-CO-CH₂- or -NH-CH₂-CH₂-; and


Z₁ is -NH₂, -NH(lower alkyl) or lower alkyl;

provided that

when X₁ is ethylene, then Y₁ should be C₂-C₆ alkylene,
10 -CH₂-CO-, -CH₂-CH₂-CO-, -CH₂-CH₂-CO-CH₂- or -NH-CH₂-CH₂-,


when X₁ is a bond, then Y₁ should be a bond, methylene,
C₃-C₆ alkylene, -CH₂-CO-, -CH₂-CH₂-CO-, -CH₂-CH₂-CO-CH₂- or
-NH-CH₂-CH₂-, and

when R¹ is acetyl, X₁ is ethylene, Y₁ is ethylene and Z₁ is
15 -NH₂, then Y₁ should be attached to *ortho* or *meta* position of
the phenyl group;




wherein


20 R¹ is alkylcarbonyl;



wherein R^a is (lower alkyl)sulfonyl, aminosulfonyl or
di(lower alkyl)aminosulfonyl,



25 wherein R^b is mono- or di-(lower alkyl)amino,



wherein R^c is lower alkyl and R^d is (lower alkyl)sulfonyl, di(lower alkyl)aminocarbonyl, alkylcarbonyl or nitro, or $-\text{CH}=\text{CH}-\text{CO}-\text{di}(\text{lower alkyl})\text{amino}$;


5 X_2 is a bond or lower alkylene;

Y_2 is a bond, lower alkylene, $-\text{CH}_2-\text{CO}-$ or $-\text{NH}-\text{CO}-\text{CH}_2-$; and

Z_2 is $-\text{NH}_2$;



provided that

when R^1 is acetyl, X_2 is ethylene, Y_2 is a bond and Z_2 is $-\text{NH}_2$, then R^2 should not be 3-(methanesulfonyl)benzyl, 4-(methanesulfonyl)benzyl, 4-(ethanesulfonyl)benzyl and 2-(dimethylaminocarbonyl)pyrrolidin-1-ylmethyl;



15 wherein


R^1 is alkylcarbonyl;

R^3 is  or  ;

X_3 is lower alkylene; and

Y_3 is lower alkylene;

20



wherein

R^1 is alkylcarbonyl; and

X_4 is lower alkylene;

25 or a pharmaceutically acceptable salt thereof.

[2] The compound of [1], wherein R^1 is acetyl, or a

pharmaceutically acceptable salt thereof.

[3] The compound of [1], wherein Z₁ is -NH₂, or a pharmaceutically acceptable salt thereof.

[4] The compound of [1], wherein the compound is

- 5 N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-thiazol-2-yl}acetamide,
2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-
10 [amino(imino)methyl]acetamide,
(3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide,
(3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
15 phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide,
N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-(methylsulfonyl)benzamide, or
20 N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-nitrobenzamide,
or a pharmaceutically acceptable salt thereof.

[5] The compound of [1] or a pharmaceutically acceptable salt
25 thereof for use as a medicament.

[6] A pharmaceutical composition, which comprises, as an active ingredient, the compound of [1] or a pharmaceutically acceptable salt thereof.

[7] A use of the compound of [1] or a pharmaceutically
30 acceptable salt thereof for preparing a medicament as a VAP-1 inhibitor.

[8] The use of [7], wherein the compound is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-

(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,
 N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-
 thiazol-2-yl}acetamide,
 2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-
 5 [amino(imino)methyl]acetamide,
 (3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 phenyl)ethyl]-1,3-thiazol-5-yl)methyl}-N,N-dimethyl-3-
 pyrrolidinecarboxamide,
 (3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 10 phenyl)ethyl]-1,3-thiazol-5-yl)methyl}-N,N-dimethyl-3-
 pyrrolidinecarboxamide,
 N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 phenyl)ethyl]-1,3-thiazol-5-yl)methyl}-N-methyl-4-
 (methylsulfonyl)benzamide, or
 15 N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 phenyl)ethyl]-1,3-thiazol-5-yl)methyl}-N-methyl-4-
 nitrobenzamide.

[9] A use of the compound of [1] or a pharmaceutically
 acceptable salt thereof for preparing a medicament for the
 20 prophylaxis or treatment of a VAP-1 associated disease.

[10] The use of [9], wherein said VAP-1 associated disease is
 selected from the group consisting of cirrhosis, essential
 stabilized hypertension, diabetes, arthrosis, endothelium
 damage (in diabetes, atherosclerosis and hypertension), a
 25 cardiovascular disorder associated with diabetes and uremia,
 pain associated with gout and arthritis, retinopathy (in
 diabetes patients), an (connective tissue) inflammatory
 disease or condition (rheumatoid arthritis, ankylosing
 spondylitis, psoriatic arthritis and osteoarthritis or
 30 degenerative joint disease, Reiter's syndrome, Sjögren's
 syndrome, Behçet's syndrome, relapsing polychondritis,
 systemic lupus erythematosus, discoid lupus erythematosus,
 systemic sclerosis, eosinophilic fasciitis, polymyositis,

dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis), a gastrointestinal inflammatory disease or
5 condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphthous stomatitis], a central nervous system inflammatory disease or condition (multiple sclerosis,
10 Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke), a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis,
15 allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris), a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies,
20 retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis
25 and obesity), a vascular disease [atheromatous atherosclerosis, nonatheromatous atherosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic
30 arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM)) and vascular complication

(heart attack, angina, strokes, amputations, blindness and renal failure)], macular edema (diabetic and non-diabetic macular edema), hepatitis and transplantation.

[11] The use of [10], wherein said VAP-1 associated disease is
5 macular edema.

[12] The use of [11], wherein said macular edema is diabetic macular edema.

[13] The use of [11], wherein said macular edema is non-diabetic macular edema.

10 [14] A VAP-1 inhibitor, which comprises the compound of [1] or a pharmaceutically acceptable salt thereof.

[15] A method for preventing or treating macular edema, which method comprises administering to a subject in need thereof a VAP-1 inhibitor in an amount sufficient to treat said subject
15 for macular edema.

[16] The method of [15], wherein the VAP-1 inhibitor is
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-
20 thiazol-2-yl}acetamide,
2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-[amino(imino)methyl]acetamide,
(3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-
25 pyrrolidinecarboxamide,
(3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide,
N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-
30 (methylsulfonyl)benzamide, or
N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-

nitrobenzamide,

or a pharmaceutically acceptable salt thereof.

[17] A method for preventing or treating a VAP-1 associated disease, which method comprises administering an effective
5 amount of the compound of [1] or a pharmaceutically acceptable salt thereof to a mammal.

[18] The method of [17], wherein said VAP-1 associated disease is selected from the group consisting of cirrhosis, essential
10 stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in
diabetes patients), an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing
15 spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjögren's syndrome, Behçet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis,
20 dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis), a gastrointestinal inflammatory disease or condition [Crohn's disease,
25 ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphthous stomatitis], a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and
30 ischemia-reperfusion injury associated with ischemic stroke), a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease), a (chronic) skin

inflammatory disease or condition (psoriasis, allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris), a disease related to carbohydrate metabolism

5 (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and

10 increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity), a vascular disease [atheromatous atherosclerosis, nonatheromatous atherosclerosis, ischemic heart disease

15 including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes

20 (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM)) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)], macular edema (diabetic and non-diabetic macular edema), hepatitis and transplantation.

25 [19] The method of [18], wherein said VAP-1 associated disease is macular edema.

[20] The method of [19], wherein said macular edema is diabetic macular edema.

[21] The method of [19], wherein said macular edema is non-

30 diabetic macular edema.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated on the discovery

that an inhibitor for vascular adhesion protein-1 (VAP-1; also referred to as semicarbazide sensitive amine oxidase (SSAO) or copper-containing amine oxidase) is effective in treating or ameliorating VAP-1 associated diseases,
5 especially macular edema, and the like. Accordingly, the present invention provides Compounds (I), (II), (III) and (IV) and a pharmaceutically acceptable salt thereof useful as a VAP-1 inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, and
10 the like.

In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions to be included within the scope of the invention are explained in detail as follows.

15 Suitable "halogen" includes fluorine, chlorine, bromine and iodine.

The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.

20 Suitable "lower alkyl" includes straight or branched alkyl having 1 to 6 carbon atom(s) (i.e., C₁-C₆ alkyl), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C₁-C₄ alkyl.

25 Suitable "lower alkylene" includes straight or branched alkylene having 1 to 6 carbon atom(s) (i.e., C₁-C₆ alkylene), such as methylene, ethylene, trimethylene, tetramethylene, propylene, ethylidene and propylidene, in which more preferred one is C₁-C₄ alkylene, still more preferred one is
30 C₂-C₄ alkylene.

Suitable "alkylcarbonyl" includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is C₁-C₆ alkyl of the above "lower alkyl"], such as

acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl, in which more preferred one is C₁-C₄ alkyl-carbonyl.

Suitable "-NH(lower alkyl)" includes an amino group
5 substituted with the "lower alkyl" defined above (i.e., C₁-C₆ alkyl amino), such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, tert-pentylamino, hexylamino and the like.

10 Suitable "mono- or di-(lower alkyl)amino" includes an amino group substituted with 1 or 2 of the "lower alkyl" defined above (i.e., mono- or di-(C₁-C₆ alkyl)amino), such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino,
15 pentylamino, tert-pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di(sec-butyl)amino, di(tert-butyl)amino, dipentylamino, di(tert-pentyl)amino, dihexylamino and the like. The lower alkyls may be same or different.

20 Suitable "(lower alkyl)sulfonyl" includes a sulfonyl group having the "lower alkyl" defined above (i.e., (C₁-C₆ alkyl)sulfonyl), such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl,
25 pentylsulfonyl, tert-pentylsulfonyl, hexylsulfonyl and the like.

Suitable "di(lower alkyl)aminosulfonyl" includes a sulfonyl group having the "di(lower alkyl)amino" defined above (i.e., di(C₁-C₆ alkyl)aminosulfonyl), such as
30 dimethylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, diisopropylaminosulfonyl, dibutylaminosulfonyl, diisobutylaminosulfonyl, di(sec-butyl)aminosulfonyl, di(tert-butyl)aminosulfonyl,

dipentylaminosulfonyl, di(tert-pentyl)aminosulfonyl, dihexylaminosulfonyl and the like. The lower alkyls may be same or different.

Suitable "di(lower alkyl)aminocarbonyl" includes a
 5 carbonyl group having the "di(lower alkyl)amino" defined above (i.e., di(C₁-C₆ alkyl)aminocarbonyl), such as dimethylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, diisopropylaminocarbonyl, dibutylaminocarbonyl, diisobutylaminocarbonyl, di(sec-
 10 butyl)aminocarbonyl, di(tert-butyl)aminocarbonyl, dipentylaminocarbonyl, di(tert-pentyl)aminocarbonyl, dihexylaminocarbonyl and the like. The lower alkyls may be same or different.

Suitable "-CH=CH-CO-di(lower alkyl)amino" includes a
 15 carbonylvinyl group having the "di(lower alkyl)amino" defined above (i.e., -CH=CH-CO-di(C₁-C₆ alkyl)amino), such as (E) or (Z) dimethylaminocarbonylvinyl, diethylaminocarbonylvinyl, dipropylaminocarbonylvinyl, diisopropylaminocarbonylvinyl, dibutylaminocarbonylvinyl,
 20 diisobutylaminocarbonylvinyl, di(sec-butyl)aminocarbonylvinyl, di(tert-butyl)aminocarbonylvinyl, dipentylaminocarbonylvinyl, di(tert-pentyl)aminocarbonylvinyl, dihexylaminocarbonylvinyl and the like. The lower alkyls may be same or different.

25 In Compound (I), X₁ may be attached to 4- or 5-position of the thiazolyl group.

In Compound (I), Y₁ may be attached to *ortho*, *meta* or *para* position of the phenyl group.

In Compound (I), when X₁ is ethylene, then Y₁ should be
 30 C₂-C₆ alkylene, -CH₂-CO-, -CH₂-CH₂-CO-, -CH₂-CH₂-CO-CH₂- or -NH-CH₂-CH₂-, when X₁ is a bond, then Y₁ should be a bond, methylene, C₃-C₆ alkylene, -CH₂-CO-, -CH₂-CH₂-CO-, -CH₂-CH₂-CO-CH₂- or -NH-CH₂-CH₂-, and when R¹ is acetyl, X₁ is

ethylene, Y_1 is ethylene and Z_1 is $-NH_2$, then Y_1 should be attached to *ortho* or *meta* position of the phenyl group.

In Compound (II), Y_2 may be attached to *ortho*, *meta* or *para* position of the phenyl group.

5 The substitution site of R^a on the phenyl is not particularly limited.

The substitution site of $-COR^b$ on the pyrrolidinyl is not particularly limited.

The substitution site of R^d on the phenyl is not
10 particularly limited.

In Compound (II), when R^1 is acetyl, X_2 is ethylene, Y_2 is a bond and Z_2 is $-NH_2$, then R^2 should not be 3-(methanesulfonyl)benzyl, 4-(methanesulfonyl)benzyl, 4-(ethanesulfonyl)benzyl and 2-(dimethylaminocarbonyl)-
15 pyrrolidin-1-ylmethyl.

In Compound (III), X_3 may be attached to 4- or 5-position of the thiazolyl group.

In Compound (III), Y_3 may be attached to *ortho*, *meta* or *para* position of the phenyl group.

20 In Compound (IV), X_4 may be attached to 4- or 5-position of the thiazolyl group.

Any nitrogen atom in the amino (i.e. $-NH_2$), imino (i.e. $=NH$ or $-NH-$) or the like in Compound (I), (II), (III) or (IV) may be protected according to the methods, which are
25 known to those skilled in the art, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.

When Compound (I), (II), (III) or (IV) has an asymmetric carbon atom in the structure, those skilled in
30 the art will recognize that Compound (I), (II), (III) or (IV) includes all stereoisomers.

When Compound (I), (II), (III) or (IV) has a double bond (i.e., $>C=C<$) in the structure, those skilled in the

art will recognize that Compound (I), (II), (III) or (IV) includes E or Z isomer and mixture thereof.

The "vascular adhesion protein-1 (VAP-1) associated disease" comprise a disease selected from the group
5 consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uremia, pain associated with gout and arthritis, retinopathy (in diabetes patients), an
10 (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjögren's syndrome, Behçet's syndrome, relapsing polychondritis, systemic lupus erythematosus,
15 discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid
20 arthritis), a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphtous stomatitis], a central nervous system
25 inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke), a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease), a
30 (chronic) skin inflammatory disease or condition (psoriasis, allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris), a disease related to carbohydrate metabolism

(diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity), a vascular disease [atheromatous atherosclerosis, nonatheromatous atherosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM)) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)], macular edema (e.g., diabetic and non-diabetic macular edema), hepatitis, transplantation and the like.

The "preventing or treating a vascular adhesion protein-1 (VAP-1) associated disease" and "prophylaxis or treatment of a vascular adhesion protein-1 (VAP-1) associated disease", particularly "preventing or treating macular edema" and "prophylaxis or treatment of macular edema" are intended to include administration of a compound having VAP-1 inhibitory activity (i.e. VAP-1 inhibitor) to a subject for therapeutic purposes, which may include prophylaxis, amelioration, prevention and cure of the above described VAP-1 associated disease, particularly macular edema. As used herein, by the "subject" is meant a target of the administration of VAP-1 inhibitor in the present

invention, which is specifically various animals such as mammal, e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.

The therapeutic method comprises administration of a
5 VAP-1 inhibitor in an amount sufficient to treat the VAP-1 associated disease, especially macular edema. Any VAP-1 inhibitor can be used in the method of the present invention as long as it is safe and effective. Herein, the "VAP-1 inhibitor" will be used to refer to such
10 compounds/medicaments, which include Compound (I), (II), (III) or (IV), and is intended to encompass all compounds that inhibit enzyme activity of VAP-1 at any and all points in the action mechanism thereof.

For example, the VAP-1 inhibitor used in the present
15 invention may further include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1,3,4-oxadiazine derivatives, 4-alkyl-5-alkoxycarbonyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine derivatives, 2,6-diethoxybenzylamine, 2,6-di(n-
20 propoxy)benzylamine, 2,6-diisopropoxybenzylamine, 2,6-di(n-butoxy)benzylamine, 2,6-bis(methoxymethoxy)benzylamine, 2,6-bis(methoxymethyl)benzylamine, 2,6-diethylbenzylamine, 2,6-di-n-propylbenzylamine, 2,6-bis(2-hydroxyethoxy)benzylamine, and the like.

25 The above compounds can be exemplified as follows.

- 1) fluoroallylamine derivatives, semicarbazide derivatives and hydrazide derivatives described in WO 93/23023,
- 2) hydrazino derivatives described in WO 02/02090,
- 3) 1,3,4-oxadiazine derivatives described in WO 02/02541,
- 30 4) 4-alkyl-5-alkoxycarbonyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine derivatives described in WO 02/38153,
- 5) 2,6-diethoxybenzylamine, 2,6-di(n-propoxy)benzylamine, 2,6-diisopropoxybenzylamine, 2,6-di(n-butoxy)benzylamine, 2,6-

bis(methoxymethoxy)benzylamine, 2,6-bis(methoxymethyl)benzylamine, 2,6-diethylbenzylamine, 2,6-di-n-propylbenzylamine and 2,6-bis(2-hydroxyethoxy)benzylamine described in USP 4,888,283.

5 The compounds exemplified in the description of the present invention, in WO 93/23023 as an SSAO inhibitor, such as those described by Lyles et al. (Biochem. Pharmacol. 36:2847, 1987), and in USP 4,650,907, USP 4,916,151, USP 4,943,593, USP 4,965,288, USP 5,021,456, USP 5,059,714, USP 10 4,699,928, European patent application No. 295604, European patent application No. 224924 and European patent application No. 168013, are also encompassed in the VAP-1 inhibitor.

Of the above-mentioned compounds, preferred are 15 Compound (I), (II), (III) and (IV), more preferably, N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (Production Example 3), N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3- 20 thiazol-2-yl}acetamide (Production Example 7), 2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-[amino(imino)methyl]acetamide (Production Example 9), (3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3- 25 pyrrolidinecarboxamide (Production Example 12), (3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide (Production Example 14), N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}- 30 phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-(methylsulfonyl)benzamide (Production Example 16), and N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-

nitrobenzamide (Production Example 19), and derivatives thereof.

The term "derivative" is intended to include all compounds derived from the original compound.

5 In the present invention, the VAP-1 inhibitor can be administered as a prodrug to a subject. The term "prodrug" is intended to include all compounds that convert to the VAP-1 inhibitor in the body of the administration subject. The prodrug can be any pharmaceutically acceptable prodrug
10 of VAP-1 inhibitor.

Moreover, the VAP-1 inhibitor can be administered to the administration subject as a pharmaceutically acceptable salt.

The pharmaceutically acceptable salt of the VAP-1
15 inhibitor is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like), alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like),
20 ammonium salt, and amine salt (e.g., triethylamine salt, N-benzyl-N-methylamine salt and the like).

In addition, the pharmaceutically acceptable salt of the VAP-1 inhibitor includes a pharmaceutically acceptable acid addition salt. Examples of the pharmaceutically acceptable
25 acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids,
30 for example, p-toluenesulfonic acid.

As a pharmaceutically acceptable salt of the VAP-1 inhibitor represented by the formula (I), (II), (III) or (IV), a pharmaceutically acceptable acid addition salt such as

hydrochloride and hydriodide, particularly (mono-, di- or tri-)hydrochloride, is preferable.

Some VAP-1 inhibitors except Compound (I), (II), (III) and (IV) may be commercially available or can be produced
5 based on known references.

Also, Compounds (I), (II), (III) and (IV) can be synthesized according to the following Production Method, Reference Example, Production Examples, the analogous methods thereto and the organic synthetic methods known to
10 the art.

The VAP-1 inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method via any suitable route. Suitable routes of administration include systemic, such as orally or
15 by injection, topical, periocular (e.g., subTenon's), subconjunctival, intraocular, subretinal, suprachoroidal and retrobulbar administrations. The manner in which the VAP-1 inhibitor is administered is dependent, in part, upon whether the treatment of a VAP-1 associated disease is
20 prophylactic or therapeutic.

The VAP-1 inhibitor is preferably administered as soon as possible after it has been determined that a subject such as mammal, specifically a human, is at risk for a VAP-1 associated disease (prophylactic treatments) or has begun to
25 develop a VAP-1 associated disease (therapeutic treatments). Treatment will depend, in part, upon the particular VAP-1 inhibitor to be used, the amount of the VAP-1 inhibitor to be administered, the route of administration, and the cause and extent, if any, of a VAP-1 associated disease realized.

30 One skilled in the art will appreciate that suitable methods of administering a VAP-1 inhibitor, which is useful in the present inventive method, are available. Although more than one route can be used to administer a particular

VAP-1 inhibitor, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are merely exemplary and are in no way limiting.

5 The dose of the VAP-1 inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention, should be sufficient to effect the desired response in the subject over a reasonable time frame. One
10 skilled in the art will recognize that dosage will depend upon a variety of factors, including the strength of the particular VAP-1 inhibitor to be employed; the age, species, conditions or disease states, and body weight of the subject; and the degree of a VAP-1 associated disease. The
15 size of the dose also will be determined depending on the route, timing and frequency of administration; the existence, nature and extent of any adverse side effects that might accompany the administration of a particular VAP-1 inhibitor; and the desired physiological effect. It will
20 be appreciated by one of ordinary skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.

Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of
25 ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.

30 Generally, the VAP-1 inhibitor can be administered in the dose of from about 1 μ g/kg/day to about 300 mg/kg/day, preferably from about 0.1 mg/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in

a sustained manner.

Pharmaceutical compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-1 inhibitor
5 sufficient to treat a VAP-1 associated disease, especially macular edema, prophylactically or therapeutically as an active ingredient. The carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as the solubility and lack of the
10 reactivity of the compound, and by the route of administration.

The VAP-1 inhibitor can be administered in various manners to achieve the desired VAP-1 inhibitory effect. The VAP-1 inhibitor can be administered alone or in combination
15 with pharmaceutically acceptable carriers or diluents, the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice. The VAP-1 inhibitor may be
20 administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions. The inhibitor may also be injected parenterally in the form of sterile solutions or suspensions. Solid oral forms may contain conventional excipients, for instance,
25 lactose, sucrose, magnesium stearate, resins, and similar materials. Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing or suspending agents. Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may
30 contain certain various preserving, stabilizing, buffering, solubilizing or suspending agents. If desired, additives, such as saline or glucose, may be added to make the solutions isotonic.

The present inventive method also can involve the co-administration of other pharmaceutically active compound(s). By "co-administration" is meant administration of the other pharmaceutically active compound(s) before, concurrently
5 with, e.g., in combination with a VAP-1 inhibitor in the same formulation or in separate formulations, or after administration of the VAP-1 inhibitor as described above. For example, corticosteroids, prednisone, methylprednisolone, dexamethasone or triamcinolone
10 acetinide, or noncorticosteroid anti-inflammatory compounds, such as ibuprofen or flubiprofen, can be co-administered. Similarly, vitamins and minerals (e.g., zinc), anti-oxidants (e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein)), and micronutrients can be co-
15 administered.

In addition, the VAP-1 inhibitor according to the present invention is useful for preparing a medicament such as a therapeutic or prophylactic agent for the VAP-1 associated diseases.

20


Compounds (I), (II), (III) and (IV) can be synthesized according to the Production Method given below.

Production Method

25 Compounds (I), (II), (III) and (IV) are prepared in accordance with, but is not limited to, the following procedures. Those skilled in the art will recognize that these procedures can be modified according to the conventional methods known *per se*.

30

Procedure A: Synthesis of Compounds (I) to (IV)




wherein

R^1 and R^2 are as defined above;

L_1 is a leaving group such as halogen (e.g., chlorine, bromine, iodine);

T is alkylcarbonyloxy(lower alkyl) wherein the alkylcarbonyl and the lower alkyl are defined above (e.g., acetyloxymethyl),



wherein R^3 , X_1 , X_2 , X_3 , X_4 , Y_1 , Y_2 , Y_3 , Z_1 and Z_2 are as defined above; and

L_2 is a leaving group such as $-\text{OH}$, halogen (e.g., chlorine, bromine, iodine), $-\text{O}$ -alkylcarbonyl wherein the alkylcarbonyl is as defined above (e.g., $-\text{O}$ -acetyl and the like).

Formation of Thiazole Moiety

Compound (1) is reacted with Compound (2) or its salt to give Compound (3).

Suitable salt of Compound (2) may be the same as those

exemplified for Compound (I), (II), (III) or (IV).

Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known *per se*.

5 The reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.

10 The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.

Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration *in vacuo*, solvent extraction, crystallization, recrystallization, phase transfer,
15 chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV).

Acylation

20 Compound (3) or its salt is reacted with Compound (4) to give Compound (5). Since R^1 is an alkylcarbonyl group, this reaction is an acylation.

The conventional acylation methods may be employed in the present invention.

25 Compound (4) may be commercially available or can be prepared in accordance with the methods known *per se*.

The reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the
30 reaction, or a mixture thereof.

The reaction is also preferably carried out in the presence of a conventional base such as 4-dimethylamino-pyridine, pyridine etc. A liquid base can be also used as

the solvent.


The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.

Compound (5) thus obtained can be isolated or purified
 5 by known separation or purification means, such as concentration, concentration *in vacuo*, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt
 10 same as those exemplified for Compound (I), (II), (III) or (IV).

The acylation may be applied to Compound (1) in advance.

The nitrogen atom(s) in Compound (1), (2), (3) or (5) may be protected or deprotected, as necessary, in accordance
 15 with methods known *per se* such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980), and the like.

Procedure B: Synthesis of Compounds (I) to (IV) wherein X₁,
 20 X₂, X₃ and X₄ are lower alkylene such as ethylene (i.e. -CH₂-CH₂-), for example,




wherein

25 R¹ and R² are as defined above;

L₃ is a leaving group such as halogen (e.g., chlorine, bromine,

iodine) and/or halogenotriphenylphosphinyl (e.g., BrPh₃P-);
and

U is carboxy(lower alkyl)phenyl (e.g., carboxymethylphenyl),



5 wherein R³, Y₁, Y₂, Y₃, Z₁ and Z₂ are as defined above.

Formation of Olefin Compound

Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8).

10 Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I), (II), (III) or (IV).

Compounds (6) and (7) or salts thereof may be commercially available or can be prepared in accordance with the methods known *per se*.

15 The reaction is usually carried out in a conventional solvent such as N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.

20 The reaction is also usually carried out in the presence of triphenylphosphine and/or a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.

The reaction temperature is not critical, and the
25 reaction can be carried out under cooling to heating.

Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as

concentration, concentration *in vacuo*, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or
5 (IV).

Reduction

Compound (8) or its salt is reduced in accordance with a conventional method to give Compound (9).

10 The conventional reduction includes hydrogenation, catalytic hydrogenation, etc.

Among others, catalytic hydrogenation is preferable.

The catalytic hydrogenation is carried out in the presence of a catalyst such as palladium on carbon,
15 preferably 10% palladium on carbon.

The catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, methanol, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.



20 The catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like. A liquid acid can be also used as the solvent.

The reaction temperature is not critical, and the
25 reaction can be carried out under cooling to heating.

Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration *in vacuo*, solvent extraction, crystallization, recrystallization, phase transfer,
30 chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I), (II), (III) or (IV).

Therefore, as indicated in the following scheme,

Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above. Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I), (II),
 5 (III) or (IV).



wherein R¹, R² and U are as defined above.

Suitable "lower alkenylene" includes straight or branched
 10 alkenylene having 2 to 6 carbon atom(s), wherein the position and the number of the double bond are not particularly limited, such as -CH=CH-, -CH₂-CH=CH-, -CH₂-CH=CH-CH₂-, -CH₂-CH₂-CH=CH-, -CH=CH-CH=CH-, -CH=CH-CH₂-CH₂-CH₂-, -CH=CH-CH=CH-CH₂-CH₂- and
 15 -CH=CH-CH=CH-CH=CH- etc.


The nitrogen atom(s) in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known *per se* such as the methods described in Protective Groups in Organic Synthesis,
 20 published by John Wiley and Sons (1980), and the like.

The present invention is explained in more detail in the following by way of Reference Example, Production Examples and Example, which are not to be construed as limitative.

25

Reference Example 1: Synthesis of N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide

Step 1



A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the
 5 resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-1,3-thiazol-4-yl)methyl acetate hydrochloride (3.5 g) as white crystals.
¹H-NMR (DMSO-d₆), δ (ppm): 2.07 (3H, s), 4.92 (2H, s), 6.87 (1H, s).

10 MS: 173 (M+H)⁺

Step 2



To a mixture of (2-amino-1,3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane
 15 (560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L). The organic layer was dried over sodium sulfate and
 20 concentrated *in vacuo*. The residual solid was collected by filtration with isopropyl ether to give (2-(acetylamino)-1,3-thiazol-4-yl)methyl acetate (47 g) as white crystals.

¹H-NMR (CDCl₃), δ (ppm): 2.12 (3H, s), 2.29 (3H, s), 5.08 (2H, s), 6.93 (1H, s).

25 MS: 215 (M+H)⁺

Step 3



A mixture of (2-(acetylamino)-1,3-thiazol-4-yl)methyl
 5 acetate (46 g) and potassium carbonate (30 g) in methanol (640
 ml) was stirred for 3 hours at ambient temperature. The
 reaction mixture was concentrated *in vacuo*. The residue was
 diluted with chloroform, and the insoluble material was
 filtered off. The resulting solution was purified by flash
 10 column chromatography on silica-gel with methanol / chloroform
 (1/99). The resulted solid was collected by filtration with
 isopropyl ether to give N-(4-(hydroxymethyl)-1,3-thiazol-2-
 yl)acetamide (35 g) as white crystals.

¹H-NMR (DMSO-d₆), δ (ppm): 2.12 (3H, s), 4.44 (2H, d, J=5.0Hz),
 15 5.20 (1H, t, J=5.0Hz), 6.88 (1H, s), 12.02 (1H, brs).

MS: 173 (M+H)⁺

Step 4




N-(4-(Hydroxymethyl)-1,3-thiazol-2-yl)acetamide (2.8 g)
 was dissolved in methanol (10 ml) and chloroform (200 ml).
 20 Then, manganese (IV) oxide (28.3 g) was added to the solution
 under nitrogen atmosphere. The reaction mixture was stirred at
 room temperature for 7 hours, and filtered through a celite
 pad. The filtrate was concentrated *in vacuo*. The resulting
 solid was washed with ethyl ether to give N-(4-formyl-1,3-
 25 thiazol-2-yl)acetamide (2.01 g) as an off-white solid.

mp. 195.5-199°C

¹H-NMR (DMSO-d₆), δ (ppm): 2.17 (3H, s), 8.28 (1H, s), 9.79 (1H,

s), 12.47 (1H, brs).

Step 5




1-(Bromomethyl)-4-nitrobenzene (1.9 g), triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2.5 hours. Then, potassium tert-butoxide (1.19 g) and N-(4-formyl-1,3-thiazol-2-yl)acetamide (1.5 g) were added and the mixture was stirred at room temperature for 14 hours. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with 1N-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) → (1:2) as an eluent, and triturated with ethyl ether to give N-{4-[(Z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl}acetamide (1.59 g) as a yellow solid.

mp. 155-157°C

¹H-NMR (DMSO-d₆), δ (ppm): 2.13 (3H, s), 6.64 (1H, d, J=12.5Hz), 6.71 (1H, d, J=12.5Hz), 7.18 (1H, s), 7.79 (2H, d, J=9.0Hz), 8.17 (2H, d, J=9.0Hz), 12.02 (1H, brs).

MS: 290 (M+H)⁺

Step 6



A mixture of N-{4-[(Z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl}acetamide (2 g) and 10% palladium on carbon (400


mg) in methanol (25 ml), tetrahydrofuran (25 ml) and acetic acid (18 ml) was stirred under 4 atm hydrogen at ambient temperature for 5 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated *in vacuo*. The residue was dissolved in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:2) → ethyl acetate as an eluent, and triturated with ethyl alcohol / ethyl ether to give N-(4-(2-(4-aminophenyl)ethyl)-1,3-thiazol-2-yl)acetamide (539.6 mg) as an off-white solid.

mp. 102.5-104°C

¹H-NMR (DMSO-d₆), δ (ppm): 2.11(3H, s), 2.75(4H, brs), 4.82(2H, s), 6.46(2H, d, J=8.5Hz), 6.69(1H, s), 6.83(2H, d, J=8.5Hz), 12.07(1H, brs).

MS: 262 (M+H)⁺

Step 7



To a suspension of N-(4-(2-(4-aminophenyl)ethyl)-1,3-thiazol-2-yl)acetamide (26 g) in ethanol (500 ml) was added 4N hydrogen chloride in ethyl acetate (25 ml) and cyanamide (6.3 g). The mixture was refluxed for 26 hours. The reaction mixture was cooled to ambient temperature and poured into a mixture of ethyl acetate (500 ml) and saturated sodium hydrogen carbonate solution (500 ml). The resulted precipitate was collected by filtration and washed with water (300 ml) and ethanol (300 ml) to give N-{4-[2-(4-([amino(imino)methyl]-amino)phenyl)ethyl]-1,3-thiazol-2-yl}acetamide (18 g) as white

crystals.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 2.10 (3H, s), 2.85 (4H, s), 6.79 (1H, s), 6.83 (2H, d, $J=7\text{Hz}$), 7.10 (2H, d, $J=7\text{Hz}$).

MS: 304 ($\text{M}+\text{H}$) $^+$

5

Production Example 1: Synthesis of N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl]acetamide

Step 1

10 A mixture of 3-(methylthio)benzoic acid (15 g), N,O-dimethylhydroxylamine hydrochloride (8.7 g), 1-hydroxybenzotriazole (3.71 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (4.07 g) in N,N-dimethylformamide (DMF, 150 ml) was stirred at ambient
15 temperature for 13 hours. The reaction mixture was poured into saturated NaHCO_3 , and extracted with ethyl acetate (AcOEt, 2 times). The combined organic layer was washed with water and brine, dried over anhydrous MgSO_4 , and concentrated *in vacuo* to give N-methoxy-N-methyl-3-(methylthio)benzamide
20 (18.3 g) as a yellow oil.

$^1\text{H-NMR}$ (CDCl_3) δ (ppm): 2.50 (3H, s), 3.36 (3H, s), 3.56 (3H, s), 7.28-7.45 (3H, m), 7.54 (1H, s).

MS: 212 ($\text{M}+\text{H}$) $^+$

Step 2

25 To a stirred solution of N-methoxy-N-methyl-3-(methylthio)benzamide (18 g) in dry tetrahydrofuran (THF, 360 ml) was added dropwise diisobutylaluminum hydride (DIBALH, 170 ml) at -78°C over 40 min under N_2 atmosphere. The reaction mixture was stirred for 2.5 hours at r.t., and then the
30 reaction was quenched with MeOH at 0°C . AcOEt and 1N-HCl were added to the mixture, and the mixture was extracted. The organic layer was washed with brine, dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The residual oil (12.9 g),

methyl (triphenylphosphoranylidene)acetate (28.5 g) and THF (260 ml) were combined at r.t. under N₂ atmosphere, and the reaction mixture was refluxed for 2 hours. The solvent was removed *in vacuo*, and the residue was suspended in AcOEt. The solid was filtered off, and the filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (3:1) as an eluent to give methyl (2E)-3-[3-(methylthio)phenyl]acrylate (14.4g) as a colorless wax.

¹H-NMR (DMSO-d₆) δ (ppm): 2.51 (3H, s), 3.81 (3H, s), 6.44 (1H, d, J=16.0Hz), 7.24-7.32 (3H, m), 7.38 (1H, m), 7.65 (1H, d, J=16.0Hz).

Step 3

Methyl (2E)-3-[3-(methylthio)phenyl]acrylate (14 g), methanol (MeOH, 140 ml), acetic acid (AcOH, 70 ml) and then 10% palladium on carbon (6.72 g) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 9 hours under H₂ atmosphere (4 atm), and filtered through a celite pad. The filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (3:1) as an eluent to give methyl 3-[3-(methylthio)phenyl]propanoate (12.5 g) as a colorless oil.

¹H-NMR (DMSO-d₆) δ (ppm): 2.48 (3H, s), 2.62 (2H, t, J=8.0Hz), 2.92 (2H, t, J=8.0Hz), 3.68 (3H, s), 6.94-7.00 (1H, m), 7.07-7.14 (2H, m), 7.15-7.24 (1H, m).

Step 4

28 % Sodium methoxide solution in MeOH (10.8 ml) was added dropwise to the mixture of methyl 3-[3-(methylthio)phenyl]propanoate (11.8 g) and diethyl oxalate (15.2 ml) at 0 °C with stirring. The reaction mixture was stirred at 65 °C for 2 hours under reduced pressure. 15 % aqueous H₂SO₄ (90 ml) was added to the mixture, and refluxed

for 13 hours. After cooled to r.t., the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The residual oil was dissolved in EtOH (50 ml),
5 and concentrated H_2SO_4 (0.5 ml) was added dropwise to the solution. The reaction mixture was refluxed for 6 hours. After cooled to r.t., EtOH was removed *in vacuo*. AcOEt and water were added to the residue, and the mixture was extracted. The organic layer was washed with water and
10 brine, dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (6:1) as an eluent to give ethyl 4-[3-(methylthio)phenyl]-2-oxobutanoate (6.9 g) as a pale yellow oil.

15 $^1\text{H-NMR}$ (CDCl_3) δ (ppm): 1.36 (3H, t, $J=7.5\text{Hz}$), 2.48 (3H, s), 2.92 (2H, t, $J=7.0\text{Hz}$), 3.17 (2H, t, $J=7.0\text{Hz}$), 4.32 (2H, q, $J=7.5\text{Hz}$), 6.94-7.01 (1H, m), 7.05-7.13 (2H, m), 7.17-7.26 (1H, m).

Step 5

20 To a suspension of copper (II) bromide (18.1 g) in AcOEt (140 ml) was added a solution of ethyl 4-[3-(methylthio)phenyl]-2-oxobutanoate (6.8 g) in 70 ml of CHCl_3 . The reaction mixture was refluxed for 10.5 hours, cooled to r.t., and filtered through a short pad of silica gel eluting
25 with AcOEt / n-hexane (1:1). The solvent was removed *in vacuo* to give ethyl 3-bromo-4-[3-(methylthio)phenyl]-2-oxobutanoate (8.6g) as a pale brown oil.

$^1\text{H-NMR}$ (CDCl_3) δ (ppm): 1.38 (3H, t, $J=7.5\text{Hz}$), 2.47 (3H, s), 3.21 (1H, dd, $J=14.5, 7.5\text{Hz}$), 3.50 (1H, dd, $J=14.5, 7.5\text{Hz}$),
30 4.36 (2H, q, $J=7.5\text{Hz}$), 5.21 (1H, t, $J=7.5\text{Hz}$), 6.98-7.05 (1H, m), 7.11-7.29 (3H, m).

Step 6

Ethyl 3-bromo-4-[3-(methylthio)phenyl]-2-oxobutanoate

(8.5 g) was dissolved in EtOH (85 ml), and then thiourea (3.91 g) was added to the solution. The reaction mixture was refluxed for 2.5 hours under N₂ atmosphere. The cooled reaction mixture was evaporated *in vacuo*. Saturated NaHCO₃ and
5 water were added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with CHCl₃ / AcOEt (1:1) as an eluent to give ethyl
10 2-amino-5-[3-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (7.1 g) as a brown oil.

¹H-NMR (DMSO-d₆) δ (ppm): 1.25 (3H, t, J=7.0Hz), 2.45 (3H, s), 4.21 (2H, q, J=7.0Hz), 4.30 (2H, s), 6.96-7.29 (4H, m).

MS: 309 (M+H)⁺

15 Step 7

Ethyl 2-amino-5-[3-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (7 g) was dissolved in CH₂Cl₂ (100 ml) under N₂ atmosphere. Then pyridine (3.85 ml) and AcCl (1.78 ml) were added dropwise to the solution at 0 °C. The reaction mixture
20 was stirred at r.t. for 1.5 hours. The precipitate was filtered *in vacuo* to give ethyl 2-(acetylamino)-5-[3-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (4.77 g) as a colorless solid.

mp. 187.5-188.5 °C

25 ¹H-NMR (DMSO-d₆) δ (ppm): 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s), 2.45 (3H, s), 4.28 (2H, q, J=7.0Hz), 4.45 (2H, s), 7.00-7.23 (3H, m), 7.26 (1H, t, J=7.5Hz), 12.43 (1H, s).

MS: 351 (M+H)⁺

Step 8

30 Ethyl 2-(acetylamino)-5-[3-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (7.3 g) was suspended in THF (100 ml), and then lithium borohydride (907 mg) was added portionwise to the solution at 0 °C. The reaction mixture was refluxed for 10

WO 2006/011631

PCT/JP2005/014136

hours. $\text{Na}_2\text{SO}_4 \cdot 10\text{H}_2\text{O}$ was added to the mixture, and the mixture was stirred at r.t. for 2 hours. The suspension was filtered *in vacuo*. The filtrate was concentrated *in vacuo*, and purified by flash column chromatography over silica gel with CHCl_3 /

5 MeOH (10:1) as an eluent. The solid was washed with ethyl ether to give N-{4-(hydroxymethyl)-5-[3-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide (5.1 g) as a colorless solid.

mp. 140-141.5 °C

$^1\text{H-NMR}$ (DMSO-d_6) δ (ppm): 2.08 (3H, s), 2.44 (3H, s), 4.08 (2H, s), 4.48 (2H, d, $J=5.5\text{Hz}$), 5.08 (1H, t, $J=5.5\text{Hz}$), 5.08 (1H, t, $J=5.5\text{Hz}$), 6.99-7.19 (3H, m), 11.94 (1H, s).

MS: 309 (M+H)+

Step 9

N-{4-(Hydroxymethyl)-5-[3-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide (5 g) was dissolved in MeOH (5 ml) and CHCl_3 (50 ml). Then, manganese (IV) oxide (14.1 g) was added to the solution under N_2 atmosphere. The reaction mixture was stirred at r.t. for 20 hours, and filtered through a celite pad. The filtrate was concentrated *in vacuo*. The residual oil was solidified with ethyl ether to give N-{4-formyl-5-[3-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide (4.46 g) as an off-white solid.

mp. 148-149.5 °C

$^1\text{H-NMR}$ (DMSO-d_6) δ (ppm): 2.12 (3H, s), 2.45 (3H, s), 4.50 (2H, s), 6.99-7.25 (3H, m), 7.27 (1H, t, $J=7.5\text{Hz}$), 10.04 (1H, s), 12.35 (1H, brs).

MS: 307 (M+H)+

Step 10

1-(Bromomethyl)-4-nitrobenzene (959 mg), triphenylphosphine (1.16 g) and DMF (12 ml) were combined under N_2 atmosphere. The reaction mixture was stirred at r.t. for 2.5 hours. Then, potassium tert-butoxide (586 mg) and N-{4-formyl-5-[3-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide

WO 2006/011631

PCT/JP2005/014136

(800 mg) were added to the mixture at 0 °C, and the mixture was stirred at r.t. for 15 hours. The reaction mixture was poured into ice-water, and extracted with AcOEt. The organic layer was washed with 1N-HCl, water and brine, dried over
5 anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with CHCl₃ / AcOEt (1:1) as an eluent to give a mixture of N-{5-[3-(methylthio)benzyl]-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide and N-{5-[3-(methylthio)benzyl]-4-[(Z)-
10 2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (1.08 g) as yellow amorphous.

¹H-NMR (DMSO-d₆) δ (ppm): 2.08 (3H×2/3, s), 2.12 (3H×1/3, s), 2.44 (3H, s), 4.06 (2H×2/3, s), 4.32 (2H×1/3, s), 6.73 (1H×2/3, d, J=12.5Hz), 6.87 (1H×2/3, d, J=12.5Hz), 6.97-8.27
15 (26/3H, m), 11.87 (1H×2/3, s), 12.19 (1H×1/3, s).

MS: 426 (M+H)+

Step 11

Potassium peroxymonosulfate (1.55 g) was suspended in water (2.5 ml) and THF (8 ml), and then a mixture of N-{5-[3-(methylthio)benzyl]-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide and N-{5-[3-(methylthio)benzyl]-4-[(Z)-
20 2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (1.07 g) in THF (2 ml) was added dropwise to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 1 hour, and then water was added to the suspension. The mixture was extracted with AcOEt (twice). The combined organic layer was washed with brine, dried over anhydrous MgSO₄, and concentrated *in vacuo* to give N-{5-[3-(methylsulfonyl)benzyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide
30 (940.7 mg) as brown amorphous.

¹H-NMR (DMSO-d₆) δ (ppm): 2.08 (3H, s), 3.18 (3H, s), 4.24 (2H, s), 6.73 (1H, d, J=12.5Hz), 6.87 (1H, d, J=12.5Hz), 6.84-7.44 (8H, m), 11.92 (1H, s).

MS: 458 (M+H)+

Step 12

N-{5-[3-(Methylsulfonyl)benzyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (1 g), 10%
5 palladium on carbon (656 mg), MeOH (10 ml), THF (10 ml) and AcOH (1 ml) were combined. The reaction mixture was stirred at r.t. for 2 hours under 4 atm H₂ atmosphere, and filtered through a celite pad. The filtrate was concentrated *in vacuo*, and purified by flash column chromatography over silica gel
10 with CHCl₃ / MeOH (20:1) as an eluent to give N-{4-[2-(4-aminophenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (479.5 mg) as yellow amorphous.

¹H-NMR (DMSO-d₆) δ (ppm): 2.08 (3H, s), 2.59-2.86 (4H, m), 3.18 (3H, s), 4.02 (2H, s), 4.84 (2H, brs), 6.46 (2H, d, J=8.5Hz),
15 6.78 (2H, d, J=8.5Hz), 7.25-7.88 (4H, m), 12.03 (1H, s).

MS: 430 (M+H)+

Step 13

N-{4-[2-(4-Aminophenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (470 mg),
20 N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (340 mg) and THF (5 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 18 hours, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with CHCl₃ / AcOEt
25 (1:1) as an eluent to give di-tert-butyl ({[4-(2-{2-(acetylamino)-5-[3-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}methylidene)biscarbamate (502.9 mg) as yellow amorphous.

¹H-NMR (DMSO-d₆) δ (ppm): 1.39 (9H, s), 1.51 (9H, s), 2.09 (3H, s), 2.85 (4H, s), 3.18 (3H, s), 4.06 (2H, s), 7.13 (2H, d, J=8.0Hz), 7.37-7.45 (1H, m), 7.41 (2H, d, J=8.0Hz), 7.56 (1H, t, J=8.0Hz), 7.74-7.80 (2H, m), 9.94 (1H, s), 11.44 (1H, s),
30 12.05 (1H, s).

MS: 672 (M+H)+

Step 14

Di-tert-butyl ({[4-(2-{2-(acetylamino)-5-[3-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}methylidene)biscarbamate (480 mg), 4N HCl in 1,4-dioxane solution (8 ml) and MeOH (2 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 14 hours. The solvent was removed *in vacuo*. The residue was dissolved in water and AcOEt. The mixture was made
 5 basic (pH=8) with saturated NaHCO₃. The precipitate was collected *in vacuo*. The solid was washed with CH₃CN to give N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (157.1 mg) as an off-white solid.

15 mp. 212-213.5 °C

¹H-NMR (DMSO-d₆) δ (ppm): 2.08 (3H, s), 2.67-2.91 (4H, m), 3.19 (3H, s), 4.08 (2H, s), 6.80 (2H, d, J=8.0Hz), 7.04 (2H, d, J=8.0Hz), 7.42 (1H, d, J=8.0Hz), 7.57 (1H, t, J=8.0Hz), 7.77 (1H, s), 7.79 (1H, d, J=8.0Hz).

20 MS: 472 (M+H)+

Production Example 2: Synthesis of N-{4-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide hydrochloride

25 Step 1

Ethyl 4-acetylbenzoate (10 g) was dissolved in AcOH (80 ml), and then 90 % pyridinium tribromide (22.2 g) and 33 % hydrobromic acid in AcOH (30 ml) were added to the solution at 0 °C. The reaction mixture was stirred at r.t.
 30 for 1 hour, and poured into ice-water. The precipitate was collected *in vacuo* to give ethyl 4-(bromoacetyl)benzoate (15.1 g) as an off-white solid.

mp. 67-68.5 °C

WO 2006/011631

PCT/JP2005/014136

¹H-NMR (DMSO-d₆) δ (ppm): 1.34 (3H, t, J=7.0Hz), 4.36 (2H, q, J=7.0Hz), 5.00 (2H, s), 8.09 (2H, d, J=9.0Hz), 8.14 (2H, d, J=9.0Hz).

Step 2

5 Ethyl 4-(bromoacetyl)benzoate (15 g), triphenylphosphine (14.5 g), CH₃CN (200 ml) and pyridine (0.1 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 5 hours. The solvent was removed *in vacuo*. The residual amorphous was solidified with THF / ethyl ether to give {2-[4-
10 (ethoxycarbonyl)phenyl]-2-oxoethyl}(triphenyl)phosphonium bromide (22.7 g) as a colorless solid.

mp. 201-202.5 °C

¹H-NMR (DMSO-d₆) δ (ppm): 1.35 (3H, t, J=7.0Hz), 4.37 (2H, q, J=7.0Hz), 6.31 (2H, d, J=13.0Hz), 7.70-7.96 (15H, m), 8.14
15 (2H, d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz).

Step 3

Na₂CO₃ (5.96 g) was added to {2-[4-(ethoxycarbonyl)phenyl]-2-oxoethyl}(triphenyl)phosphonium bromide (15 g), benzene (140 ml) and water (140 ml) in a
20 separatory funnel. The mixture was shaken until the solids dissolved (about 30 min). The aqueous layer was separated and extracted with benzene. The combined organic layer was washed with brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. Benzene (110 ml) was added, followed by 4-
25 (methylthio)benzaldehyde (4.71 g), and the solution was heated at reflux for 22 hours. After cooled to r.t., the mixture was concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (3:1) as an eluent, and triturated with n-hexane to give ethyl
30 4-{(2E)-3-[4-(methylthio)phenyl]-2-propenoyl}-benzoate (5 g) as a yellow solid.

mp. 115-115.5 °C

¹H-NMR (CDCl₃) δ (ppm): 1.43 (3H, t, J=7.5Hz), 2.53 (3H, s),

WO 2006/011631

PCT/JP2005/014136

4.42 (2H, q, J=7.5Hz), 7.26 (2H, d, J=8.5Hz), 7.46 (1H, d, J=15.5Hz), 7.57 (2H, d, J=8.5Hz), 7.79 (1H, d, J=15.5Hz), 8.04 (2H, d, J=8.5Hz), 8.17 (2H, d, J=8.5Hz).

MS: 327 (M+H)+

⁵ Step 4

Ethyl 4-{3-[4-(methylsulfonyl)phenyl]propanoyl}benzoate was prepared from the compound of Step 3 of Production Example 2 in a manner similar to Step 11 of Production Example 1.

mp. 118-119.5 °C

¹⁰ ¹H-NMR (DMSO-d₆) δ (ppm): 1.34 (3H, t, J=7.0Hz), 3.06 (2H, t, J=7.5Hz), 3.19 (3H, s), 3.51 (2H, t, J=7.5Hz), 4.35 (2H, q, J=7.0Hz), 7.58 (2H, d, J=8.5Hz), 7.84 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.5Hz), 8.12 (2H, d, J=8.5Hz).

MS: 361 (M+H)+

¹⁵ Step 5

Ethyl 4-{2-bromo-3-[4-(methylsulfonyl)phenyl]propanoyl}benzoate was prepared from the compound of Step 4 of Production Example 2 in a manner similar to Step 5 of Production Example 1.

²⁰ ¹H-NMR (DMSO-d₆) δ (ppm): 1.34 (3H, t, J=7.0Hz), 3.21 (3H, s), 3.38 (1H, dd, J=14.5, 9.0Hz), 3.70 (1H, dd, J=14.5, 5.0Hz), 4.36 (2H, q, J=7.0Hz), 6.06 (1H, dd, J=9.0, 5.0Hz), 7.58 (2H, d, J=8.5Hz), 7.90 (2H, d, J=8.5Hz), 8.10 (2H, d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz).

²⁵ MS: 439 (M+H)+

Step 6

Ethyl 4-{2-amino-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}benzoate was prepared from the compound of Step 5 of Production Example 2 in a manner similar to Step 6 of Production Example 1.

³⁰ mp. 205.5-207 °C

¹H-NMR (DMSO-d₆) δ (ppm): 1.32 (3H, t, J=7.0Hz), 3.20 (3H, s), 4.26 (2H, s), 4.31 (2H, q, J=7.0Hz), 7.03 (2H, s), 7.47 (2H,

WO 2006/011631

PCT/JP2005/014136

d, J=8.0Hz), 7.69 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.0Hz), 7.97 (2H, d, J=8.5Hz).

MS: 417 (M+H)+

Step 7

5 Ethyl 4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}benzoate was prepared from the compound of Step 6 of Production Example 2 in a manner similar to Step 7 of Production Example 1.

¹H-NMR (DMSO-d₆) δ (ppm): 1.31 (3H, t, J=7.0Hz), 2.13 (3H, s),
10 3.20 (3H, s), 4.33 (2H, q, J=7.0Hz), 4.42 (2H, s), 7.49 (2H, d, J=8.0Hz), 7.77 (2H, d, J=8.0Hz), 7.88 (2H, d, J=8.0Hz), 8.03 (2H, d, J=8.0Hz), 12.28 (1H, s).

MS: 459 (M+H)+

Step 8

15 N-{4-[4-(Hydroxymethyl)phenyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide was prepared from the compound of Step 7 of Production Example 2 in a manner similar to Step 8 of Production Example 1.

¹H-NMR (DMSO-d₆) δ (ppm): 2.12 (3H, s), 3.12 (3H, s), 4.35 (2H,
20 s), 4.53 (2H, d, J=5.5Hz), 5.22 (1H, t, J=5.5Hz), 7.38 (2H, d, J=8.5Hz), 7.46 (2H, d, J=8.5Hz), 7.56 (2H, d, J=8.5Hz), 7.87 (2H, d, J=8.5Hz), 12.20 (1H, s).

MS: 417 (M+H)+

Step 9

25 N-{4-[4-(Hydroxymethyl)phenyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (1.25 g), CHCl₃ (12 ml), CH₃CN (12 ml) and Dess-Martin periodinate (1.91 g) were combined at 0 °C under N₂ atmosphere. The reaction mixture was stirred at r.t. for 1 hour, and diluted in CHCl₃.
30 The organic solution was washed with saturated NaHCO₃, water and brine, dried over anhydrous MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (20:1) as an eluent to give

WO 2006/011631

PCT/JP2005/014136

N-{4-(4-formylphenyl)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (1.99 g) as a brown oil.

¹H-NMR (DMSO-d₆) δ (ppm): 2.14 (3H, s), 3.20 (3H, s), 4.45 (2H, s), 7.49 (2H, d, J=8.0Hz), 7.85 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.0Hz), 7.99 (2H, d, J=8.5Hz), 10.04 (1H, s), 12.28 (1H, s).

MS: 415 (M+H)+

Step 10

N-{4-(4-Formylphenyl)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (1.99 g), methyl (triphenylphosphoranylidene)acetate (3.21 g) and THF (20 ml) were combined at r.t. under N₂ atmosphere, and the mixture was refluxed for 1 hour. The solvent was removed *in vacuo*. The residual solid was washed with AcOEt to give methyl (2E)-3-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)acrylate (779.3 mg) as an off-white solid.

mp. 217-218.5 °C

¹H-NMR (DMSO-d₆) δ (ppm): 2.13 (3H, s), 3.20 (3H, s), 3.73 (3H, s), 4.41 (2H, s), 6.67 (1H, d, J=16.0Hz), 7.48 (2H, d, J=8.0Hz), 7.65 (2H, d, J=8.5Hz), 7.69 (1H, d, J=16.0Hz), 7.80 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.0Hz), 12.23 (1H, s).

MS: 471 (M+H)+

Step 11

Methyl (2E)-3-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)acrylate (2.3 g), 10% palladium on carbon (1.96 g), MeOH (23 ml), THF (23 ml) and AcOH (2.3 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 7 hours under H₂ atmosphere (4 atm), and the mixture was filtered through a celite pad. The filtrate was concentrated *in vacuo* to give methyl 3-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)propanoate (1.28 g) as a colorless solid.

mp. 129-131 °C

¹H-NMR (DMSO-d₆) δ (ppm): 2.12 (3H, s), 2.66 (2H, t, J=7.0Hz),

2.88 (2H, t, J=7.0Hz), 3.20 (3H, s), 3.58 (3H, s), 4.35 (2H, s), 7.29 (2H, d, J=8.0Hz), 7.46 (2H, d, J=8.0Hz), 7.52 (2H, d, J=8.0Hz), 7.88 (2H, d, J=8.0Hz), 12.17 (1H, s).

MS: 473 (M+H)

5 Step 12

Methyl 3-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)propanoate (1.01 g), 1N-NaOH (5.34 ml) and 1,4-dioxane (10 ml) were combined at 0 °C, and the reaction mixture was stirred at
10 r.t. for 1 hour. The organic solvent was evaporated *in vacuo*. The residual aqueous solution was washed with AcOEt. The aqueous layer was acidified with 1N-HCl. The precipitate was filtered off *in vacuo* to give 3-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)propanoic acid
15 (800.5 mg) as a colorless solid.

mp. 208.5-210 °C

¹H-NMR (DMSO-d₆) δ (ppm): 2.12 (3H, s), 2.55 (2H, t, J = 7.5 Hz), 2.85 (2H, t, J = 7.5 Hz), 3.20 (3H, s), 4.35 (2H, s), 7.30 (2H, d, J = 8.5 Hz), 7.46 (2H, d, J = 8.5 Hz), 7.51 (2H, d, J = 8.5 Hz), 7.87 (2H, d, J = 8.5 Hz), 12.16 (1H, brs),
20 12.18 (1H, s).

MS: 459 (M+H)

Step 13

3-(4-{2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)propanoic acid (400 mg), Et₃N (0.182 ml) and t-BuOH (8 ml) were combined under N₂ atmosphere. Diphenylphosphoryl azide (0.226 ml) was added dropwise to the solution at r.t. The reaction mixture was refluxed for 10 hours, and cooled to r.t. The mixture was diluted with AcOEt.
30 The organic solution was washed with 1N-HCl, water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography over NH

silica gel with CHCl₃ / MeOH (20:1) as an eluent to give tert-butyl [2-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)ethyl]carbamate (168.3 mg) as colorless amorphous.

¹H-NMR (DMSO-d₆) δ (ppm): 1.36 (9H, s), 2.12 (3H, s), 2.72 (2H, m), 3.15 (2H, m), 3.20 (3H, s), 4.35 (2H, s), 6.88 (1H, t, J = 5.5 Hz), 7.26 (2H, d, J = 8.5 Hz), 7.46 (2H, d, J = 8.5 Hz), 7.52 (2H, d, J = 8.5 Hz), 7.88 (2H, d, J = 8.5 Hz), 12.17 (1H, s).

MS: 530 (M+H)

Step 14

tert-Butyl [2-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)ethyl]carbamate (146.5 mg), 4N HCl in 1,4-dioxane solution (3 ml) and MeOH (1 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 2 hours, and concentrated *in vacuo*. The residue, di-tert-butyl (1H-pyrazol-1-ylmethylidene)biscarbamate (85.8 mg), N,N-diisopropylethylamine (0.0964 ml), THF (3 ml) and DMF (1 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 2 hours, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (20:1) as an eluent to give di-tert-butyl ([2-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)ethylamino]methylidene)biscarbamate (118.8 mg) as colorless amorphous.

¹H-NMR (DMSO-d₆) δ (ppm): 1.39 (9H, s), 1.44 (9H, s), 2.12 (3H, s), 2.85 (2H, m), 3.33 (3H, s), 3.56 (2H, m), 4.35 (2H, s), 7.31 (2H, d, J = 8.0 Hz), 7.46 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.0 Hz), 7.87 (2H, d, J = 8.0 Hz), 8.36 (1H, t, J = 5.5 Hz), 11.49 (1H, s), 12.17 (1H, s).

MS: 672 (M+H)

Step 15

Di-tert-butyl ({2-(4-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}phenyl)ethylamino}methylenedibiscarbamate (144.7 mg), MeOH (1 ml) and 4N HCl in 1,4-dioxane solution (3 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at r.t. for 19 hours. The solvent was removed *in vacuo*. The residue was washed with AcOEt to give N-{4-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide hydrochloride (67.3 mg) as a pale brown amorphous solid.

¹H-NMR (DMSO-d₆) δ (ppm): 2.13 (3H, s), 2.76-2.90 (2H, m), 3.21 (3H, s), 3.32-3.49 (2H, m), 4.36 (2H, s), 7.35 (2H, d, J=8.0Hz), 7.46 (2H, d, J=8.0Hz), 7.54 (2H, d, J=8.0Hz), 7.68 (1H, t, J=5.5Hz), 7.88 (2H, d, J=8.0Hz), 12.18 (1H, s).

MS: 472 (M+H) free

Production Example 3: Synthesis of N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide hydrochloride

Step 1

To a suspension of copper(II) bromide (9.75 g) in AcOEt (150 ml) was added a solution of ethyl 2-oxo-4-phenylbutanoate (3 g) in 75 ml of CHCl₃. The reaction mixture was refluxed for 23 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1). The solvent was removed *in vacuo* to give ethyl 3-bromo-2-oxo-4-phenylbutanoate (4.2g) as a yellow liquid.

¹H-NMR (CDCl₃) δ (ppm): 1.37 (3H, t, J=7.0Hz), 3.25 (1H, dd, J=14.5, 7.5Hz), 3.54 (1H, dd, J=14.5, 7.5Hz), 4.35 (2H, q, J=7.0Hz), 5.27 (1H, d, J=7.5Hz), 7.18-7.41 (5H, m).

Step 2

Ethyl 3-bromo-2-oxo-4-phenylbutanoate (5.8 g) was dissolved in EtOH (110 ml), and then thiourea (3.1 g) was added to the solution. The reaction mixture was refluxed for 2 hours under N₂ atmosphere. The cooled reaction mixture was
5 evaporated *in vacuo*. The residual solid was suspended (pH=8) in saturated NaHCO₃ and water. The solid was collected by filtration, and purified by flash column chromatography over silica gel with CHCl₃ / MeOH (10:1) as an eluent to give ethyl 2-amino-5-benzyl-1,3-thiazole-4-carboxylate (808.2 mg) as a
10 yellow wax.

¹H-NMR (DMSO-d₆) δ (ppm): 1.25 (3H, t, J=7.0Hz), 4.21 (2H, q, J=7.0Hz), 4.33 (2H, s), 7.02 (2H, s), 7.11-7.39 (5H, m).

MS: 263 (M+H)⁺

Step 3

15 Ethyl 2-amino-5-benzyl-1,3-thiazole-4-carboxylate (2.1 g) was dissolved in pyridine (21 ml), and then acetyl chloride (1.71 ml) was added dropwise to the solution at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2.5 hr. Water was added to the solution at 0
20 °C, and the precipitate was filtered off *in vacuo*. The solid was washed with diethyl ether to give ethyl 2-(acetylamino)-5-benzyl-1,3-thiazole-4-carboxylate (1.92 g) as a brown solid.
mp. 178-180 °C

¹H-NMR (DMSO-d₆) δ (ppm): 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s),
25 4.28 (2H, q, J=7.0Hz), 4.48 (2H, s), 7.19-7.39 (5H, m), 12.41 (1H, s).

MS: 305 (M+H)⁺

Step 4

Ethyl 2-(acetylamino)-5-benzyl-1,3-thiazole-4-carboxylate
30 (1.0 g) was dissolved in THF (20 ml), and then lithium borohydride (124 mg) was added portionwise to the solution at 0 °C. The reaction mixture was refluxed for 4.5 hr, and the reaction was quenched with MeOH. The mixture was concentrated

in vacuo, and purified by flash column chromatography over silica gel with CHCl₃ / MeOH (20:1) as an eluent. The residual amorphous substance was dissolved in MeOH (1 ml) and CHCl₃ (8 ml). Then manganese(IV) oxide (1.26 g) was added to the
5 solution under N₂ atmosphere. The reaction mixture was stirred at r.t. for 12 hours, and filtered through a celite pad. The filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (20:1) as an eluent to give N-(5-benzyl-4-formyl-1,3-
10 thiazol-2-yl)acetamide (251 mg) as a pale yellow solid.

mp. 191-192.5 °C

¹H-NMR (DMSO-d₆), δ (ppm): 2.12 (3H, s), 4.53 (2H, s), 7.19-7.40 (5H, m), 10.04 (1H, s), 12.34 (1H, s).

MS: 261 (M+H)⁺

15 Step 5

N-{5-Benzyl-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide was prepared from the compound of Step 4 of Production Example 3 in a manner similar to Step 10 of Production Example 1.

20 ¹H-NMR (DMSO-d₆), δ (ppm): 2.06, 2.13 (3H, s), 4.03, 4.18 (2H, s), 6.69 (1H, s), 7.17-7.35 (6H, m), 7.40, 7.54 (2H, dx2, J = 8.9 Hz), 7.99, 8.20 (2H, dx2, J = 8.9 Hz), 9.97, 10.19 (1H, sx2).

MS: 380 (M+H)⁺

25 Step 6

To the solution of N-{5-benzyl-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide in chloroform was added chlorosulfonic acid dropwise under ice-cooling. This was stirred at room temperature for 15 hr and then rotary
30 evaporated to a reduced volume. To the solution was added aq. saturated NaHCO₃ solution. The mixture was extracted with THF.

The organic layer was dried over MgSO_4 and concentrated to give 4-({2-(acetylamino)-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl}methyl)benzenesulfonyl chloride as crude oil.

This was used for the next reaction without further

5 purification.

MS: 478 (M+H)+

Step 7

To a solution of 4-({2-(acetylamino)-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl}methyl)benzenesulfonyl
10 chloride (170 mg) in THF (5 ml) was added ammonium hydroxide (28%, 1.5 ml) at 5 °C. The mixture was stirred at 25 °C for 12 hr. The reaction was quenched with aq. saturated ammonium chloride solution. The mixture was extracted with Ethyl acetate, dried over MgSO_4 , filtered, concentrated *in vacuo* to
15 give orange powder. m/z 459 (M+H)+

The resulting orange powder was dissolved in MeOH and AcOH (1 ml). To the solution was added 10 % Pd/C (50 % wet), and the mixture was stirred at 25 °C under hydrogen for 15 hr and filtered through a celite pad. The filtrate was added aq.
20 0.1N NaOH. The mixture was extracted with ethyl acetate. The organic layer was dried over MgSO_4 , filtered, concentrated *in vacuo*. The residue was purified by silicagel column chromatography with chloroform and methanol (20:1) as an eluent to give N-{4-[2-(4-aminophenyl)ethyl]-5-[4-
25 (aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (33 mg) as white powder.

$^1\text{H-NMR}$ (200MHz, DMSO-d_6) δ (ppm): 1.88 (3H, s), 3.65-2.76 (4H, m), 3.93 (2H, s), 4.84 (2H, s), 6.46 (2H, d, $J=8.3$ Hz), 6.78 (2H, d, $J=8.3$ Hz), 7.22 (2H, d, $J=8.3$ Hz), 7.28 (2H, s), 7.72
30 (2H, d, $J=8.3$ Hz), 12.00 (1H, s).

WO 2006/011631

PCT/JP2005/014136

MS: 431 (M+H)+

Step 8

Di-tert-butyl ((Z)-{[4-(2-{2-(acetylamino)-5-[4-(aminosulfonyl)benzyl]-1,3-thiazol-4-

5 yl}ethyl)phenyl]amino}methylidene)biscarbamate was prepared from the compound of Step 7 of Production Example 3 in a manner similar to Step 13 of Production Example 1.

¹H-NMR (DMSO-d₆), δ (ppm): 1.39 (9H, s), 1.50 (9H, s), 2.08 (3H, s), 2.85 (4H, br), 4.00 (2H, s), 7.15 (2H, d), 7.30 (2H, 10 d), 7.43 (2H, d), 7.72 (2H, d), 9.95 (1H, s), 11.44 (1H, s), 12.03 (1H, s).

MS: 673 (M+H)+

Step 9

The title compound was prepared from the compound of Step 15 8 of Production Example 3 in a manner similar to Step 14 of Production Example 1.

¹H-NMR (DMSO-d₆), δ (ppm): 1.95 (3H, s), 2.86 (4H, s), 3.99 (2H, s), 7.14 (2H, d, J = 8.5 Hz), 7.25 (2H, d, J = 8.5 Hz), 7.27-7.35 (8H, m), 7.74 (2H, d, J = 8.5 Hz), 10.30 (1H, s), 20 12.03 (1H, s).

MS: 473 (M+H)+

Production Example 4: Synthesis of N-(4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-{4-[(dimethylamino)sulfonyl]benzyl}-1,3-thiazol-2-yl)acetamide 25 hydrochloride

Step 1

To a solution of 4-({2-(acetylamino)-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl}methyl)benzenesulfonyl chloride (435 mg) in THF(10 ml) was added dimethylamine 30 (50 % solution, 400 μl) at 25 °C. The mixture was stirred at 25 °C for 12 hr. The reaction was quenched with aq. ammonium

chloride solution. The mixture was extracted with ethyl acetate, and the extract was dried over MgSO_4 , filtered and concentrated *in vacuo* to give orange powder.

The resulting orange powder was dissolved in DMF, MeOH
5 and AcOH (10 ml, 5 ml and 2 ml, respectively). To this solution was added 10 % Pd/C (50 % wet, 200 mg) and the mixture was stirred for 1 hr under 3 atm pressure of hydrogen, and then filtered through a celite pad. The filtrate was added aq. 0.1N NaOH solution. The mixture was
10 extracted with ethyl acetate. The organic layer was dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified by silicagel column chromatography with chloroform and methanol (20:1) as an eluent to give N-(4-[2-(4-aminophenyl)ethyl]-5-{4-[(dimethylamino)sulfonyl]benzyl}-
15 1,3-thiazol-2-yl)acetamide (200 mg) as white powder.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 2.08 (3H, s), 2.56 (4H, s), 3.36 (6H, s), 3.99 (2H, s), 4.84 (2H, s), 6.45 (2H, d), 6.75 (2H, d), 7.27 (2H, d), 7.64 (2H, d), 12.03 (1H, s).

MS: 459 (M+H)+

20 Step 2

Di-tert-butyl [(Z)-({4-[2-(2-(acetylamino)-5-{4-[(dimethylamino)sulfonyl]benzyl}-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound of Step 1 of Production Example 4 in a
25 manner similar to Step 13 of Production Example 1.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 1.38 (9H, s), 1.50 (9H, s), 2.08 (3H, s), 2.54 (6H, s), 2.84 (4H, s), 4.02 (2H, s), 7.10 (2H, d, $J = 8.4$ Hz), 7.27 (2H, d, $J = 8.4$ Hz), 7.43 (2H, d, $J = 8.4$ Hz), 7.61 (2H, d, $J = 8.4$ Hz), 9.99 (1H, s), 11.45 (1H, s).

30 Step 3

The title compound was prepared from the compound of

WO 2006/011631

PCT/JP2005/014136

Step 2 of Production Example 4 in a manner similar to Step 14 of Production Example 1.

¹H-NMR (DMSO-d₆), δ (ppm): 2.09 (3H, s), 2.57 (6H, s), 2.84 (4H, s), 4.08 (2H, s), 7.12 (2H, d, J = 8.4 Hz), 7.23 (2H, d, J = 8.4 Hz), 7.40 (2H, d, J = 8.0 Hz), 7.42 (4H, br, J = 8.0 Hz), 8.02 (2H, d, J = 8.0 Hz), 9.86 (1H, s), 12.05 (1H, s).

MS: 501 (M+H)+

Production Example 5: Synthesis of N-{4-[4-(4-{[amino(imino)methyl]amino}-3-oxobutyl)phenyl]-1,3-thiazol-2-yl}acetamide hydrochloride

Step 1

To the solution of ethyl 3-phenylpropanoate (8 g) in CH₂Cl₂ (25 ml) was added bromoacetyl chloride (6.0 ml). This solution was maintained under -5 °C. To the solution was added aluminium chloride (16.2 g) over 15 min. After addition of AlCl₃, this was stirred at 0 °C for 30 min. Then the reaction mixture was refluxed for 1 hr. Then the reaction mixture was poured into ice-water and was extracted with CH₂Cl₂. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to give green liquid of ethyl 3-[4-(bromoacetyl)phenyl]propanoate. This was used for the next reaction without further purification.

¹H-NMR (DMSO-d₆), δ (ppm): 1.23 (3H, t, J = 7.2 Hz), 2.65 (2H, t, J = 7.6 Hz), 3.02 (2H, t, J = 7.6 Hz), 4.13 (2H, q, J = 7.2 Hz), 4.43 (2H, s), 7.43 (2H, d, J = 8.1 Hz), 7.92 (2H, d, J = 8.1 Hz).

Step 2

Ethyl 3-[4-(bromoacetyl)phenyl]propanoate (13 g) was dissolved into ethanol (EtOH, 70 ml). To the solution was

added thiourea (4.8 g), and the mixture was refluxed for 3 hr, and then rotary evaporated to reduced volume. The resulting concentrated solution was poured into water, and the mixture was extracted with ethyl acetate, and the extract was dried
5 over MgSO_4 , filtered, and concentrated *in vacuo* to give ethyl 3-[4-(2-amino-1,3-thiazol-4-yl)phenyl]propanoate as pale yellow oil. This was used for the next reaction without further purification.

MS: m/z 277 (M+H)⁺

10 Step 3

To the solution of ethyl 3-[4-(2-amino-1,3-thiazol-4-yl)phenyl]propanoate (12.4 g) in CH_2Cl_2 (100 ml) were added acetyl chloride (3.82 ml) and pyridine (5.8 ml) at 25 °C. This was stirred for 12 hr at 25 °C and then concentrated *in*
15 *vacuo*. The residue was dissolved in CH_2Cl_2 and this was washed with aq. NaHCO_3 solution and ammonium chloride solution. The organic layer was dried over MgSO_4 , filtered and concentrated *in vacuo* to give a brownish solid. Resulting brown solid was dissolved in MeOH (80 ml) and THF
20 (50 ml). To this solution was added 1N NaOH (50 ml) and the mixture was stirred at 25 °C for 12 hr and was concentrated to a reduced volume. To the aqueous solution was added 1N HCl solution to give colourless precipitate. This was collected by filtration, washed with water to give 3-{4-[2-
25 (acetylamino)-1,3-thiazol-4-yl]phenyl}propanoic acid (12.1 g) as a colourless solid.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 2.15 (3H, s), 2.52 (2H, t, $J = 7.5$ Hz), 2.83 (2H, t, $J = 7.5$ Hz), 7.27 (2H, d, $J = 8.1$ Hz), 7.52 (1H, s), 7.78 (2H, d, $J = 8.1$ Hz), 12.24 (1H, s).

30 MS: 291 (M+H)⁺

Step 4

To a solution of 3-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}propanoic acid (3 g) in CH₂Cl₂ (30 ml) was added oxalyl chloride (1.35 ml) dropwise at 5 °C. After another 5 minutes, 3 drops of DMF were added. This was stirred for 1 hr at 25 °C. Then, the solvent and the reagent were evaporated. The residue was dissolved into THF (30 ml). To the ice-cooled solution of the resulting acid chloride was added another solution that was prepared from ethyl isocyanoacetate (2.82 ml) and 1,8-diazabicyclo[4.5.0]undec-7-ene (DBU, 4.64 ml) in THF (30 ml). This was stirred at 25 °C for 2 days. This was quenched with aq. 0.1N HCl and was extracted with ethyl acetate, and the extract was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified with silicagel column chromatography with CH₂Cl₂ and MeOH (5/1) as an eluent to give ethyl 5-(2-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}ethyl)-1,3-oxazole-4-carboxylate (2.25 g) as white powder.

¹H-NMR (DMSO-d₆), δ (ppm): 1.26 (3H, t, J = 7.1 Hz), 2.15 (3H, s), 2.96 (2H, t, J = 7.4 Hz), 3.33 (2H, t, J = 7.4 Hz), 4.22 (2H, q, J = 7.1 Hz), 7.21 (2H, d, J = 8.2 Hz), 7.54 (1H, s), 7.78 (2H, d), 8.37 (1H, s), 12.20 (1H, s).

MS: 386 (M+H)+

Step 5

To the solution of ethyl 5-(2-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}ethyl)-1,3-oxazole-4-carboxylate (2.14 g) in MeOH (5 ml) was added conc. HCl (10 ml). This was stirred at 80 °C for 8 hr. Then, this was concentrated *in vacuo* to give 1-amino-4-[4-(2-amino-1,3-thiazol-4-yl)phenyl]-2-butanone dihydrochloride as a crude solid. This was used for the next

reaction without further purification.

¹H-NMR (DMSO-d₆), δ (ppm): 2.93 (4H, m), 3.95 (2H, m), 7.02 (1H, s), 7.33 (2H, d, J = 8.4 Hz), 7.63 (2H, d, J = 8.4 Hz), 8.21 (3H, br), 8.77 (2H, br).

⁵ Step 6

To the solution of 1-amino-4-[4-(2-amino-1,3-thiazol-4-yl)phenyl]-2-butanone dihydrochloride (1.8 g) in methylene chloride (20 ml) and DMF (20 ml) were added N,N-diisopropylethylamine (DIPEA, 3.3 ml) and di-tert-butyl dicarbamate (1.29 g). This was stirred at room temperature for 12 hr. To the solution was added water, and the mixture was extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated. The residual oil was dissolved in pyridine (20 ml). To this solution was added acetylchloride (0.57 ml) under ice-cooling. This was stirred at 25 °C for 2 hr. The solution was poured into water and organic layer was extracted with ethyl acetate. The extract was dried over MgSO₄, the solvent was removed *in vacuo* and residual yellow oil was purified by silicagel column chromatography with hexane and ethyl acetate (10/1) as an eluent to give tert-butyl (4-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}-2-oxobutyl)carbamate (0.3 g) as white powder.

¹H-NMR (DMSO-d₆), δ (ppm): 1.38 (9H, s), 2.15 (3H, s), 2.76 (4H, br), 3.76 (2H, d, J = 5.8 Hz), 7.07 (1H, t), 7.25 (2H, d, J = 8.2 Hz), 7.53 (1H, s), 7.78 (2H, d), 12.22 (1H, s).

MS: m/z 404 (M+H)⁺

Step 7

tert-Butyl (4-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}-2-oxobutyl)carbamate (260 mg) was treated with 4N HCl in dioxane at room temperature for 2 hr. Then, the solvent

was evaporated *in vacuo*. The residue was triturated with isopropyl ether (IPE) to give N-{4-[4-(4-amino-3-oxobutyl)phenyl]-1,3-thiazol-2-yl}acetamide hydrochloride (218 mg) as colourless powder.

5 ¹H-NMR (DMSO-d₆), δ (ppm): 2.16 (3H, s), 2.89 (4H, d x2), 3.81 (2H, m), 7.28 (2H, d, J = 8.2 Hz), 7.54 (1H, s), 7.80 (2H, d, J = 8.2 Hz), 8.10 (3H, br), 12.23 (1H, br).

MS: 304 (M+H)+

Step 8

10 Di-tert-butyl {(E)-[(4-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}-2-oxobutyl)amino]methylidene}biscarbamate was prepared from the compound of Step 7 of Production Example 5 in a manner similar to Step 13 of Production Example 1.

¹H-NMR (DMSO-d₆), δ (ppm): 1.38 (9H, s), 1.43 (9H, s), 2.15 (3H, s), 2.84 (4H, s), 4.24 (2H, d, J = 4.8 Hz), 7.27 (2H, d, J = 8.2 Hz), 7.52 (1H, s), 7.79 (2H, d), 8.72 (1H, br), 10.15 (1H, s), 11.43 (1H, s), 12.22 (1H, s).

MS: 546 (M+H)+

Step 9

20 The title compound was prepared from the compound of Step 8 of Production Example 5 in a manner similar to Step 14 of Production Example 1.

¹H-NMR (DMSO-d₆), δ (ppm): 2.16 (3H, s), 2.73-2.94 (4H, m), 3.38 (2H, m), 6.53 (1H, br), 7.26 (2H, d, J = 8.0 Hz), 7.32 (2H, s), 7.54 (1H, s), 7.80 (2H, d, J = 8.0 Hz), 11.50 (1H, s), 12.05 (1H, s), 12.21 (1H, s).

MS: m/z 346 (M+H) free

Production Example 6: Synthesis of N-(4-{2-[4-(3-[amino(imino)methyl]amino)propyl]phenyl]ethyl}-1,3-thiazol-2-yl)acetamide hydrochloride

Step 1

To a solution of N-[4-(chloromethyl)-1,3-thiazol-2-yl]acetamide (23.6 g) in toluene (200 ml) and acetonitril (80 ml) was added triphenylphosphine (35.7 g) at 25 °C. The mixture was stirred at 130 °C for 12 hr. Resulting

5 precipitate was collected by filtration and washed with IPE to give {[2-(acetylamino)-1,3-thiazol-4-yl]methyl}(triphenyl)phosphonium chloride (35.7 g) as colourless powder.

¹H-NMR (DMSO-d₆), δ (ppm): 2.11 (3H, s), 5.25 (2H, d, J =
10 15.3 Hz), 6.86 (1H, d, J = 3.8 Hz), 7.68-7.92 (15H, m), 12.06 (1H, s).

Step 2

Methyl (2E)-3-(4-formylphenyl)acrylate was prepared from benzene-1,4-dicarbaldehyde in a manner similar to Step 10 of
15 Production Example 2.

¹H-NMR (200MHz, DMSO-d₆) δ (ppm): 3.75 (3H, s), 6.83 (1H, d, J=16.1 Hz), 7.74 (1H, d, J=16.1 Hz), 7.95 (4H, s), 10.03 (1H, s).

Step 3

20 Methyl (2E)-3-(4-{(E)-2-[2-(acetylamino)-1,3-thiazol-4-yl]vinyl}phenyl)acrylate was prepared from the compound of Step 1 of Production Example 6 and the compound of Step 2 of Production Example 6 in a manner similar to Step 3 of Production Example 2.

25 ¹H-NMR (DMSO-d₆), δ (ppm): 2.15 (3H, s), 3.73 (3H, s), 6.66 (1H, d, J = 16.0 Hz), 7.24 (1H, d, J = 14.5 Hz), 7.55-7.78 (2H, m), 7.95 (4H, s), 12.20 (1H, br).

MS: 329 (M+H)+

Step 4

30 Methyl 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)propanoate was prepared from the compound of Step 3 of Production Example 6 in a manner similar to Step 11 of Production Example 2.

WO 2006/011631

PCT/JP2005/014136

¹H-NMR (200MHz, CDCl₃) δ (ppm): 2.24 (3H, s), 2.61 (2H, t, J=7.8 Hz), 2.92 (2H, t, J=7.8 Hz), 2.94 (4H, s), 3.67 (3H, s), 6.49 (1H, s), 7.09 (4H, s).

MS: 333 (M+H) +

⁵ Step 5

Methyl 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)propanoate (1.0 g) was dissolved in THF (20 ml). To the solution was added lithium tetrahydroborate (1.07 g) portionwise at 5 °C. The reaction mixture was refluxed for 4.0 hr and Na₂SO₄ was added, and the mixture was stirred for 12 hr. Precipitate was removed by filtration. The organic solvent was evaporated *in vacuo*. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (3:2 - 1:1) as an eluent to give N-(4-{2-[4-(3-hydroxypropyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (200 mg) as white powder.

¹H-NMR (DMSO-d₆), δ (ppm): 1.87 (2H, m), 2.24 (3H, s), 2.68 (2H, t, J = 7.5 Hz), 2.94 (4H, s), 3.68 (2H, t, J = 7.5 Hz), 6.50 (1H, s), 7.10 (4H, s).

²⁰ MS: 305 (M+H) +

Step 6

To a solution of N-(4-{2-[4-(3-hydroxypropyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (180 mg) in THF (5 ml) were added triphenylphosphine (233 mg) and CBr₄ (294 mg) at 0 °C. This was stirred at 25 °C for 1 hr and was poured into water. The mixture was extracted with ethyl acetate. The organic layer was dried over MgSO₄, filtered, concentrated *in vacuo*. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (1/2) as an eluent to give N-(4-{2-[4-(3-bromopropyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (217.2 mg) as colourless powder.

¹H-NMR (DMSO-d₆), δ (ppm): 2.02 (2H, m), 2.11 (3H, s), 2.66

WO 2006/011631

PCT/JP2005/014136

(2H, t, $J = 7.5$ Hz), 2.87 (4H, br), 3.49 (2H, t, $J = 7.5$ Hz), 6.73 (1H, s), 7.11 (4H, s), 12.08 (1H, s).

MS: 367, 369 (M+H)+

Step 7

5 To a solution of N-(4-{2-[4-(3-bromopropyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (175 mg) in DMF (5 ml) was added potassium phthalimide at 25 °C. The mixture was stirred at 50 °C for 2.5 hr and was poured into water. The mixture was extracted with ethyl acetate. The organic layer was washed
10 with brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (1:1) as an eluent to give N-[4-(2-{4-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide
15 (174.1 mg) as white powder.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 1.95 (2H, m), 2.11 (3H, s), 2.57 (2H, t, $J = 7.1$ Hz), 2.82 (4H, s), 3.59 (2H, t, $J = 6.9$ Hz), 6.71 (1H, s), 7.08 (4H, s), 7.83 (3H, s).

MS: 434 (M+H)+

20 Step 8

N-[4-(2-{4-[3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide (87.1 mg), hydrazine monohydrate (0.174 ml) and MeCN (2 ml) were combined under N_2 atmosphere. The reaction mixture was stirred at 50 °C
25 for 1 hour. After cooled to r.t., the mixture was diluted with CHCl_3 . The precipitate was filtered off. The filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography over NH silica gel with CHCl_3 / MeOH (20:1) as an eluent to give N-(4-{2-[4-(3-aminopropyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (50 mg)
30 as colorless oil.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 1.61 (1H, m), 2.11 (3H, s), 2.56

WO 2006/011631

PCT/JP2005/014136

(2H, m), 2.87 (4H, s), 3.32 (2H, m), 6.72 (1H, s), 7.09 (4H, s).

MS: 304 (M+H)+

Step 9

5 Di-tert-butyl ((Z)-{[3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)propyl]amino}methylidene) biscarbamate was prepared from the compound of Step 8 of Production Example 6 in a manner similar to Step 13 of Production Example 1.

10 ¹H-NMR (DMSO-d₆), δ (ppm): 1.38 (9H, s), 1.47 (9H, s), 1.79 (2H, br), 2.11 (3H, s), 2.55 (2H, br), 2.86 (4H, s), 3.26 (2H, br), 6.72 (1H, s), 7.11 (4H, s), 8.30 (1H, br), 11.45 (1H, s), 12.10 (1H, s).

MS: 546 (M+H)+

15 Step 10

The title compound was prepared from the compound of Step 9 of Production Example 6 in a manner similar to Step 14 of Production Example 1.

¹H-NMR (DMSO-d₆), δ (ppm): 1.74 (2H, m), 2.11 (3H, s), 2.58 (2H, t, J = 7.1 Hz), 2.87 (4H, s x2), 3.09 (2H, m), 6.73 (1H, s), 7.12 (4H, s), 7.21 (4H, br), 7.87 (1H, br), 12.10 (1H, s).

MS: 346 (M+H)+

Production Example 7: Synthesis of N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-thiazol-2-yl}acetamide hydrochloride

25 Step 1

To a solution of 4-phenyl-1-butanol (15 g) in CH₂Cl₂ (150 ml) were added pivaloyl chloride (14.2 ml) and diisopropylethylamine (26.1 ml) at 0°C. The mixture was stirred at 25 °C for 2 hr and poured into water. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, filtered, concentrated

in vacuo. The residue was purified by silicagel column chromatography with hexane and ethyl acetate to give 4-phenylbutyl pivalate (21 g) as pale yellow oil.

¹H-NMR (DMSO-d₆), δ (ppm): 1.19 (9H, s), 1.63-1.74 (4H, m),
5 2.64 (2H, m), 4.06 (2H, m), 7.15-7.33 (5H, m).

MS: m/z 235 (M+H)⁺

Step 2

4-[4-(2-Bromoacetyl)phenyl]butyl pivalate was prepared from the compound of Step 1 of Production Example 7 in a
10 manner similar to Step 1 of Production Example 5.

¹H-NMR (DMSO-d₆), δ (ppm): 1.16 (9H, s), 1.68-1.79 (4H, m),
2.72 (2H, t, J = 7.1 Hz), 4.08 (2H, t, J = 5.9 Hz), 4.43 (2H,
s), 7.30 (2H, d, J = 8.0 Hz), 7.92 (2H, d, J = 8.0 Hz).

MS: 355, 357 (M+H)⁺

15 Step 3

4-[4-(2-Amino-1,3-thiazol-4-yl)phenyl]butyl pivalate was prepared from the compound of Step 2 of Production Example 7 in a manner similar to Step 2 of Production Example 5.

MS: 333 (M+H)⁺

20 Step 4

4-{4-[2-(Acetylamino)-1,3-thiazol-4-yl]phenyl}butyl pivalate was prepared from the compound of Step 3 of Production Example 7 in a manner similar to Step 7 of Production Example 1.

25 ¹H-NMR (DMSO-d₆), δ (ppm): 1.19 (9H, s), 1.69 (4H, m), 2.67 (2H, br), 4.08 (2H, br), 7.23 (2H, d, J = 8.0 Hz), 7.72 (2H, d, J = 8.0 Hz), 10.8 (1H, br).

MS: m/z 375 (M+H)

Step 5

30 To a solution of 4-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}butyl pivalate (1.5 g) in MeOH (10 ml) was added

WO 2006/011631

PCT/JP2005/014136

sodium methoxide in MeOH (28 %, 0.89 ml) under ice-cooling. This was stirred at 45 °C for 12 hr. The organic solvent was evaporated to reduced volume and aq. 1N HCl (10 ml) was added to the residue at 5 °C. The mixture was extracted with
5 ethylacetate. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was triturated with IPE to give N-{4-[4-(4-hydroxybutyl)phenyl]-1,3-thiazol-2-yl}acetamide as white powder.

¹H-NMR (DMSO-d₆), δ (ppm): 1.37-1.68 (4H, m), 2.15 (9H, s),
10 2.59 (2H, t, J = 7.4 Hz), 3.41 (2H, t, J = 6.3 Hz), 3.81 (1H, br), 7.24 (2H, d, J = 8.0 Hz), 7.79 (1H, d, J = 8.0 Hz), 12.22 (1H, s).

MS: m/z 291 (M+H)

Step 6

15 N-{4-[4-(4-Bromobutyl)phenyl]-1,3-thiazol-2-yl}acetamide was prepared from the compound of Step 5 of Production Example 7 in a manner similar to Step 6 of Production Example 6.

¹H-NMR (DMSO-d₆), δ (ppm): 1.63-1.89 (4H, m), 2.15 (3H, s),
2.62 (2H, t, J = 7.2 Hz), 3.56 (2H, t, J = 6.4 Hz), 7.25 (2H,
20 d, J = 8.0 Hz), 7.80 (2H, d, J = 8.0 Hz), 12.22 (1H, s).

MS: 353, 355 (M+H)+

Step 7

N-(4-{4-[4-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)butyl]phenyl}-1,3-thiazol-2-yl)acetamide was prepared from
25 the compound of Step 6 of Production Example 7 in a manner similar to Step 7 of Production Example 6.

¹H-NMR (DMSO-d₆), δ (ppm): 1.62 (4H, br), 2.15 (3H, s), 2.62 (2H, br), 3.60 (2H, br), 7.27 (2H, d), 7.51 (1H, s), 7.77 (2H, d), 7.82-7.89 (4H, m), 12.22 (1H, s).

30 MS: m/z 420 (M+H)

Step 8

N-{4-[4-(4-Aminobutyl)phenyl]-1,3-thiazol-2-yl}acetamide was prepared from the compound of Step 7 of Production Example 7 in a manner similar to Step 8 of Production Example 6.

MS: m/z 290 (M+H)

⁵ Step 9

Di-tert-butyl {(E)-[(4-{4-[2-(acetylamino)-1,3-thiazol-4-yl]phenyl}butyl)amino]methylidene}biscarbamate was prepared from the compound of Step 8 of Production Example 7 in a manner similar to Step 13 of Production Example 1.

¹⁰ ¹H-NMR (DMSO-d₆), δ (ppm): 1.37 (9H, s), 1.47 (9H, s), 1.56 (4H, m), 2.15 (3H, s), 2.62 (2H, m), 3.30 (2H, m), 7.25 (2H, d), 7.51 (1H, s), 7.29 (2H, d), 8.30 (1H, t, J = 1.2 Hz), 11.49 (1H, s), 12.21 (1H, s).

MS: m/z 532 (M+H)

¹⁵ Step 10

The title compound was prepared from the compound of Step 9 of Production Example 7 in a manner similar to Step 14 of Production Example 1.

²⁰ ¹H-NMR (DMSO-d₆), δ (ppm): 1.13-1.20 (4H, m), 2.16 (3H, s), 2.62 (2H, t, J = 7.2 Hz), 3.14 (2H, m), 7.23 (2H, d, J = 8.0 Hz), 7.53 (1H, s), 7.68 (2H, m), 7.80 (2H, d, J = 8.0 Hz), 12.23 (1H, s).

MS: m/z 332 (M+H) free

Production Example 8: Synthesis of N-(4-{2-[3-(2-[amino(imino)methyl]amino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl)acetamide hydrochloride

²⁵ Step 1

To a suspension of lithium aluminum hydride in dry tetrahydrofuran (50 ml) was added (3-bromophenyl)acetic acid (10 g) in tetrahydrofuran (100 ml) under ice cooling. The mixture was refluxed for 2 hours. After cooling, to the reaction mixture were added water and aqueous Rochelle salt.

The mixture was stirred for another 30 min. Aqueous layer was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated *in vacuo* to give 2-(3-bromophenyl)ethanol. This compound was used for the next
5 reaction without further purification.

¹H-NMR (200 MHz, CDCl₃), δ (ppm): 1.66 (1H, brs), 2.84 (2H, dd, J=6.5, 14Hz), 3.85 (2H, dt, J=6.5, 2.6Hz), 7.13-7.39 (4H, m).

Step 2

To a solution of 2-(3-bromophenyl)ethanol (7 g) in N,N-
10 dimethylformamide (100 ml) were added tert-butyldimethylsilyl chloride (5.77 g) and imidazole (2.84 g) at 25 °C. The mixture was stirred at 25 °C for 12 hr. The reaction mixture was poured into water (500 ml) and extracted with ethyl acetate (100 ml x2). The combined organic layer was dried over
15 magnesium sulfate and concentrated *in vacuo*. The residue was purified by silica gel column chromatography with mixed solvent of n-hexane and ethyl acetate to give [2-(3-bromophenyl)ethoxy](tert-butyl)dimethylsilane as colorless oil.
¹H-NMR (200 MHz, CDCl₃), δ (ppm): 0.01 (6H, s), 0.88 (9H, s),
20 2.81 (2H, dt, J=6.5, 9.5Hz), 3.81 (2H, dt, J=3.0, 6.5Hz), 7.14-7.39 (5H, brs).

Step 3

To the solution of [2-(3-bromophenyl)ethoxy](tert-butyl)dimethylsilane (2.45 g) in THF (25 ml) was added n-
25 butyl lithium (1.57 M in hexane, 5.58 ml) at -75 °C, and the mixture was stirred at same temperature for 1 hr. Then, DMF (1.69 ml) was added at the same temperature, and the mixture was stirred for 2 hr. The reaction was quenched with aq. ammonium chloride and allowed to room temperature. The
30 mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silicagel column chromatography with hexane and ethyl acetate (20/1 -

10/1) to give 3-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-benzaldehyde (0.8 g) as colourless oil.

¹H-NMR (DMSO-d₆), δ (ppm): 0.01 (6H, s), 0.85 (9H, s), 2.89 (2H, t, J = 6.6 Hz), 3.83 (2H, t, J = 6.6 Hz), 7.44-7.58
5 (2H, m), 7.71-7.74 (2H, m), 10.00 (1H, s).

Step 4

N-(4-{(E)-2-[3-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-phenyl]vinyl}-1,3-thiazol-2-yl)acetamide was prepared from the compound of Step 3 of Production Example 8 in a manner similar
10 to Step 3 of Production Example 2.

¹H-NMR (DMSO-d₆), δ (ppm): 0.00 (6H, s), 0.87 (9H, s), 2.22 (3H, s), 2.83 (2H, t), 3.82 (2H, t), 6.84-7.34 (7H, m), 10.10 (1H, br).

MS: 403 (M+H)+

15 Step 5

To the solution of N-(4-{(E)-2-[3-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenyl]vinyl}-1,3-thiazol-2-yl)acetamide (920 mg) in THF (10 ml) was added tetrabutylammonium fluoride (1 M in THF solution, 4.6 ml) at 0
20 °C. This was stirred at 25 °C for 2 hr and was poured into water. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to give N-(4-{(E)-2-[3-(2-hydroxyethyl)phenyl]vinyl}-1,3-thiazol-2-yl)acetamide (660 mg)
25 as crude oil. This was used for the next reaction without further purification.

¹H-NMR (DMSO-d₆), δ (ppm): 2.22 (3H, s), 2.89 (2H, t, J = 6.5 Hz), 3.25 (1H, m), 3.89 (2H, t, J = 6.5 Hz), 6.84-7.72 (7H, m), 10.00 (1H, br).

30 MS: 289 (M+H)+

Step 6

N-(4-{2-[3-(2-Hydroxyethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide was prepared from the compound of Step 5 of Production Example 8 in a manner similar to Step 11 of
5 Production Example 2.

¹H-NMR (DMSO-d₆), δ (ppm): 2.24 (3H, s), 2.84 (2H, t, J = 6.4 Hz), 2.95 (4H, s), 3.85 (2H, t, J = 6.4 Hz), 6.50 (1H, s), 7.01-7.07 (3H, m), 7.18-7.22 (1H, m).

MS: 291 (M+H)+

10 Step 7

N-(4-{2-[3-(2-Hydroxyethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (300 mg), methanesulfonyl chloride (0.12 ml), diisopropyl ethylamine (0.54 ml) and CH₂Cl₂ (7 ml) were combined at 0 °C under N₂ atmosphere. The reaction mixture
15 was stirred at room temperature for 1 hour, and the precipitate was filtered off. The filtrate was concentrated *in vacuo*. The residue was dissolved in DMF. To the solution were added potassium phthalimide (287 mg) and DMF (5 ml) combined under N₂ atmosphere. The reaction mixture was
20 stirred at 50 °C for 3 hours. After cooled to r.t., AcOEt and 1N-HCl were added to the reaction mixture. The organic layer was washed with water, saturated NaHCO₃ and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography over
25 silica gel with hexane / ethyl acetate (2/3) as an eluent to give N-[4-(2-{3-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide (433.6 mg) as white powder.

¹H-NMR (DMSO-d₆), δ (ppm): 2.31 (3H, s), 2.85-2.99 (6H, m),
30 3.89 (2H, dd, J = 7.8, 6.2 Hz), 6.46 (1H, s), 6.97-7.17 (4H, m), 7.72 (2H, m), 7.82 (2H, m).

MS: 420 (M+H)+

Step 8

N-(4-{2-[3-(2-Aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide was prepared from the compound of Step 7 of Production Example 8 in a manner similar to Step 8 of

5 Production Example 6.

¹H-NMR (DMSO-d₆), δ (ppm): 2.11 (3H, s), 2.61 (2H, m), 2.75 (2H, m), 2.88 (4H, s), 6.72 (1H, s), 6.99-7.21 (4H, m).

MS: 290 (M+H)⁺

Step 9

10 Di-tert-butyl ((Z)-{[2-(3-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)ethyl]amino}methylidene) biscarbamate was prepared from the compound of Step 8 of Production Example 8 in a manner similar to Step 13 of Production Example 1.

15 ¹H-NMR (DMSO-d₆), δ (ppm): 1.46 (9H, s), 1.50 (9H, s), 2.27 (3H, s), 2.84 (2H, t, J = 7.0 Hz), 2.95 (4H, s), 3.66 (2H, dd, J = 7.0, 6.0 Hz), 5.63 (1H, dd, J = 5.0, 1.5 Hz), 6.47 (1H, s), 6.98-7.05 (3H, m), 7.15-7.23 (1H, m), 8.39 (1H, br), 11.50 (1H, br).

20 MS: 532 (M+H)⁺

Step 10

The title compound was prepared from the compound of Step 9 of Production Example 8 in a manner similar to Step 14 of Production Example 1.

25 ¹H-NMR (DMSO-d₆), δ (ppm): 2.12 (3H, s), 2.75 (2H, t, J = 7.3 Hz), 2.94 (4H, br), 3.35 (2H, dt, J = 7.3, 6.2 Hz), 6.74 (1H, s), 7.04-7.25 (8H, m), 7.70 (1H, t, J = 5.4 Hz), 12.09 (1H, br).

MS: m/z 332 (M+H) free

30 Production Example 9: Synthesis of 2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-[amino(imino)methyl]acetamide
Step 1

A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration
5 and washed with ethanol (20 ml) to give (2-amino-1,3-thiazol-4-yl)methyl acetate hydrochloride (3.5 g) as white crystals.
¹H-NMR (DMSO-d₆), δ (ppm): 2.07 (3H, s), 4.92 (2H, s), 6.87 (1H, s).

MS: 173 (M+H)⁺

10 Step 2

To a mixture of (2-amino-1,3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane (560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10
15 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L). The organic layer was dried over sodium sulfate and concentrated *in vacuo*. The residual solid was collected by filtration with isopropyl ether to give (2-(acetylamino)-1,3-
20 thiazol-4-yl)methyl acetate (47 g) as white crystals.

¹H-NMR (CDCl₃), δ (ppm): 2.12 (3H, s), 2.29 (3H, s), 5.08 (2H, s), 6.93 (1H, s).

MS: 215 (M+H)⁺

Step 3

25 A mixture of (2-(acetylamino)-1,3-thiazol-4-yl)methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated *in vacuo*. The residue was diluted with chloroform, and the insoluble material was
30 filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol / chloroform (1/99). The resulted solid was collected by filtration with isopropyl ether to give N-(4-(hydroxymethyl)-1,3-thiazol-2-

yl)acetamide (35 g) as white crystals.

$^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 2.12 (3H, s), 4.44 (2H, d, $J=5.0\text{Hz}$), 5.20 (1H, t, $J=5.0\text{Hz}$), 6.88 (1H, s), 12.02 (1H, brs).

MS: 173 ($\text{M}+\text{H}$) $^+$

5 Step 4

N-(4-(Hydroxymethyl)-1,3-thiazol-2-yl)acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml).

Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at
10 room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated *in vacuo*. The resulting solid was washed with ethyl ether to give N-(4-formyl-1,3-thiazol-2-yl)acetamide (2.01 g) as an off-white solid.

mp. 195.5-199°C

15 $^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 2.17 (3H, s), 8.28 (1H, s), 9.79 (1H, s), 12.47 (1H, brs).

Step 5

To the solution of [4-(bromomethyl)phenyl]acetic acid (5.0 g) in toluene (50 ml) was added triphenylphosphine (5.8
20 g) at 25 °C. This was refluxed for 5 h. After cooling to room temperature, the resulting colourless precipitate was collected by filtration and washed with IPE to give [4-(carboxymethyl)-benzyl](triphenyl)phosphonium bromide (10.7 g) as white powder.

25 $^1\text{H-NMR}$ (DMSO-d_6), δ (ppm): 3.52 (2H, s), 5.13 (2H, d, $J = 15.6\text{ Hz}$), 6.90 (2H, dd, $J = 8.1, 2.3\text{ Hz}$), 7.11 (2H, d, $J = 8.1\text{ Hz}$), 7.58-7.91 (15H, m).

MS: 411 ($\text{M}+\text{H}$) $^+$

Step 6

30 To the solution of [4-(carboxymethyl)benzyl](triphenyl)phosphonium bromide (19.1 g) in DMF (180 ml) was added potassium tert-butoxide (11.9 g) under ice-cooling. This was

stirred at 5 °C for 30 min. To the solution was added N-(4-formyl-1,3-thiazol-2-yl)acetamide (6.0 g) in DMF (18 ml). This was stirred at 25 °C for 3 hr. The mixture was poured into water and was extracted with ethyl acetate. The aqueous phase
5 was acidified (pH 4-5) with 1N HCl to give colourless precipitate. The precipitate was collected by filtration to give a mixture of (4-{(E)-2-[2-(acetylamino)-1,3-thiazol-4-yl]vinyl}phenyl)acetic acid and (4-{(Z)-2-[2-(acetylamino)-1,3-thiazol-4-yl]vinyl}phenyl)acetic acid (10 g) as white
10 powder.

¹H-NMR (DMSO-d₆), δ (ppm): 2.12, 2.14 (3x5/6, 3x1/6H, s), 3.52, 3.54 (2x5/6, 2x1/6H, s), 6.46 (5/6H, d, J = 12.7 Hz), 6.54 (5/6H, d, J = 12.7 Hz), 6.95 (1H, s), 7.11-7.49 (4+1/6H, m), 12.09 (1H, br).

15 MS: 303 (M+H)+

Step 7

(4-{2-[2-(Acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)acetic acid was prepared from the compound of Step 6 of Production Example 9 in a manner similar to Step 11
20 of Production Example 2.

¹H-NMR (DMSO-d₆), δ (ppm): 2.11 (3H, s), 2.88 (4H, s), 3.50 (2H, s), 6.74 (1H, s), 7.14 (4H, s), 12.08 (1H, s).

MS: m/z 305 (M+H)

Step 8

25 To a solution of (4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)acetic acid (2.0 g) in DMF (15 ml) was added N,N'-carbonyldiimidazole (1.6 g). The mixture was stirred at 50 °C for 2 hr, To the mixture was added a solution of guanidine hydrochloride (3.1 g) and sodium methoxyde (28 %
30 MeOH solution, 6.4 ml) in DMF (5 ml) at 25 °C. The reaction mixture was stirred at 25 °C for 12 hr. The organic solvent was evaporated to reduced volume and the residue was poured

into water. To the mixture was added 1N HCl to adjust pH to 8. The mixture was extracted with ethyl acetate. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silicagel (amine coated) column chromatography with CH₂Cl₂ and MeOH (10/1) as an eluent to give 2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-[amino(imino)methyl]acetamide (1.4 g) as colourless powder.

¹H-NMR (DMSO-d₆), δ (ppm): 2.10 (3H, s), 2.86 (4H, m), 3.34 (2H, s), 6.74 (1H, s), 7.08 (2H, d, J=8.1 Hz), 7.12 (2H, d, J=8.1 Hz), 12.22 (1H, br).

MS: m/z 346 (M+H)

Production Example 10: Synthesis of N-[4-(2-{4-[(2-{[amino(imino)methyl]amino}ethyl)amino]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide dihydrochloride

Step 1

A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino-1,3-thiazol-4-yl)methyl acetate hydrochloride (3.5 g) as white crystals.

¹H-NMR (DMSO-d₆), δ (ppm): 2.07 (3H, s), 4.92 (2H, s), 6.87 (1H, s).

MS: 173 (M+H)⁺

Step 2

To a mixture of (2-amino-1,3-thiazol-4-yl)methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane (560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L). The organic layer was dried over sodium sulfate and

WO 2006/011631

PCT/JP2005/014136

concentrated *in vacuo*. The residual solid was collected by filtration with isopropyl ether to give (2-(acetylamino)-1,3-thiazol-4-yl)methyl acetate (47 g) as white crystals.

¹H-NMR (CDCl₃), δ (ppm): 2.12 (3H, s), 2.29 (3H, s), 5.08 (2H, s), 6.93 (1H, s).

MS: 215 (M+H)⁺

Step 3

A mixture of (2-(acetylamino)-1,3-thiazol-4-yl)methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated *in vacuo*. The residue was diluted with chloroform, and the insoluble material was filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol / chloroform (1/99). The resulted solid was collected by filtration with isopropyl ether to give N-(4-(hydroxymethyl)-1,3-thiazol-2-yl)acetamide (35 g) as white crystals.

¹H-NMR (DMSO-d₆), δ (ppm): 2.12 (3H, s), 4.44 (2H, d, J=5.0Hz), 5.20 (1H, t, J=5.0Hz), 6.88 (1H, s), 12.02 (1H, brs).
MS: 173 (M+H)⁺

Step 4

N-(4-(Hydroxymethyl)-1,3-thiazol-2-yl)acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml). Then, manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 7 hours, and filtered through a celite pad. The filtrate was concentrated *in vacuo*. The resulting solid was washed with ethyl ether to give N-(4-formyl-1,3-thiazol-2-yl)acetamide (2.01 g) as an off-white solid.

mp. 195.5-199 °C

¹H-NMR (DMSO-d₆), δ (ppm): 2.17 (3H, s), 8.28 (1H, s), 9.79 (1H, s), 12.47 (1H, brs).

Step 5

1-(Bromomethyl)-4-nitrobenzene (1.9 g),
triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml)
were combined under nitrogen atmosphere. The reaction mixture
was stirred at room temperature for 2.5 hours. Then, potassium
5 tert-butoxide (1.19 g) and N-(4-formyl-1,3-thiazol-2-
yl)acetamide (1.5 g) were added and the mixture was stirred at
room temperature for 14 hours. The reaction mixture was poured
into ice-water and extracted with ethyl acetate. The organic
layer was washed with 1N-hydrochloric acid, water and
10 saturated sodium chloride solution, dried over anhydrous
magnesium sulfate, and concentrated *in vacuo*. The residue was
purified by flash column chromatography over silica gel with
n-hexane / ethyl acetate (1:1) → (1:2) as an eluent, and
trituated with ethyl ether to give N-{4-[(Z)-2-(4-
15 nitrophenyl)ethenyl]-1,3-thiazol-2-yl}acetamide (1.59 g) as a
yellow solid.

mp. 155-157 °C

¹H-NMR (DMSO-d₆), δ (ppm): 2.13 (3H, s), 6.64 (1H, d, J=12.5Hz),
6.71 (1H, d, J=12.5Hz), 7.18 (1H, s), 7.79 (2H, d, J=9.0Hz),
20 8.17 (2H, d, J=9.0Hz), 12.02 (1H, brs).

MS: 290 (M+H)⁺

Step 6

A mixture of N-{4-[(Z)-2-(4-nitrophenyl)ethenyl]-1,3-
thiazol-2-yl}acetamide (2 g) and 10% palladium on carbon (400
25 mg) in methanol (25 ml), tetrahydrofuran (25 ml) and acetic
acid (18 ml) was stirred under 4 atm hydrogen at ambient
temperature for 5 hours. The reaction mixture was filtered
through a celite pad, and the filtrate was concentrated *in vacuo*. The residue was dissolved in ethyl acetate. The
30 organic solution was washed with saturated sodium hydrogen
carbonate solution and saturated sodium chloride solution,
dried over anhydrous magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography

over silica gel with n-hexane / ethyl acetate (1:2) → ethyl acetate as an eluent, and triturated with ethyl alcohol / ethyl ether to give N-{4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl}acetamide (539.6 mg) as an off-white solid.

5 mp. 102.5-104 °C

¹H-NMR (DMSO-d₆), δ (ppm): 2.11 (3H, s), 2.75 (4H, brs), 4.82 (2H, s), 6.46 (2H, d, J=8.5Hz), 6.69 (1H, s), 6.83 (2H, d, J=8.5Hz), 12.07 (1H, brs).

MS: 262 (M+H)⁺

10 Step 7

To a suspension of N-{4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl}acetamide (100mg) in toluene were added tert-butyl (2-bromoethyl)carbamate (87.5 mg) and N,N-diisopropylethylamine (52 μl), and the mixture was stirred at
15 80 °C for 24 hr. The reaction mixture was allowed to cool to room temperature, water (10 ml) was added, and the organic layer was separated, washed with saturated aqueous NaCl solution, dried over MgSO₄, filtered, and concentrated *in vacuo* to give tert-butyl {2-[(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)amino]ethyl}carbamate (41.0 mg) as pale brown
20 amorphous.

¹H-NMR (CDCl₃) δ (ppm): 1.45 (9H, s), 2.23 (3H, s), 2.86 (4H, s), 3.15-3.28 (2H, m), 3.15-3.47 (2H, m), 4.64-5.02 (1H, brs), 6.49 (1H, s), 6.52 (2H, d, J=8.0Hz), 6.95 (2H, d, J=8.0Hz), 9.22-
25 10.10 (1H, brs).

MS: 405.2 (M+H)⁺, 427.3 (M+Na)⁺

Step 8

tert-Butyl {2-[(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)amino]ethyl}carbamate (50.7 mg) and 4N-HCl in
30 dioxane (2 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at 20 °C for 1hr. The solvent was removed *in vacuo*. The residue was solidified with AcOEt to give N-[4-(2-{4-[(2-aminoethyl)amino]phenyl}ethyl)-1,3-thiazol-2-

yl]acetamide dihydrochloride (28.9 mg) as a pale brown solid.

¹H-NMR (DMSO-d₆) δ (ppm): 2.11(3H, s), 2.81(4H, s), 2.92-3.05(2H, m), 3.29(2H, t, J=6.2Hz), 6.67(2H, d, J=7.7Hz), 7.01(2H, d, J=8.1Hz), 7.87-8.24(3H, brs), 12.08(1H, s).

5 MS: 305.2 (M+H)⁺, 327.2 (M+Na)⁺ Free

Step 9

N-[4-(2-{4-[(2-Aminoethyl)amino]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide dihydrochloride (20.3 mg), N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamide (16.7
10 mg), N,N-diisopropylethylamine (28.1 μl), THF (0.5 ml) and DMF (0.1 ml) were combined under N₂ atmosphere, and the mixture was stirred at 15 °C for 14 hr. Volatiles were evaporated and the residue was dissolved in MeOH (0.5 ml). The reaction
15 mixture was stirred at 20 °C for 3 hr, and then AcOEt (20 ml) was added, and the mixture was washed with water and brine, dried over MgSO₄, and evaporated to give crude yellow oil (26.9 mg). The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give di-tert-butyl [(Z)-({2-[(4-{2-[2-(acetylamino)-1,3-thiazol-4-
20 yl]ethyl}phenyl)amino]ethyl}amino)methylidene]biscarbamate as pale yellow oil (23.8 mg).

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.48 (9H, s), 1.52 (9H, s), 2.22 (3H, s), 2.75 - 3.01 (4H, m), 3.20 - 3.38 (2H, m), 3.55 -
25 3.76 (2H, m), 4.15 - 4.68 (1H, brs), 6.51 (1H, s), 6.55 (2H, d, J = 8.4Hz), 6.97 (2H, d, J = 8.4Hz), 8.56 (1H, t, J=5.5Hz), 9.91 - 10.46 (1H, brs), 11.46 (1H, s).

MS: 547.28 (M+H)⁺

Step 10

30 The title compound was prepared from the compound of Step 9 of Production Example 10 in a manner similar to Step 15 of Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.81 (4H, s), 3.15 - 3.23 (2H, m), 3.28 - 3.38 (2H, m), 6.6 - 6.75 (3H, m), 7 (2H, d, J = 8Hz), 7.17 (4H, brs), 7.62 (1H, t, J = 5.1Hz), 12.07 (1H, s).

5 MS: 347.2 (M+H)⁺ free

Production Example 11: Synthesis of N-[4-(2-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]-2-{[amino(imino)methyl]amino}acetamide hydrochloride

Step 1

10 3-(4-Mercaptophenyl)propanoic acid (5 g), K₂CO₃ (11.4 g) and DMF (30 ml) were combined, and iodomethane (5.12 ml) was added dropwise to the mixture at 0 °C under N₂ atmosphere. The reaction mixture was stirred at r.t. for 13 hours, and poured into ice-water. The mixture was extracted with AcOEt. The
15 organic layer was washed with water (twice) and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo* to give methyl 3-[4-(methylthio)phenyl]propanoate (4.19 g) as pale yellow oil.

¹H-NMR (CDCl₃), δ (ppm): 2.47 (3H, s), 2.61 (2H, t, J=8.0Hz),
20 2.91 (2H, t, J=8.0Hz), 3.67 (3H, s), 7.12 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz).

Step 2

28% Sodium methoxide solution in MeOH (3.67 ml) were added dropwise to the mixture of methyl 3-[4-(
25 (methylthio)phenyl]propanoate (4 g) and diethyl oxalate (5.17 ml) at 0 °C with stirring. The reaction mixture was stirred at 65 °C for 30 minutes under reduced pressure. 15% Aqueous H₂SO₄ (35 ml) was added to the mixture, and the mixture was refluxed for 15 hours. After cooled to r.t., the mixture was extracted
30 with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residual oil was dissolved in EtOH (20 ml), and conc. H₂SO₄ (0.4 ml) was added dropwise to the solution. The reaction

mixture was refluxed for 2 hours. After cooled to r.t., EtOH was removed *in vacuo*. AcOEt and water were added to the residue, and the mixture was extracted. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with *n*-hexane / AcOEt (6:1) as an eluent to give ethyl 4-[4-(methylthio)phenyl]-2-oxobutanoate (2.43 g) as a yellow liquid.

¹H-NMR (CDCl₃), δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.46 (3H, s), 2.92 (2H, t, J=7.0Hz), 3.16 (2H, t, J=7.0Hz), 4.31 (2H, q, J=7.0Hz), 7.13 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz).

Step 3

To a suspension of copper(II) bromide (6.11 g) in AcOEt (110 ml) was added a solution of ethyl 4-[4-(methylthio)phenyl]-2-oxobutanoate (2.3 g) in 55 ml of CHCl₃. The reaction mixture was refluxed for 17 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / *n*-hexane (1:1). The solvent was removed *in vacuo* to give ethyl 3-bromo-4-[4-(methylthio)phenyl]-2-oxobutanoate (2.56 g) as yellow oil.

¹H-NMR (CDCl₃), δ (ppm): 1.37 (3H, t, J=7.0Hz), 2.47 (3H, s), 3.20 (1H, dd, J=14.5, 7.5Hz), 3.49 (1H, dd, J=14.5, 7.5Hz), 4.35 (2H, q, J=7.0Hz), 5.22 (1H, d, J=7.5Hz), 7.17 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz).

Step 4

Ethyl 3-bromo-4-[4-(methylthio)phenyl]-2-oxobutanoate (2.4 g) was dissolved in EtOH (40 ml), and then thiourea (1.1 g) was added to the solution. The reaction mixture was refluxed for 1 hour under N₂ atmosphere. The cooled reaction mixture was evaporated *in vacuo*. Saturated NaHCO₃ and water were added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The

residue was purified by flash column chromatography over silica gel with CHCl_3 / MeOH (20:1) as an eluent to give ethyl 2-amino-5-[4-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (2.01 g) as yellow amorphous.

¹H-NMR (DMSO-d_6), δ (ppm): 1.25 (3H, t, $J=7.0\text{Hz}$), 2.44 (3H, s), 4.20 (2H, q, $J=7.0\text{Hz}$), 4.28 (2H, s), 7.02 (2H, s), 7.19 (4H, s).

MS: 309 ($\text{M}+\text{H}$)⁺

Step 5

10 Ethyl 2-amino-5-[4-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (1.9 g) was dissolved in CH_2Cl_2 (38 ml) and pyridine (1.05 ml), and then acetyl chloride (0.482 ml) was added dropwise to the solution at 0 °C under N_2 atmosphere. The reaction mixture was stirred at r.t. for 1 hour. The organic
15 solution was washed with 1N-HCl, water and brine, dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The residual solid was washed with IPE to give ethyl 2-(acetylamino)-5-[4-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (2.01 g) as an off-white solid.

20 mp. 205-206 °C

¹H-NMR (DMSO-d_6), δ (ppm): 1.28 (3H, t, $J=7.0\text{Hz}$), 2.09 (3H, s), 2.45 (3H, s), 4.27 (2H, q, $J=7.0\text{Hz}$), 4.43 (2H, s), 7.22 (4H, s), 12.41 (1H, s).

MS: 351 ($\text{M}+\text{H}$)⁺

25 Step 6

Ethyl 2-(acetylamino)-5-[4-(methylthio)benzyl]-1,3-thiazole-4-carboxylate (1.0 g) was dissolved in THF (20 ml), and then lithium borohydride (124 mg) was added portionwise to the solution at 0 °C. The reaction mixture was refluxed for
30 4.5 hours and the reaction was quenched with MeOH. The mixture was concentrated *in vacuo*, and purified by flash column chromatography over silica gel with CHCl_3 / MeOH (20:1) as an eluent. The residual off-white solid (548.5 mg) was dissolved

in MeOH (2 ml) and CHCl₃ (20 ml). Then, manganase(IV) oxide (2.48 g) was added to the solution under N₂ atmosphere. The reaction mixture was stirred at r.t. for 12 hours, and filtered through a celite pad. The filtrate was concentrated
5 in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (20:1) as an eluent to give N-{4-formyl-5-[4-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide (500.1 mg) as a yellow wax.

¹H-NMR (DMSO-d₆), δ (ppm): 2.12 (3H, s), 2.45 (3H, s), 4.48
10 (2H, s), 7.23 (4H, s), 10.03 (1H, s), 12.33 (1H, s).

MS: 307 (M+H)⁺

Step 7

1-(Bromomethyl)-4-nitrobenzene (564 mg), triphenylphosphine (685 mg) and DMF (9 ml) were combined under
15 N₂ atmosphere. The reaction mixture was stirred at r.t. for 2 hours. Then, potassium tert-butoxide (345 mg) and N-{4-formyl-5-[4-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide (470.5 mg) were added to the mixture, and the mixture was stirred at r.t. for 2 hours. The reaction mixture was poured into ice-water,
20 and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHCl₃ / AcOEt (1:1) as an eluent to give a mixture of N-{5-[4-(methylthio)benzyl]-4-
25 [(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide and N-{5-[4-(methylthio)benzyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (671 mg) as yellow amorphous.

¹H-NMR (DMSO-d₆), δ (ppm): 2.08 (3Hx2/3, s), 2.12 (3Hx1/3, s),
30 2.44 (3H, s), 4.04 (2Hx2/3, s), 4.30 (2Hx1/3, s), 6.71 (1Hx2/3, d, J=12.5Hz), 6.84 (1Hx2/3, d, J=12.5Hz), 7.18 (4Hx2/3, s), 7.23 (4Hx1/3, s), 7.24 (1Hx1/3, d, J=15.5Hz), 7.40 (1Hx1/3, d, J=15.5Hz), 7.65 (2Hx2/3, d, J=9.0Hz), 7.92

WO 2006/011631

PCT/JP2005/014136

(2Hx1/3, d, J=9.0Hz), 8.12 (2Hx2/3, d, J=9.0Hz), 8.22 (2Hx1/3, d, J=9.0Hz), 11.85 (1Hx2/3, brs), 12.16 (1Hx1/3, brs).

MS: 426 (M+H)⁺

Step 8

5 Potassium peroxymonosulfate (1.41 g) was suspended in water (4 ml) and THF (4 ml), and then a mixture of N-{5-[4-(methylthio)benzyl]-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide and N-{5-[4-(methylthio)benzyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (E : Z =
10 1 : 2) (650 mg) in THF (9 ml) was added dropwise to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 1 hour, and then water was added to the suspension. The mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and
15 concentrated *in vacuo* to give a mixture of N-{5-[4-(methylsulfonyl)benzyl]-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide and N-{5-[4-(methylsulfonyl)benzyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (E : Z = 1 : 2) (693.3 mg) as yellow amorphous.

20 Z : E = 2 : 1

¹H-NMR (DMSO-d₆), δ (ppm): 2.09 (3Hx2/3, s), 2.13 (3Hx1/3, s), 3.18 (3H, s), 4.24 (2Hx2/3, s), 4.49 (2Hx1/3, s), 6.73 (1Hx2/3, d, J=12.5Hz), 6.86 (1Hx2/3, d, J=12.5Hz), 7.33 (1Hx1/3, d, J=15.5Hz), 7.41-7.97 (5/3H, m), 7.48 (2Hx2/3, d, J=9.0Hz), 7.55 (2Hx1/3, d, J=9.0Hz), 7.65 (2Hx2/3, d, J=9.0Hz), 7.85 (2Hx2/3, d, J=9.0Hz), 8.14 (2Hx2/3, d, J=9.0Hz), 8.22 (2Hx1/3, d, J=9.0Hz), 11.90 (1Hx2/3, s), 12.22 (1Hx1/3, s).

MS: 458 (M+H)⁺

30 Step 9

A mixture of N-{5-[4-(methylsulfonyl)benzyl]-4-[(E)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide and N-{5-[4-(methylsulfonyl)benzyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-

thiazol-2-yl}acetamide (E : Z = 1 : 2) (380 mg), 10% palladium on carbon (380 mg), MeOH (3.5 ml), THF (3.5 ml) and AcOH (0.5 ml) were combined. The reaction mixture was stirred under 3 atm H₂ at r.t. for 3 hours, and filtered through a celite pad.
5 The filtrate was concentrated *in vacuo*. 1N-NaOH was added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography over silica gel with
10 CHCl₃ / MeOH (30:1→10:1) as an eluent to give N-{4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (161.8 mg) as off-white amorphous.
¹H-NMR (DMSO-d₆), δ (ppm): 2.08 (3H, s), 2.58-2.87 (4H, m), 3.18 (3H, s), 3.98 (2H, s), 4.85 (2H, s), 6.46 (2H, d, J=8.5Hz), 6.77 (2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz), 7.82
15 (2H, d, J=8.5Hz), 12.02 (1H, s).

MS: 430 (M+H)⁺

Step 10

A mixture of N-{4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide (73.3 mg),
20 [(tert-butoxycarbonyl)amino]acetic acid (29.9 mg), 1-hydroxybenzotriazole (25.4 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (34.3 mg) in DMF (1 ml) was stirred at r.t. for 7 hours. The reaction
25 mixture was poured into saturated NaHCO₃, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was purified by preparative silica gel chromatography with CHCl₃ / MeOH (20:1) as an eluent to give tert-butyl (2-
30 {[4-(2-{2-(acetyl-amino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}-2-oxoethyl)carbamate (75 mg) as an off-white solid.

Step 11

tert-Butyl (2-{[4-(2-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}-2-oxoethyl)carbamate (61.2 mg) and 4N HCl in 1,4-dioxane solution (1 ml) were combined under N₂ atmosphere. The
5 reaction mixture was stirred at r.t. for 1 hour. The solvent was removed *in vacuo*. The residue was solidified with AcOEt to give N-[4-(2-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]-2-aminoacetamide hydrochloride (56.2 mg) as an off-white solid.

10 Step 12

N-[4-(2-{2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]-2-aminoacetamide hydrochloride (30 mg), N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (17.8 mg), N,N-diisopropylethylamine (20.0 μl),
15 THF (0.5 ml) and DMF (0.1 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at 15 °C for 14 hr, and concentrated *in vacuo*. The residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give di-tert-
20 butyl {(Z)-[(2-{[4-(2-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}-2-oxoethyl)amino]methylidene}biscarbamate as a colorless solid (17.3 mg).

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.50 (18H, s), 2.24 (3H, s),
25 2.74 - 2.94 (4H, m), 3.05 (3H, s), 3.85 (2H, s), 4.21 (2H, d, J = 5.7Hz), 6.9 (2H, d, J = 8.3Hz), 7.08 (2H, d, J = 8.3Hz), 7.35 (2H, d, J = 8.4Hz), 7.75 (2H, d, J = 8.2Hz), 8.99 (1H, t, J = 5.5Hz), 9.32 - 9.48 (1H, brs), 9.53 (1H, s), 11.35 (1H, s).

30 MS: 729.29 (M+H)+

Step 13

The title compound was prepared from the compound of Step 12 of Production Example 11 in a manner similar to Step 15 of Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.09 (3H, s), 2.84 (4Hx3/4, s), 2.88 (4Hx1/4, s), 3.17 (3Hx3/4, s), 3.19 (3Hx1/4, s), 3.98 - 4.07 (4H, m), 7.02 - 7.64 (11H, m), 7.78 (2Hx3/4, d, J = 8.4Hz), 7.84 (2Hx1/4, d, J = 8.4Hz), 10.18 (1H, s), 12.05 (1H, s).

MS: 529.2 (M+H)⁺ free

Production Example 12: Synthesis of (3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide dihydrochloride

Step 1

To a solution of N-{4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (293 mg) in acetic acid (1.8 ml) were added methyl (3R)-3-pyrrolidinecarboxylate hydrochloride (201 mg) and paraformaldehyde (36.5 mg), and the mixture was stirred at 100 °C (bath temp.) for 2 hr. The solvent was removed *in vacuo*, the residue was adjusted to pH=9 with saturated aq. NaHCO₃, extracted with AcOEt. The organic layer was washed with brine, dried over MgSO₄ and evaporated to give methyl (3R)-1-({2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl}methyl)-3-pyrrolidinecarboxylate as orange foam (402.2 mg), that was used as crude in the next reaction.

MS: 431.18 (M+H)⁺

Step 2

Methyl (3R)-1-({2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl}methyl)-3-pyrrolidinecarboxylate (400 mg), MeOH (7 ml), THF (7 ml) and then 10 % Pd/C (50 % wet) (810 mg) were combined under N₂

atmosphere. The mixture was stirred at 15 °C for 10 min under H₂ atmosphere (3 atm). The reaction mixture was filtered through a celite pad, and the filtrate was concentrated *in vacuo* to give yellow foam (367.1 mg, 101.3 %, MS: 403.20

5 (M+H)⁺).

To a solution of the yellow foam (367.1 mg) in THF (4.5 ml) was added N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamide (419 mg), and the mixture was stirred for 62 hr at 15 °C. Volatiles were evaporated, and the residue (895.9
10 mg) was purified by flash column chromatography over silica gel with CHCl₃ : AcOEt (100:0-100:2) as an eluent to give methyl (3R)-1-[(2-(acetylamino)-4-{2-[4-({(Z)-[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}-amino)phenyl]ethyl}-1,3-thiazol-5-yl)methyl]-3-pyrrolidinecarboxylate (237.8 mg) as pale yellow foam.
15

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.53 (9H, s), 1.98 - 2.14 (2H, m), 2.22 (3H, s), 2.39 - 2.76 (3H, m), 2.78 - 3.11 (6H, m), 3.55 (2H, s), 3.68 (3H, s), 7.07 (2H, d, J = 8.5Hz), 7.45 (2H, d, J = 8.5Hz), 9.06 (1H, brs), 10.24 (1H, s), 11.64
20 (1H, s).

MS: 645.3 (M+H)⁺, 667.3 (M+Na)⁺

Step 3

Methyl (3R)-1-[(2-(acetylamino)-4-{2-[4-({(Z)-[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)phenyl]ethyl}-1,3-thiazol-5-yl)methyl]-3-pyrrolidinecarboxylate (232.2 mg), 1N-NaOH (0.9 ml) and dioxane (3 ml) were combined at 0 °C, and the mixture was stirred at 20 °C for 2 hr. To the mixture was added 1N-HCl (0.9 ml), and the solvent was evaporated *in vacuo*. To the
30 residue was added CHCl₃. The insoluble salt was removed by filtration, and the filtrate was concentrated *in vacuo* to

give (3R)-1-[(2-(acetylamino)-4-{2-[4-((Z)-[(tert-butoxycarbonyl)amino]-[(tert-butoxycarbonyl)imino]methyl}amino)phenyl]ethyl}-1,3-thiazol-5-yl)methyl]-3-pyrrolidinecarboxylic acid (175.5 mg) as a
 5 white solid, that was used as crude in the next reaction.
 MS: 631.29 (M+H)+

Step 4

To a solution of (3R)-1-[(2-(acetylamino)-4-{2-[4-((Z)-[(tert-butoxycarbonyl)amino]-[(tert-butoxycarbonyl)imino]methyl}amino)phenyl]ethyl}-1,3-thiazol-5-yl)methyl]-3-pyrrolidinecarboxylic acid (60 mg) in 0.5 ml of
 10 dichloromethane were added methylamine hydrochloride (10.1 mg), 1-hydroxybenzotriazole hydrate (HOBt, 19.3 mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
 15 (EDCI, 52.118 μ l), and then the mixture was stirred for 14 hr at 20 °C. The reaction mixture was diluted with 4ml of dichloromethane and washed with water. The organic layer was dried over diatomaceous earth and evaporated under vacuum to give crude pale yellow oil. The crude oil was purified by
 20 preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give di-tert-butyl {(Z)-[(4-{2-[2-(acetylamino)-5-((3R)-3-[(dimethylamino)carbonyl]-1-pyrrolidinyl)methyl)-1,3-thiazol-4-yl]ethyl}phenyl)amino]methylidene}biscarbamate
 25 (45.4 mg) as a white solid.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.54 (9H, s), 1.96 - 2.11 (2H, m), 2.22 (3H, s), 2.31 - 2.42 (1H, m), 2.44 - 2.53 (1H, m), 2.82 - 2.92 (5H, m), 2.94 (3H, s), 3.01 (3H, s), 3.01 - 3.08 (1H, m), 3.15 - 3.27 (1H, m), 3.57 (2H, s),
 30 7.08 (2H, d, J = 8.4Hz), 7.46 (2H, d, J = 8.4Hz), 8.88 (1H,

brs), 10.24 (1H, s), 11.63 (1H, s).

MS: 659.3 (M+H)+, 680.3 (M+Na)+

Step 5

The title compound was prepared from the compound of Step 4 of Production Example 12 in a manner similar to Step 15 of Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.72 - 3.74 (20H, m), 4.42 - 4.57 (2H, m), 7.12 - 7.18 (2H, m), 7.27 - 7.35 (2H, m), 7.43 (4H, brs), 9.91 (1Hx3/5, m), 9.97 (1Hx2/5, m), 10.26 (1Hx2/5, m), 11.01 (1Hx3/5, m), 12.32 (1Hx3/5, m), 12.34 (1Hx2/5, m).

MS: 458.4 (M+H)+, 480.2 (M+Na)+ free

Production Example 13: Synthesis of (3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-3-pyrrolidinecarboxamide dihydrochloride
Step 1

Di-tert-butyl {(Z)-[(4-{2-[2-(acetylamino)-5-({(3R)-3-[(methylamino)carbonyl]-1-pyrrolidinyl}methyl)-1,3-thiazol-4-yl]ethyl}phenyl)amino]methylidene}biscarbamate was prepared from the compound of Step 3 of Production Example 12 in a manner similar to Step 4 of Production Example 12.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.54 (9H, s), 1.88 - 1.99 (1H, m), 2.09 - 2.21 (1H, m), 2.24 (3H, s), 2.25 - 2.37 (2H, m), 2.78 (3H, d, J = 4.7Hz), 2.79 - 2.37 (7H, m), 3.52 (1H, d, J = 13.9Hz), 3.58 (1H, d, J = 14.2Hz), 6.75 (1H, d, J = 4.4Hz), 7.06 (2H, d, J = 8.4Hz), 7.45 (2H, d, J = 8.4Hz), 8.91 (1H, brs), 10.24 (1H, s), 11.63 (1H, s).

MS: 644.2 (M+H)+, 666.3 (M+Na)+

Step 2

The title compound was prepared from the compound of Step 1 of Production Example 13 in a manner similar to Step 15 of Production Example 2.

WO 2006/011631

PCT/JP2005/014136

¹H-NMR (400MHz, DMSO-d₆): 1.79 - 3.74 (17H, m), 4.41 - 4.57 (2H, m), 7.11 - 7.18 (2H, m), 7.27 - 7.35 (2H, m), 7.42 (4H, brs), 8.13 - 8.25 (1H, m), 9.88 (1Hx2/3, s), 9.95 (1Hx1/3, s), 10.34 (1Hx1/3, brs), 10.99 (1Hx2/3, brs), 12.32 (1Hx2/3, s),
 5 12.33 (1Hx1/3, s).

MS: 444.2 (M+H)+, 466.1 (M+Na)+ free

Production Example 14: Synthesis of (3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl)methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide
 10 dihydrochloride

Step 1

Methyl (3S)-1-({2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl)methyl)-3-pyrrolidinecarboxylate was prepared from N-{4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide in a manner
 15 similar to Step 1 of Production Example 12.

MS: 431.16 (M+H)+

Step 2

Methyl (3S)-1-[(2-(acetylamino)-4-{2-[4-((Z)-[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl)-amino]phenyl]ethyl}-1,3-thiazol-5-yl)methyl]-3-pyrrolidinecarboxylate was prepared from the compound of Step 1 of Production Example 14 in a manner similar to Step 2 of
 20 Production Example 12.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.53 (9H, s), 1.99 - 2.14 (2H, m), 2.22 (3H, s), 2.38 - 2.75 (3H, m), 2.79 - 3.07 (6H, m), 3.53 (2H, s), 3.68 (3H, s), 7.07 (2H, d, J = 8.5Hz), 7.46 (2H, d, J = 8.5Hz), 9.51 (1H, brs), 10.24 (1H, s), 11.64 (1H, s).

30 MS: 645.3 (M+H)+, 667.3 (M+Na)+

Step 3

(3S)-1-[(2-(Acetylamino)-4-{2-[4-((Z)-[(tert-

butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}
 amino)phenyl]ethyl}-1,3-thiazol-5-yl)methyl]-3-
 pyrrolidinecarboxylic acid was prepared from the compound of
 Step 2 of Production Example 14 in a manner similar to Step 3
 5 of Production Example 12.

MS: 631.29 (M+H)+

Step 4

Di-tert-butyl {(Z)-[(4-{2-[2-(acetylamino)-5-({(3S)-3-
 [(dimethylamino)carbonyl]-1-pyrrolidinyl)methyl]-1,3-
 10 thiazol-4-yl]ethyl}phenyl)amino]methylidene)biscarbamate was
 prepared from the compound of Step 3 of Production Example 14
 in a manner similar to Step 4 of Production Example 12.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.54 (9H, s),
 1.96 - 2.12 (2H, m), 2.22 (3H, s), 2.31 - 2.41 (1H, m), 2.44
 15 - 2.52 (1H, m), 2.82 - 2.92 (5H, m), 2.94 (3H, s), 3.01 (3H,
 s), 3.01 - 3.08 (1H, m), 3.15 - 3.27 (1H, m), 3.57 (2H, s),
 7.08 (2H, d, J = 8.4Hz), 7.46 (2H, d, J = 8.8Hz), 8.87 (1H,
 brs), 10.24 (1H, s), 11.63 (1H, s).

MS: 658.3 (M+H)+, 680.3 (M+Na)+

Step 5

The title compound was prepared from the compound of Step
 4 of Production Example 14 in a manner similar to Step 15 of
 Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.74 - 3.73 (20H, m), 4.42 -
 25 4.58 (2H, m), 7.12 - 7.19 (2H, m), 7.27 - 7.35 (2H, m), 7.42
 (4H, brs), 9.87 (1Hx4/7, s), 9.93 (1Hx3/7, s), 10.22 (1Hx3/7,
 brs), 10.94 (1Hx4/7, brs), 12.32 (1Hx4/7, s), 12.34 (1Hx3/7,
 s).

MS: 458.4 (M+H)+, 480.2 (M+Na)+ free

30 Production Example 15: Synthesis of (3S)-1-({2-(acetylamino)-
 4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-
 5-yl)methyl)-N-methyl-3-pyrrolidinecarboxamide dihydrochloride

Step 1

Di-tert-butyl {(Z)-[(4-{2-[2-(acetylamino)-5-({(3S)-3-
[(methylamino)carbonyl]-1-pyrrolidinyl)methyl]-1,3-thiazol-
4-yl]ethyl}phenyl)amino]methylidene}biscarbamate was prepared
5 from the compound of Step 3 of Production Example 14 in a
manner similar to Step 4 of Production Example 12.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.54 (9H, s), 1.88
- 1.99 (1H, m), 2.09 - 2.21 (1H, m), 2.24 (3H, s), 2.26 - 2.37
(2H, m), 2.76 - 2.94 (10H, m), 3.52 (1H, d, J = 13.9Hz), 3.58
10 (1H, d, J = 13.9Hz), 6.76 (1H, d, J = 4.4Hz), 7.06 (2H, d, J =
8.4Hz), 7.45 (2H, d, J = 8.4Hz), 8.91 (1H, brs), 10.25 (1H,
s), 11.64 (1H, s).

MS: 644.3 (M+H)⁺, 666.3 (M+Na)⁺

Step 2

15 The title compound was prepared from the compound of Step
1 of Production Example 15 in a manner similar to Step 15 of
Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.79 - 3.76 (17H, m), 4.41 -
4.57 (2H, m), 7.11 - 7.18 (2H, m), 7.27 - 7.35 (2H, m), 7.43
20 (4H, brs), 8.1 - 8.3 (1H, m), 9.9 (1Hx2/3, s), 9.98 (1Hx1/3,
s), 10.37 (1Hx1/3, brs), 11.04 (1Hx2/3, brs), 12.32 (1Hx2/3,
s), 12.33 (1Hx1/3, s).

MS: 444.2 (M+H)⁺, 467.2 (M+Na)⁺ free

Production Example 16: Synthesis of N-({2-(acetylamino)-4-[2-
25 (4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-
yl)methyl)-N-methyl-4-(methylsulfonyl)benzamide hydrochloride

Step 1

To a solution of N-{4-[(Z)-2-(4-nitrophenyl)vinyl]-
1,3-thiazol-2-yl}acetamide (1.0 g) in acetic acid (10 ml)
30 were added N-methylamine hydrochloride (2.33 g) and
paraformaldehyde (124 mg), and the mixture was stirred at
100 °C (bath temp.) for 1 hr. The solvent was removed in

vacuo, the residue was adjusted to pH=9 with aq. sat. NaHCO₃, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄ and evaporated to give N-{5-[(methylamino)methyl]-4-[(Z)-2-(4-

5 nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide as orange foam (0.92 g), that was used as crude in the next reaction.

MS: 333.29 (M+H)+

Step 2

To a solution of N-{5-[(methylamino)methyl]-4-[(Z)-2-(4-
10 nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (100 mg) in 1 ml of dichloromethane were added 4-(methylsulfonyl)benzoic acid (60.2 mg), HOBt (61 mg) and EDCI HCl (86.5 mg), and then the mixture was stirred for 3 hr at 20 °C. The reaction mixture was diluted with 4 ml of dichloromethane and washed with
15 water. The organic layer was dried over diatomaceous earth and evaporated under vacuum to give crude pale yellow oil (144.3 mg, 93.2 %). The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give N-({2-(acetylamino)-4-[(Z)-2-(4-
20 nitrophenyl)vinyl]-1,3-thiazol-5-yl)methyl)-N-methyl-4-(methylsulfonyl)benzamide (144.3 mg).

¹H-NMR (200MHz, CDCl₃) δ (ppm): 2.11 (3H, s), 3.00 (3H, s), 3.08 (3H, s), 4.79 (2H, s), 6.53 - 6.99 (2H, m), 7.3 - 8.28 (8H, m), 10.06 (1H, brs).

25 MS: 537.1 (M+Na)+

Step 3

N-({2-(Acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl)methyl)-N-methyl-4-(methylsulfonyl)benzamide (131.9 mg), MeOH (3.5 ml), THF (3.5 ml), AcOH (0.5 ml) and
30 then 10 % Pd/C (50 % wet) (256 mg) were combined under N₂ atmosphere. The mixture was stirred at 20 °C for 30 min under H₂ atmosphere (3 atm). The reaction mixture was filtered through a celite pad, and the filtrate was

WO 2006/011631

PCT/JP2005/014136

concentrated *in vacuo*. The residue was adjusted to pH=9 with saturated aq. NaHCO₃, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over MgSO₄, and concentrated *in vacuo* to give N-({2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-(methylsulfonyl)benzamide as colorless oil, that was used as crude in the next reaction.

MS: 487.15 (M+H)⁺

Step 4

To a solution of N-({2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-(methylsulfonyl)benzamide (103.6 mg) in THF (0.2 ml) was added N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamide (99.1 mg), and the mixture was stirred for 14 hr at 20 °C. Volatiles were evaporated *in vacuo* and the residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent to give di-tert-butyl {(E)-[(4-{2-[2-(acetylamino)-5-({methyl[4-(methylsulfonyl)benzoyl]amino}methyl)-1,3-thiazol-4-yl]ethyl}phenyl)amino]methylidene}biscarbamate (52.8 mg).

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.48 (9H, s), 1.53 (9H, s), 2.25 (3H, s), 2.55 - 3.02 (7H, m), 3.06 (3H, s), 4.2 (2Hx2/7, brs), 4.61 (2Hx5/7, brs), 6.85 - 6.99 (2Hx2/7, m), 7.09 (2Hx5/7, d, J = 7.3Hz), 7.37 - 7.51 (2H, m), 7.53 - 7.7 (2H, m), 7.99 (2H, d, J = 7.7Hz), 8.96 (1H, s), 10.24 (1H, s), 11.62 (1H, s).

MS: 729.24 (M+H)⁺

Step 5

The title compound was prepared from the compound of Step 4 of Production Example 16 in a manner similar to Step 15 of

Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.13 (3H, s), 2.7 - 2.85 (3H, m), 2.94 (4H, s), 3.26 (3H, s), 4.4 (2Hx1/4, s), 4.63 (2Hx3/4, s), 7.14 (2H+2Hx1/4, d, J = 8.1Hz), 7.27 (2Hx3/4, d, J = 8Hz),
5 7.34 (4H, brs), 7.62 (2H, d, J = 8Hz), 7.99 (2H, d, J = 8Hz), 9.68 (1H, s), 12.13 (1H, s).

MS: 529.2 (M+H)+, 551.2 (M+Na)+ Free

Production Example 17: Synthesis of N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N',N'-trimethylterephthalamide hydrochloride
10 Step 1

N-({2-(Acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl}methyl)-N,N',N'-trimethylterephthalamide was prepared from the compound of Step 1 of Production Example
15 16 in a manner similar to Step 2 of Production Example 16.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 2.14 (3H, s), 2.97 (3H, s), 3.00 (3H, s), 3.12 (3H, s), 4.75 (2H, brs), 6.55 - 6.97 (2H, m), 7.3 - 8.29 (8H, m), 10.17 (1H, bs).

MS: 508.0 (M+H)+, 530.2 (M+Na)+

20 Step 2

N-({2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N',N'-trimethylterephthalamide was prepared from the compound of Step 1 of Production Example 17 in a manner similar to Step 3 of Production Example 16.

25 MS: 480.22 (M+H)+

Step 3

Di-tert-butyl [(Z)-({4-[2-(2-(acetylamino)-5-{{4-[(dimethylamino)carbonyl]benzoyl}(methyl)amino)methyl]-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylidene]biscarbamate was
30 prepared from the compound of Step 2 of Production Example 17 in a manner similar to Step 4 of Production Example 16.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.49 (9H, s), 1.53 (9H, s),

WO 2006/011631

PCT/JP2005/014136

2.27 (3H, s), 2.6 - 2.88 (4H, m), 2.95 (6H, s), 3.12 (3H, s), 4.16 - 4.68 (2H, m), 6.89 - 7.18 (2H, m), 7.44 (6H, s), 10.27 (1H, s), 11.62 (1H, s).

MS: 722.3 (M+H)+, 744.2 (M+Na)+

⁵ Step 4

The title compound was prepared from the compound of Step 3 of Production Example 17 in a manner similar to Step 15 of Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.13 (3H, s), 2.76 (3H, s),
¹⁰ 2.84 - 3.06 (10H, m), 4.34 - 4.7 (2H, m), 7.03 - 7.56 (12H, m), 9.76 (1H, s), 12.12 (1H, s).

MS: 522.24 (M+H)+ Free

Production Example 18: Synthesis of 4-acetyl-N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)-ethyl]-1,3-thiazol-5-yl)methyl)-N-methylbenzamide
¹⁵ hydrochloride

Step 1

4-Acetyl-N-({2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl)methyl)-N-methylbenzamide was prepared from the compound of Step 1 of
²⁰ Production Example 16 in a manner similar to Step 2 of Production Example 16.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 2.16 (3H, s), 2.63 (3H, s), 2.89 (3H, s), 4.78 (2H, brs), 6.58 - 6.98 (2H, m), 7.32 -
²⁵ 8.32 (8H, m), 10.03 (1H, brs).

MS: 479.2 (M+H)+, 501.1 (M+Na)+

Step 2

4-Acetyl-N-({2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl)methyl)-N-methylbenzamide was prepared from
³⁰ the compound of Step 1 of Production Example 18 in a manner similar to Step 3 of Production Example 16.

MS: 451.17 (M+H)+

Step 3

Di-tert-butyl [(E)-({4-[2-(2-(acetylamino)-5-{{(4-acetylbenzoyl)(methyl)amino}methyl)-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylidene]biscarbamate was prepared
5 from the compound of Step 2 of Production Example 18 in a manner similar to Step 4 of Production Example 16.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.49 (9H, s), 1.53 (9H, s),
2.22 (3H, s), 2.62 (3H, s), 2.64 - 3.12 (7H, m), 4.05 - 4.77
(2H, m), 6.77 - 7.18 (2H, m), 7.31 - 7.65 (4H, m), 7.98 (2H,
10 d, J = 8.0Hz), 10.23 (1H, s), 11.62 (1H, s).

MS: 693.1 (M+H)+, 715.3 (M+Na)+

Step 4

The title compound was prepared from the compound of
Step 3 of Production Example 18 in a manner similar to Step 15
15 of Production Example 2.

¹H-NMR (400MHz, CD₃OD) δ (ppm): 2.29 (3H, s), 2.62 (3H, s),
2.86 (3H, s), 2.96 - 3.18 (4H, m), 4.44 - 4.65 (2H, m), 7.02
- 8.19 (9H, m).

MS: 493.17 (M+H)+ Free

20 **Production Example 19:** Synthesis of N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl)methyl)-N-methyl-4-nitrobenzamide hydrochloride

Step 1

To a solution of N-{5-[(methylamino)methyl]-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (100 mg) in
25 dichloromethane (1.5 ml) were added N,N-diisopropylethylamine (0.177 ml) and trifluoroacetic anhydride (0.127 ml) at 0 °C, and the mixture was stirred for 2 hours at same temperature. To the reaction mixture was
30 added aq. saturated NaHCO₃ (30 ml), and the mixture was extracted with dichloromethane (30 mlx3), the extract was washed with brine, dried over MgSO₄ and evaporated *in vacuo*

WO 2006/011631

PCT/JP2005/014136

to give N-({2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)vinyl]-1,3-thiazol-5-yl)methyl}-2,2,2-trifluoro-N-methylacetamide as pale yellow foam (160.4 mg), that was used as crude in the next reaction.

5 MS: 429.06 (M+H)+

Step 2

Di-tert-butyl [(E)-({4-[2-(2-(acetylamino)-5-{[methyl(trifluoroacetyl)amino]methyl}-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylidene]biscarbamate was prepared
10 from the compound of Step 1 of Production Example 19 in a manner similar to Step 2 of Production Example 12.
¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.53 (9H, s), 2.26 - 2.32 (3H, m), 2.82 - 3.11 (7H, m), 4.33 - 4.42 (2H, m), 6.97 - 7.13 (2H, m), 7.41 - 7.51 (2H, m), 10.3 (1H, brs), 11.63
15 (1H, brs).

MS: 643.2 (M+H)+

Step 3

To a solution of di-tert-butyl [(E)-({4-[2-(2-(acetylamino)-5-{[methyl(trifluoroacetyl)amino]methyl}-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylidene]biscarbamate
20 (26.4 mg) in methanol (0.5 ml) was added aq. 10 % K₂CO₃ (0.25 ml) at 0 °C, and then the mixture was stirred for 1.5 hr at 20 °C. The reaction mixture was evaporated *in vacuo*, brine (50 ml) was added, and the mixture was extracted with CHCl₃
25 (10 mlx3), the extract was dried over MgSO₄ and evaporated to give di-tert-butyl ((E)-{[4-(2-{2-(acetylamino)-5-[(methylamino)methyl]-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylidene)biscarbamate (20.5 mg) as
pale yellow foam, that was used as crude in the next
30 reaction.

MS: 547.3 (M+H)+

Step 4

To a solution of di-tert-butyl ((E)-{[4-(2-{2-(acetylamino)-5-[(methylamino)methyl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}methylenidene)biscarbamate (20 mg) in dichloromethane (0.5 ml) were added 4-nitrobenzoic acid
5 (6.11 mg), HOBt (7.42 mg) and EDCI HCl (10.5 mg), and then the mixture was stirred for 3 hr at 20 °C. The reaction mixture was diluted with dichloromethane (4 ml) and the solution was washed with water. The organic layer was dried over MgSO₄ and evaporated under vacuum to give crude pale
10 yellow oil. The crude oil was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (15:1) as an eluent and purified by PTLC (0.5 mmx2, CHCl₃:MeOH=15:1 then CHCl₃:AcOEt=1:1) to give di-tert-butyl
[(E)-({4-[2-(2-(acetylamino)-5-{[methyl(4-nitrobenzoyl)amino]methyl}-1,3-thiazol-4-yl)ethyl]phenyl}amino)methylenidene]biscarbamate (14.3 mg).
15 ¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.4 - 1.62 (18H, m), 2.18 - 2.3 (3H, m), 2.54 - 3.1 (7H, m), 3.97 - 4.75 (2H, m), 6.68 - 8.37 (8H, m), 10.23 (1H, brs), 11.62 (1H, brs).
20 MS: 696.27 (M+H)⁺

Step 5

The title compound was prepared from the compound of Step 4 of Production Example 19 in a manner similar to Step 15 of Production Example 2.

25 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.13 (3H, s), 2.69 - 3.04 (7H, m), 4.63 (2H, s), 7.14 (2H, d, J = 8Hz), 7.27 (2H, d, J = 8.4Hz), 7.31 (4H, s), 7.63 (2H, d, J = 8.4Hz), 8.29 (2H, d, J = 8.4Hz), 9.63 (1H, s), 12.12 (1H, s).
MS: 496.1 (M+H) Free

30 Production Example 20: Synthesis of (2E)-3-{2-(acetylamino)-4-

[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}-N,N-dimethylacrylamide hydrochloride

Step 1

Ethyl 4-chloro-3-oxobutanoate (35 g) was dissolved in
5 dichloromethane (70 ml), and then sulfuryl chloride (17.1 ml)
in dichloromethane (20 ml) was added dropwise to the solution
at 0 °C over 15 minutes under nitrogen atmosphere. The
reaction mixture was stirred at room temperature for 3 hours,
and concentrated *in vacuo*. The residual oil, N'-((E)-
10 ethanoyl)carbamimidiothioic acid (25.1 g) and acetone (600 ml)
were combined. The reaction mixture was refluxed for 2.5
hours. After cooled to room temperature, the mixture was
concentrated *in vacuo*. The residual solid was washed with
water and isopropyl ether to give ethyl 2-(acetylamino)-4-
15 (chloromethyl)-1,3-thiazole-5-carboxylate (21.2 g) as a pale
yellow solid.

mp. 164-165 °C

¹H-NMR (DMSO-d₆), δ (ppm): 1.30 (3H, t, J=7.0Hz), 2.19 (3H, s),
4.29 (2H, q, J=7.0Hz), 5.00 (2H, s), 12.72 (1H, s).

20 MS: 263 (M+H)⁺

Step 2: Ethyl 2-(acetylamino)-4-[(E)-2-(4-
nitrophenyl)ethenyl]-1,3-thiazole-5-carboxylate

To a stirring solution of ethyl 2-(acetylamino)-4-
(chloromethyl)-1,3-thiazole-5-carboxylate (1.0 g, 3.81 mmol)
25 in N,N-dimethylformamide (20 mL) was added triphenylphosphine
(1.2 g, 4.57 mmol) at room temperature. The resultant mixture
was stirred at 65 °C for 5 hours. To the mixture was added
potassium tert-butoxide (555 mg, 4.95 mmol) at 5 °C, and the
resultant mixture was stirred at 5 °C for 30 minutes.
30 p-Nitrobenzaldehyde (805 mg, 5.33 mmol) was added at 5 °C.
After stirring for 1 hour at room temperature, the reaction
was quenched with water, and the mixture was filtered to give
the title compound (1.0 g, 72.7%) as a yellow solid.

WO 2006/011631

PCT/JP2005/014136

¹H-NMR (CDCl₃), δ (ppm): 1.40 (3H, t, J=7.2Hz), 2.33 (3H, s), 4.38 (2H, q, J=7.2Hz), 7.59 (1H, d, J=16.0Hz), 7.70 (2H, d, J=8.8Hz), 8.18 (1H, d, J=16.0Hz), 8.22 (2H, d, J=8.8Hz), 8.90 (1H, m).

5 Step 3

Ethyl 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazole-5-carboxylate was prepared from the compound of Step 2 of Production Example 20 in a manner similar to Step 6 of Production Example 10.

10 ¹H-NMR (CDCl₃), δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.27 (3H, s), 2.84 (2H, m), 3.28 (2H, m), 3.56 (2H, m), 4.31 (2H, q, J=7.0Hz), 6.61 (2H, d, J=8.3Hz), 7.01 (2H, d, J=8.3Hz), 9.12 (1H, m).

Step 4

15 Ethyl 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazole-5-carboxylate (310 mg) was dissolved in tetrahydrofuran (6 ml) under nitrogen atmosphere. Then, di(tert-butyl) dicarbonate (223 mg) in tetrahydrofuran (1 ml) was added to the solution at room temperature. The reaction
20 mixture was refluxed for 2 hours. After cooled to room temperature, the mixture was concentrated *in vacuo*. The residual solid was washed with ethyl ether to give ethyl 2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)amino]phenyl}-ethyl)-1,3-thiazole-5-carboxylate (370.7 mg) as an off-white
25 solid.

mp. 213-214 °C

¹H-NMR (DMSO-d₆), δ (ppm): 1.26 (3H, t, J=7.0Hz), 1.46 (9H, s), 2.17 (3H, s), 2.85 (2H, t, J=7.5Hz), 3.23 (2H, t, J=7.5Hz), 4.22 (2H, q, J=7.0Hz), 7.04 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.23 (1H, brs), 12.55 (1H, brs).

MS: 434 (M+H)⁺

Step 5

Ethyl 2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)-

amino]phenyl}ethyl)-1,3-thiazole-5-carboxylate (3 g), 1N-aqueous sodium hydroxide solution (17.3 ml) and ethanol (30 ml) were combined, and the mixture was refluxed for 5 hours. After cooled to room temperature, the organic solvent was
5 removed *in vacuo*. The aqueous solution was acidified (pH=4) with 1N-hydrochloric acid, and extracted with ethyl acetate (twice). The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated *in vacuo*. The residual solid was dissolved in pyridine (45 ml), and then acetyl
10 chloride (1.48 ml) was added dropwise to the solution at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 13 hours, and pyridine was removed *in vacuo*. Water was added to the residue, and the mixture was acidified with 1N-hydrochloric acid. The precipitate was
15 collected *in vacuo*. The solid was washed with water and ethyl ether to give 2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)-amino]phenyl}ethyl)-1,3-thiazole-5-carboxylic acid (2.23 g) as an off-white solid.

mp. 237-238 °C

20 ¹H-NMR (DMSO-d₆), δ (ppm): 1.46 (9H, s), 2.16 (3H, s), 2.85 (2H, m), 3.23 (2H, m), 7.04 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.24 (1H, s), 12.46 (1H, s).

MS: 404 (M-H)⁺

Step 6

25 To a solution of 2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazole-5-carboxylic acid in CH₂Cl₂ (3 ml) and DMF (3 ml) were added N,O-dimethylhydroxyamine hydrochloride (118 mg), EDCI (0.509 ml) and HOBt (188 mg), and then the mixture was stirred for 3 days
30 at ambient temperature. The reaction mixture was diluted with AcOEt (50 ml) and washed with water (50 mlx3). The organic layer was dried over MgSO₄ and evaporated under vacuum. The residue was triturated with IPE and collected by filtration to

give tert-butyl {4-[2-(2-(acetylamino)-5-[methoxy(methyl)amino]-carbonyl)-1,3-thiazol-4-yl]ethyl}phenyl}carbamate (366 mg) as a pale yellow solid.

¹H-NMR (CDCl₃), δ (ppm): 1.46 (9H, s), 2.15 (3H, s), 2.74-2.93 (2H, m), 3.12-3.29 (2H, m), 3.22 (3H, s), 3.59 (3H, s), 7.05 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 9.21 (1H, s), 12.34 (1H, s).

MS: 471.1 (M+Na)⁺

Step 7

To a solution of the compound obtained in Step 6 of Production Example 20 (3.93 g) in THF (80 mL) was added lithium aluminium hydride (499 mg) slowly (over 15 min) at 5-10 °C (under ice-cooling). The mixture was stirred at 5 °C for 1 hr. 30 mL of aqueous solution of sodium potassium tartrate (1 M) was added slowly under ice-cooling, and then the mixture was stirred for another 0.5 hr at r.t. The mixture was extracted with ethyl acetate, and the organic layer was dried over MgSO₄, and concentrated in vacuo to give pale yellow oil. This oil was triturated with IPE and EtOAc to give tert-butyl (4-{2-[2-(acetylamino)-5-formyl-1,3-thiazol-4-yl]ethyl}phenyl)carbamate as pale yellow powder (2.67g).

¹H-NMR (200MHz, DMSO-d₆), δ (ppm): 1.46 (9H, s), 2.19 (3H, s), 2.90 (2H, t, J=7.3 Hz), 3.22 (2H, t, J=7.3 Hz), 7.01 (2H, d, J=8.5 Hz), 7.32 (2H, d, J=8.5 Hz), 9.22 (1H, s), 9.77 (1H, s), 12.68 (1H, s).

MS: 390 (M+H)⁺

Step 8

To a suspension of tert-butyl (4-{2-[2-(acetylamino)-5-formyl-1,3-thiazol-4-yl]ethyl}phenyl)carbamate (500 mg) in CHCl₃ (10 ml) was added (carbethoxymethylene)triphenylphosphorane (894 mg) at 20 °C, and the mixture was stirred for 1hr. To the reaction mixture was added brine, the mixture was extracted with CHCl₃, dried over MgSO₄ and

evaporated. The residue was purified by SiO₂-column chromatography (toluene:AcOEt = 1 : 1) to give a mixture of ethyl (2E)-3-[2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazol-5-yl]acrylate
5 and ethyl (2Z)-3-[2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazol-5-yl]acrylate as a pale yellow solid (495.9 mg).

Step 9

A mixture of ethyl (2E)-3-[2-(acetylamino)-4-(2-{4-
10 [(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazol-5-yl]acrylate and ethyl (2Z)-3-[2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazol-5-yl]acrylate (290 mg) was purified by SiO₂-column chromatography (CHCl₃:MeOH = 100:0-100:2) to give ethyl (2E)-3-[2-(acetylamino)-4-(2-{4-
15 [(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazol-5-yl]acrylate (118.6 mg) as a white solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.22 (3H, t, J = 7.1Hz), 1.46 (9H, s), 2.16 (3H, s), 2.84 (2H, t, J = 7.3Hz), 2.97 (2H, t, J = 7.3Hz), 4.13 (2H, q, J = 7.1Hz), 5.88 (1H, d, J = 15.4Hz),
20 7.01 (2H, d, J = 8.4Hz), 7.32 (2H, d, J = 8.4Hz), 7.55 (1H, d, J = 15.4Hz), 9.22 (1H, s), 12.45 (1H, s).

MS: 457.67 (M+H)⁺

Step 10

Ethyl (2E)-3-[2-(acetylamino)-4-(2-{4-[(tert-butoxycarbonyl)amino]phenyl}ethyl)-1,3-thiazol-5-yl]acrylate
25 (53.8 mg) and trifluoroacetic acid (TFA, 2 ml) were combined at 0 °C. The reaction mixture was stirred at 25 °C for 30 min and concentrated *in vacuo*. To the residue were added AcOEt (20 ml), THF (1 ml) and aq. saturated NaHCO₃ solution (20 ml). The
30 organic layer was separated, dried over magnesium sulfate and evaporated to give crude ethyl (2E)-3-[2-(acetylamino)-4-(2-

{4-aminophenyl}ethyl)-1,3-thiazol-5-yl]acrylate as a yellow oil (46.2 mg, MS: 360.14 (M+H)+)

The crude ethyl (2E)-3-[2-(acetylamino)-4-(2-{4-aminophenyl}ethyl)-1,3-thiazol-5-yl]acrylate (46.2 mg), N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamide (54.5 mg) and THF (0.5 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at 20 °C for 17 hr, and then concentrated *in vacuo*. The residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give ethyl (2E)-3-(2-(acetylamino)-4-{2-[4-((Z)-[(tert-butoxycarbonyl)amino]-[(tert-butoxycarbonyl)imino]methyl}amino)phenyl]ethyl}-1,3-thiazol-5-yl)acrylate (65.6 mg).

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.32 (3H, t, J = 7.3Hz), 1.49 (9H, s), 1.53 (9H, s), 2.23 (3H, s), 2.8 - 3.13 (4H, m), 4.24 (2H, q, J = 7.2Hz), 6.03 (1H, d, J = 15.6Hz), 7.09 (2H, d, J = 8.5Hz), 7.43 (2H, d, J = 8.5Hz), 7.65 (1H, d, J = 15.6Hz), 9.99 - 10.56 (1H, brs), 11.64 (1H, s).

MS: 602.2 (M+H)+, 624.2 (M+Na)+

Step 11

Ethyl (2E)-3-(2-(acetylamino)-4-{2-[4-((Z)-[(tert-butoxycarbonyl)amino] [(tert-butoxycarbonyl)imino]methyl}amino)phenyl]ethyl}-1,3-thiazol-5-yl)acrylate (65.4 mg), 1N-NaOH (0.543 ml) and dioxane (1 ml) were combined at 0 °C, and the mixture was stirred at 60 °C for 2 hr. The mixture was adjusted to pH=2 with 1N-HCl, and the organic solvent was evaporated *in vacuo*. The residual aqueous solution was extracted with AcOEt:THF (10:1). The organic layer was washed with water and brine, dried over MgSO₄, and concentrated *in vacuo* to give crude (2E)-3-(2-(acetylamino)-4-{2-[4-((Z)-[(tert-butoxycarbonyl)amino]-[(tert-

butoxycarbonyl)imino]methyl}amino)phenyl]ethyl}-1,3-thiazol-5-yl)acrylic acid as a yellow solid, that was used as crude in the next reaction.

MS: 574.19 (M+H)+

5 Step 12

Di-tert-butyl ((Z)-{[4-(2-{2-(acetylamino)-5-[(1E)-3-(dimethylamino)-3-oxo-1-propen-1-yl]-1,3-thiazol-4-yl}ethyl)phenyl]amino}methylenidene)biscarbamate was prepared from the compound of Step 11 of Production Example 20 in a
10 manner similar to Step 4 of Production Example 12.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.53 (9H, s), 2.26 (3H, s), 2.85 - 3.21 (10H, m), 6.49 (1H, d, J = 14.6Hz), 7.11 (2H, d, J = 8.4Hz), 7.45 (2H, d, J = 8.4Hz), 7.71 (1H, d, J = 15Hz), 9.15 (1H, brs), 10.25 (1H, s), 11.63 (1H, s).

15 MS: 601.0 (M+H)+, 623.2 (M+Na)+

Step 13

The title compound was prepared from the compound of Step 12 of Production Example 20 in a manner similar to Step 15 of Production Example 2.

20 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.17 (3H, s), 2.85 - 3.03 (7H, m), 3.08 (3H, s), 6.56 (1H, d, J = 15Hz), 7.14 (2H, d, J = 8.4Hz), 7.25 (2H, d, J = 8.4Hz), 7.35 (4H, s), 7.39 (1H, d, J = 15Hz), 9.71 (1H, s), 12.36 (1H, s).

MS: 401.2 (M+H)+, 423.3 (M+Na)+ Free

25 Production Example 21: Synthesis of N-{4-[2-(2-amino-1H-benzimidazol-7-yl)ethyl]-1,3-thiazol-2-yl}acetamide

Step 1

To NaBH₄ (678 mg) in THF (10 ml) at 0 °C under N₂ was added 2,3-dinitrobenzoic acid (2 g) in THF (4 ml) dropwise
30 over 15 min, then added boron trifluoride diethyl ether complex (3.23 ml) dropwise over 30 min. The reaction mixture was stirred for 2 hr at 20 °C, and then the reaction was

quenched with 1N-HCl (40 ml), and the mixture was extracted with ethyl acetate (20 mlx3). The combined organic layers were washed with water and brine, dried over MgSO₄, filtered and evaporated to give 2,3-dinitrobenzylalcohol (2.52 g) as
5 a yellow solid, and that was used as crude in the next reaction.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 4.81 (2H, s), 7.73 (1H, t, J = 8Hz), 8.02 (1H, d, J = 8Hz), 8.09 (1H, d, J = 8Hz).

Step 2

10 Crude 2,3-dinitrobenzylalcohol (2.52 g) was added slowly to 48 % hydrobromic acid (66 ml), and the mixture was stirred for 6 h at 90 °C. The reaction mixture was cooled to 20 °C, diluted with water (60 ml) and extracted with tert-butyl methyl ether (40 mlx3). The combined organic layers were
15 washed with water and aq. NaHCO₃ solution, dried over Na₂SO₄, filtered and evaporated to give 1-bromomethyl-2,3-dinitrobenzene (2.34 g) as a yellow solid.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 4.48 (2H, s), 7.71 (1H, t, J = 8Hz), 7.9 (1H, dd, J = 1.3, 8Hz), 8.14 (1H, dd, J = 1.5, 8Hz).

20 Step 3

To a solution of 1-bromomethyl-2,3-dinitrobenzene (2.29 g) in acetone (60 g) was added triphenylphosphine (2.31 g), and the mixture was refluxed for 3 hr (bath temp.=70 °C). The reaction mixture was cooled to 20 °C, the resulting
25 precipitate was collected by filtration and washed with diethyl ether to give (2,3-dinitrobenzyl)triphenylphosphonium bromide as a yellow solid.

¹H-NMR (200MHz, DMSO-d₆): 5.29 (2H, d, J = 15Hz), 7.47 - 8.01 (17H, m), 8.3 (1H, d, J = 8Hz).

30 MS: 443.2 (M-Br-)+

Step 4

(2,3-Dinitrobenzyl)triphenylphosphonium bromide (615 mg) and DMF (2 ml) were combined under N₂ atmosphere, and then potassium tert-butoxide (145 mg) was added to the suspension at 0 °C. The reaction mixture was stirred at 0 °C
5 for 10 min, and N-(4-formyl-1,3-thiazol-2-yl)acetamide (200 mg) was added to the mixture at 0 °C. The reaction mixture was stirred at 20 °C for 2 hr. To the reaction mixture was added ethyl acetate (50 ml), and the mixture was washed with water (20 mlx3) and brine. The organic layer was dried over
10 magnesium sulfate and evaporated to give crude brown oil (750 mg). The crude oil was purified by flash column chromatography over silica gel with CHCl₃ / AcOEt (1:1) as an eluent to give N-{4-[(Z)-2-(2,3-dinitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide (135.6 mg) as orange foam.
15 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.09 (3H, s), 6.45 (1H, d, J = 12.2Hz), 6.83 (1H, d, J = 12.3Hz), 7.12 (1H, s), 7.79 (1H, dd, J = 8, 8Hz), 7.89 (1H, d, J = 7.5Hz), 8.27 (1H, dd, J = 1, 8.1Hz), 11.8 (1H, s).
MS: 335.0 (M+H)+, 357.1 (M+Na)+

20 Step 5

N-{4-[2-(2,3-Diaminophenyl)ethyl]-1,3-thiazol-2-yl}acetamide was prepared from the compound of Step 4 of Production Example 21 in a manner similar to Step 3 of Production Example 16.
25 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.7 - 2.86 (4H, m), 4.18 (2H, s), 4.41 (2H, s), 6.28 - 6.36 (2H, m), 6.41 (1H, dd, J = 2.2, 7Hz), 6.77 (1H, s), 12.07 (1H, s).
MS: 277.09 (M+H)+

Step 6

30 To a suspension of N-{4-[2-(2,3-diaminophenyl)ethyl]-1,3-thiazol-2-yl}acetamide (21.6 mg) in MeOH (0.2 ml) was added cyanic bromide (12.4 mg), and then the mixture was stirred at

20 °C for 14 hr. To the reaction mixture was added aq. 1N-NaOH (0.117 ml), and the mixture was concentrated *in vacuo*. To the residue was added CHCl₃:MeOH=10:1 (10 ml), and the insoluble material was removed by filtration. The filtrate was purified
5 by preparative NH-silica gel thin-layer chromatography with chloroform / methanol (10:1) as an eluent to give a solid (16.4 mg). The solid was washed with CH₂Cl₂ to give N-{4-[2-(2-amino-1H-benzimidazol-7-yl)ethyl]-1,3-thiazol-2-yl}acetamide (15.4 mg) as an off-white solid.

10 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.85 - 3 (2H, m), 3 - 3.15 (2H, m), 5.81 - 6.21 (2H, m), 6.59 - 6.85 (3H, m), 6.9 - 6.98 (1H, m), 10.56 - 10.96 (1H, m), 12.07 (1H, s).
MS: 302.2 (M+H)+, 324.1 (M+Na)+

Production Example 22: Synthesis of N-{4-[3-(4-
15 {[amino(imino)methyl]amino}phenyl)propyl]-1,3-thiazol-2-yl}acetamide hydrochloride

Step 1

N-{4-[3-(4-Nitrophenyl)propyl]-1,3-thiazol-2-yl}acetamide (100 mg) and 10 % palladium on carbon (50 %
20 wet) (98.2 mg) in methanol (2 ml), tetrahydrofuran (2 ml) and acetic acid (0.3 ml) were stirred under 3 atm hydrogen atmosphere at 20 °C for 5 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated *in vacuo*. The residue was dissolved in ethyl
25 acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated *in vacuo* to give N-{4-[3-(4-aminophenyl)propyl]-1,3-thiazol-2-yl}acetamide (94.3 mg) as
30 pale yellow oil, that was used as crude in the next reaction.

MS: 276.21 (M+H)+

Step 2

Di-tert-butyl {(Z)-[(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)amino]methylidene}biscarbamate was prepared from the compound of Step 1 of Production Example 22 in a manner similar to Step 4 of Production Example 16.

5 ¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.5 (9H, s), 1.53 (9H, s), 1.86 - 2.07 (2H, m), 2.22 (3H, s), 2.62 (2H, t, J = 8Hz), 2.66 (2H, t, J = 8Hz), 6.53 (1H, s), 7.12 (2H, d, J = 8.4Hz), 7.48 (2H, d, J = 8.4Hz), 10.26 (1H, s), 11.64 (1H, s).

MS: 518.2 (M+H)⁺, 540.3 (M+Na)⁺

10 Step 3

The title compound was prepared from the compound of Step 2 of Production Example 22 in a manner similar to Step 15 of Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.86 - 1.98 (2H, m), 2.11
15 (3H, s), 2.57 - 2.65 (4H, m), 6.75 (1H, s), 7.15 (2H, d, J = 8.3Hz), 7.27 (2H, d, J = 8.3Hz), 7.41 (4H, s), 9.82 (1H, s), 12.03 (1H, s).

MS: 318.3 (M+H)⁺ free

Production Example 23: Synthesis of N-(4-{3-[4-
20 ({[amino(imino)methyl]amino)methyl]phenyl]propyl}-1,3-thiazol-2-yl)acetamide hydrochloride

Step 1

To a solution of methyl 4-(4-oxopentyl)benzoate (6.395 g) in MeOH (64 ml) was added Br₂ (1.35 ml), and the mixture
25 was stirred for 2 hr at 20 °C. To the reaction mixture were added thiourea (2.21 g) and K₂CO₃ (10 g), the mixture was stirred for 2 hr at 50 °C, and then cooled to 20 °C, and CHCl₃ (256 ml) was added. The resulting precipitate was removed by filtration. The filtrate was evaporated, and to the residue
30 was added CHCl₃ (200 ml), and the insoluble material was removed by filtration, and the filtrate was evaporated in vacuo to give crude brown oil. The crude oil was purified by

flash column chromatography over silica gel with CH₂Cl₂ / MeOH (100: 0-100:2) as an eluent to give methyl 4-[3-(2-amino-1,3-thiazol-4-yl)propyl]benzoate (1.68 g) as brown oil.

5 ¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.89 - 2.09 (2H, m), 2.57 (2H, t, J = 7.6Hz), 2.71 (2H, t, J = 7.6Hz), 3.9 (3H, s), 5.19 (2H, brs), 6.08 (1H, s), 7.26 (2H, d, J = 8.2Hz), 7.95 (2H, d, J = 8.2Hz).

MS: 277.14 (M+H)+

10 Step 2

Methyl 4-[3-(2-amino-1,3-thiazol-4-yl)propyl]benzoate (1.68 g) was dissolved in CH₂Cl₂ (16.8 ml) under N₂ atmosphere. Then, pyridine (1.57 ml) and AcCl (0.692 ml) were added dropwise to the solution at 0 °C. The reaction mixture was
15 stirred at 20 °C for 30 min. The organic solution was washed with 1N-HCl, water and brine, then dried over MgSO₄, and concentrated *in vacuo* to give crude brown oil (2.52 g, 130 %). The crude oil was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (100:0-100:2) as an eluent to give
20 methyl 4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}benzoate (1.974 g) as a pale yellow solid.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.92 - 2.11 (2H, m), 2.27 (3H, s), 2.68 (2H, t, J = 7.3Hz), 2.71 (2H, t, J = 7.3Hz), 3.91 (3H, s), 6.52 (1H, s), 7.25 (2H, d, J = 8Hz), 7.96 (2H, d, J =
25 8Hz).

MS: 319.11 (M+H)+

Step 3

To a stirred solution of methyl 4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}benzoate (1.968 g) in dry THF (40
30 ml) was added dropwise diisobutylaluminum hydride, 1.0 M

solution in toluene (18.5 ml) over 10 min at -78 °C under N₂ atmosphere. The reaction mixture was stirred at -78 °C for 10 min, at 20 °C for 2 hr, and then the reaction was quenched with MeOH. 1N-HCl was added to the mixture and the mixture
5 was extracted with AcOEt. The organic layer was washed with brine, dried over MgSO₄, and concentrated *in vacuo* to give crude yellow oil (1.36 g). The crude oil was purified by flash column chromatography over silica gel with CHCl₃ / AcOEt (100:0-1:1) as an eluent to give N-(4-{3-[4-
10 (hydroxymethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide (523 mg) as a yellow solid.
¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.99 (2H, quintet, J = 7.7Hz), 2.13 (3H, s), 2.65 (4H, t, J = 7.5Hz), 4.66 (2H, s), 6.54 (1H, s), 7.15 (2H, d, J = 8Hz), 7.27 (2H, d, J = 8Hz).
15 MS: 291.3 (M+H)⁺, 313.1 (M+Na)⁺

Step 4

N-(4-{3-[4-(Hydroxymethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide (100 mg), CH₂Cl₂ (1 ml) and DMF (1 ml) were combined under N₂ atmosphere, and then Et₃N (60.0 μl) and
20 methanesulfonyl chloride (30.7 μl) were added to the suspension at 0 °C. The reaction mixture was stirred at 20 °C for 16 hr. CHCl₃ and water were added to the mixture. The organic layer was washed with brine, dried over MgSO₄, and concentrated *in vacuo* to give crude N-(4-{3-[4-
25 (chloromethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide as oil (MS: 309.03 (M+H)⁺). To the crude N-(4-{3-[4-(chloromethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide in DMF (1 ml) was added phthalimide potassium salt (63.7 mg) and the mixture was stirred at 50 °C for 7 h, then water was
30 added to the reaction mixture, the mixture was extracted

WO 2006/011631

PCT/JP2005/014136

with ethyl acetate, and the extract was washed with brine, dried over magnesium sulfate and evaporated to give crude N-[4-(3-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}propyl)-1,3-thiazol-2-yl]acetamide (147.7

5 mg), that was used as crude in the next reaction.

¹H-NMR (200MHz, CDCl₃) δ (ppm): 1.84 - 2.06 (2H, m), 2.25 (3H, s), 2.62 (2H, t, J = 7.5Hz), 2.66 (2H, t, J = 7.5Hz), 4.81 (2H, s), 6.51 (1H, s), 7.12 (2H, d, J = 8Hz), 7.35 (2H, d, J = 8Hz), 7.63 - 7.93 (4H, m).

10 MS: 420.2 (M+H)⁺, 442.1 (M+Na)⁺

Step 5

To a solution of N-[4-(3-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}propyl)-1,3-thiazol-2-yl]acetamide (140 mg) in acetonitrile (1.4 ml) was added hydrazine
15 monohydrate (162 μl), and the mixture was stirred at 50 °C for 30 min. Volatiles were evaporated. To the mixture was added chloroform (1 ml) and the insoluble material was removed by filtration to give N-(4-{3-[4-(aminomethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide as crude pale yellow foam (103.4 mg),
20 that was used as crude in the next reaction.

MS: 290.10 (M+H)⁺

Step 6

Di-tert-butyl {(Z)-[(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}benzyl)amino]methylidene}biscarbamate was prepared
25 from the compound of Step 5 of Production Example 23 in a manner similar to Step 4 of Production Example 16.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.48 (9H, s), 1.52 (9H, s), 1.97 - 2.07 (2H, m), 2.3 (3H, s), 2.59 - 2.74 (4H, m), 4.6 (2H, d, J = 5.1Hz), 6.55 (1H, s), 7.16 (2H, d, J = 8.4Hz),
30 7.23 (2H, d, J = 8Hz), 8.56 (1H, s), 10.23 (1H, brs), 11.54 (1H, s).

MS: 532.3 (M+H)+

Step 7

The title compound was prepared from the compound of Step 6 of Production Example 23 in a manner similar to Step 15 of
5 Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.85 - 1.95 (2H, m), 2.11 (3H, s), 2.54 - 2.63 (4H, m), 4.34 (2H, d, J = 6.2Hz), 6.75 (1H, s), 7.22 (4H, s), 7.32 (4H, brs), 8.08 (1H, t, J = 5.9Hz), 12.04 (1H, s).

10 MS: 332.2 (M+H)+ Free

Production Example 24: Synthesis of N-(4-{3-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide

Step 1

15 To a solution of N-(4-{3-[4-(hydroxymethyl)phenyl]propyl}-1,3-thiazol-2-yl)acetamide (423 mg) in chloroform (10 ml) and MeOH (0.6 ml) was added MnO₂ (3.80 g) at 20 °C under N₂ atmosphere, and the mixture was stirred for 2 days. The reaction mixture was filtered through a celite pad. The
20 filtrate was evaporated to give N-{4-[3-(4-formylphenyl)propyl]-1,3-thiazol-2-yl}acetamide (409.4 mg) as a pale yellow solid, that was used as crude in the next reaction.

MS: 289.04 (M+H)+

25 Step 2

To a suspension of N-{4-[3-(4-formylphenyl)propyl]-1,3-thiazol-2-yl}acetamide (409.4 mg) in chloroform (8 ml) was added (carbethoxymethylene)triphenylphosphorane (989 mg) at 20 °C, and the mixture was stirred for 1 hr. The reaction mixture
30 was evaporated. The residue was purified by column chromatography over silica gel with hexane / ethyl acetate (1:1-1:2) as an eluent to give ethyl (2E)-3-(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)acrylate (463.9

mg) as a pale yellow solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.26 (3H, t, J = 7.1Hz), 1.87
- 1.98 (2H, m), 2.11 (3H, s), 2.54 - 2.68 (4H, m), 4.18 (2H,
q, J = 7.1Hz), 6.58 (1H, d, J = 15.7Hz), 6.76 (1H, s), 7.25
5 (2H, d, J = 8Hz), 7.58 - 7.68 (3H, m), 12.04 (1H, s).

MS: 359.2 (M+H)+

Step 3

Ethyl (2E)-3-(4-{3-[2-(acetylamino)-1,3-thiazol-4-
yl]propyl}phenyl)acrylate (100 mg), MeOH (2 ml), THF (2 ml)
10 and then 10 % Pd/C (50 % wet) (97.6 mg) were combined under
N₂ atmosphere. The mixture was stirred at 20 °C for 1 hr
under H₂ atmosphere (3 atm). The reaction mixture was
filtered through a celite pad, and the filtrate was
concentrated *in vacuo* to give ethyl 3-(4-{3-[2-
15 (acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)propanoate
(109.8 mg) as colorless oil, that was used as crude in the
next reaction.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.14 (3H, t, J = 7.1Hz),
1.83 - 1.95 (2H, m), 2.1 (3H, s), 2.52 - 2.62 (6H, m), 2.76
20 - 2.84 (2H, m), 4.03 (2H, q, J = 7.1Hz), 6.74 (1H, s), 7.09
(2H, d, J = 8.4Hz), 7.13 (2H, d, J = 8Hz), 12.03 (1H, s).

MS: 361.3 (M+H)+

Step 4

To a solution of ethyl 3-(4-{3-[2-(acetylamino)-1,3-
25 thiazol-4-yl]propyl}phenyl)propanoate (95.8 mg) in dioxane
(958 μl) was added 1N-NaOH (664.394 μl) at 0 °C, then the
mixture was stirred for 30 min at 20 °C. Volatiles were
evaporated *in vacuo*. The residue was dissolved in water (20
ml) and washed with AcOEt (20 ml). The aqueous layer was
30 adjusted to pH=2, and the resulting precipitate was
collected by filtration to give 3-(4-{3-[2-(acetylamino)-

WO 2006/011631

PCT/JP2005/014136

1,3-thiazol-4-yl]propyl}phenyl)propanoic acid (79.3 mg) as a white solid.

¹H-NMR (200MHz, DMSO-d₆) δ (ppm): 1.77 - 2 (2H, m), 2.1 (3H, s), 2.43 - 2.65 (6H, m), 2.78 (2H, t, J = 7.3Hz), 6.75 (1H, s), 7.09 (2H, d, J = 8.5Hz), 7.14 (2H, d, J = 8.5Hz), 12.03 (2H, s).

MS: 333.3 (M+H)⁺, 355.1 (M+Na)⁺

Step 5

tert-Butyl [2-(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)ethyl]carbamate was prepared from the compound of Step 4 of Production Example 24 in a manner similar to Step 13 of Production Example 2.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.36 (9H, s), 1.84 - 1.95 (2H, m), 2.10 (3H, s), 2.53 - 2.69 (6H, m), 3.06 - 3.15 (2H, m), 6.74 (1H, s), 6.86 (1H, t, J = 5.7Hz), 7.1 (4H, s), 12.02 (1H, s).

MS: 404.2 (M+H)⁺, 426.2 (M+Na)⁺

Step 6

tert-Butyl [2-(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)ethyl]carbamate (36.9 mg) and 4N HCl in dioxane (1 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at 25 °C for 4 hr. Volatiles were evaporated in vacuo to give a white solid. To the solid in DMF (0.9 ml) were added N,N-diisopropylethylamine (60.524 μl) and N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (85.136 mg), and the mixture was stirred for 48 hr at 25 °C. Volatiles were evaporated, and the residue was purified by preparative silica gel thin-layer chromatography with chloroform / ethyl acetate (2:1) as an eluent to give di-tert-butyl ((Z)-{[2-(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)ethyl]amino}methylidene)biscarbamate (44.6 mg) as colorless oil.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.47 (9H, s), 1.5 (9H, s), 1.93 - 2.04 (2H, m), 2.25 (3H, s), 2.56 - 2.71 (4H, m), 2.84 (2H, t, J = 7.3Hz), 3.6 - 3.7 (2H, m), 6.53 (1H, s), 7.1 (2H, d, J = 8.4Hz), 7.13 (2H, d, J = 8.4Hz), 8.33 - 8.42 (1H, m), 11.47
5 (1H, brs).

MS: 546.46 (M+H)+

Step 7

Di-tert-butyl ((Z)-{[2-(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)ethyl]amino}methylidene)
10 biscarbamate (39.1 mg) and 4N HCl in dioxane (2 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at 20 °C for 14 hr. The solvent was removed in vacuo. The residue was dissolved in water, the solution was adjusted to pH=9 with aq. saturated NaHCO₃, extracted with AcOEt:THF=1:1,
15 the extract was dried over MgSO₄ and evaporated to give a colorless oil (25 mg). The oil was purified by preparative NH-silica gel thin-layer chromatography with chloroform / methanol (4:1) as an eluent to give N-(4-{3-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]propyl}-1,3-thiazol-2-
20 yl)acetamide (7.7 mg) as a colorless oil.

¹H-NMR (400MHz, CDCl₃:CD₃OD=1:1) δ (ppm): 1.98 (2H, quintet, J = 7.6Hz), 2.23 (3H, s), 2.57 - 2.73 (4H, m), 2.86 (2H, t, J = 7.1Hz), 3.41 (2H, t, J = 7.1Hz), 6.55 (1H, s), 7.15 (4H, s).

MS: 346.38 (M+H)+

25 **Production Example 25:** Synthesis of N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide

Di-tert-butyl ((Z)-{[2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)ethyl]amino}methylidene)
30 biscarbamate (443.1 mg) and 4N HCl in 1,4-dioxane solution (10 ml) were combined under N₂ atmosphere. The reaction mixture was stirred at 20 °C for 14 hours. The solvent was removed in vacuo. The residue was dissolved in water. The solution was

made basic (pH=9) by saturated sodium hydrogen carbonate aqueous solution. The precipitate was filtered *in vacuo* to give N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (667.7 mg) as a white solid.

5 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.02 (3H, brs), 2.64 - 2.96 (6H, m), 3.13 - 3.5 (2H, m), 6.55 (1H, brs), 7.14 (4H, s), 8.32 (4H, brs).

MS: 332.2 (M+H)+

Production Example 26: Synthesis of 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-[amino(imino)methyl]propanamide

Step 1

To a solution of methyl 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)propanoate (2.73 g) in dioxane (27 ml) was added 1N-NaOH (22.5 ml) at 0 °C, and then the mixture was stirred for 30 min at 20 °C. Volatiles were evaporated *in vacuo*. The residue was dissolved in water (20 ml) and washed with AcOEt (20 ml). The aqueous layer was adjusted to pH=2, and the resulting precipitate was collected by

15 filtration to give 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)propanoic acid (2.672 g) as a white solid.

¹H-NMR (200MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.43 - 2.56 (2H, m), 2.77 (2H, t, J = 7.8Hz), 2.87 (4H, s), 6.73 (1H, s), 7.11 (4H, s), 12.09 (2H, s).

25 MS: 319.09 (M+H)+

Step 2

To a solution of 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)propanoic acid (100 mg) in DMF (2 ml) was added 1,1'-carbonyldiimidazole (56 mg). The mixture was

30 stirred at 50 °C for 2 hr. To the mixture was added a mixture of guanidine hydrochloride (150 mg), DMF (1 ml) and 28 % sodium methoxide in MeOH (0.307 ml) at 20 °C. The reaction mixture was stirred at 20 °C for 15 hr, and concentrated *in*

vacuo. The residue was dissolved in water, and the solution was adjusted to pH=8 with 1N-HCl. The precipitate was collected. The solid was washed with water, CH₃CN and AcOEt to give 3-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-
5 N-[amino(imino)methyl]propanamide (101.3 mg) as a white powder.

¹H-NMR (200MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.36 (2H, t, J = 7.8Hz), 2.76 (2H, t, J = 8Hz), 2.86 (4H, s), 6.73 (1H, s), 6.95 (4H, brs), 7.08 (4H, s), 11.99 (1H, brs).

10 MS: 360.3 (M+H)+

Production Example 27: Synthesis of N-[4-(2-{4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide

Step 1

15 To a solution of phthalimide potassium salt (46.2 g) in N,N-dimethylformamide (300 ml) was added dropwise 4-(2-bromoethyl)benzaldehyde (40.92 g) in N,N-dimethylformamide (50 ml) at 60 °C and the mixture was stirred for 2 hr. The reaction mixture was cooled to 20 °C, and then poured into
20 water (1.5 L). The resulting presipitate was collected by filtration to give a yellow solid. The solid was dissolved in chloroform (250 ml) and the insoluble material was removed by filtration. The filtrate was concentrated in *vacuo*. The residue was washed with diethyl ether and
25 collected by filtration to give 4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]benzaldehyde (19.65 g) as an off-white solid.

¹H-NMR (200MHz, DMSO-d₆) δ (ppm): 3.04 (2H, t, J = 7Hz), 3.88 (2H, t, J = 7Hz), 7.44 (2H, d, J = 8.5Hz), 7.75 - 7.89 (6H, m), 9.94 (1H, s).

30 MS: 280.1 (M+H)+

Step 2

{[2-(Acetylamino)-1,3-thiazol-4-yl]methyl}(triphenyl)phosphonium chloride (46.9 mg) and DMF (190 ml) were combined under N₂ atmosphere, and then potassium tert-butoxide (12.8 g) was added to the suspension at 0 °C.

5 The reaction mixture was stirred at 0 °C for 15 min, and 4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]benzaldehyde (19.28 g) was added to the mixture at 0 °C. The reaction mixture was stirred at 20 °C for 2 hr. The reaction mixture was poured into water, and the resulting precipitate was

10 collected by filtration to give a crude brown solid. The brown solid was washed with CHCN:IPE=1:1, then CHCN to give N-[4-((E)-2-{4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}vinyl)-1,3-thiazol-2-yl]acetamide (24.88 g) as a beige solid.

15 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.15 (3H, s), 2.94 (2H, t, J = 7.1Hz), 3.83 (2H, t, J = 7.1Hz), 7.12 (1H, d, J = 15.8Hz), 7.14 (1H, d, J = 15.8Hz), 7.16 (1H, s), 7.19 (2H, d, J = 8Hz), 7.44 (2H, d, J = 8.4Hz), 7.8 - 7.88 (4H, m), 12.22 (1H, s).

MS: 418.1 (M+H)+

20 Step 3

N-[4-((E)-2-{4-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}vinyl)-1,3-thiazol-2-yl]acetamide (24.88 g), DMF (800 ml), MeOH (80 ml), AcOH (8 ml) and then 10 % Pd/C (50 % wet) (24.4 g) were combined under N₂ atmosphere. The

25 mixture was stirred at 20 °C for 16 hr under H₂ atmosphere (4 atm). The catalyst was renewed every 4 hr in a period of reaction time. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated *in vacuo*. The residue was washed with IPE (200 ml) and purified by flash

30 column chromatography over silica gel with CHCl₃ / AcOEt

(1:1) as an eluent. The fractions containing the object compound were combined, and evaporated under reduced pressure. The residue was washed with IPE (200 ml) and collected by filtration to give N-[4-(2-{4-[2-(1,3-dioxo-
5 1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide (17.86 g) as an off-white solid.
¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.78 - 2.92 (6H, m), 3.79 (2H, t, J = 7.3Hz), 6.66 (1H, s), 7.08 (2H, d, J = 8.9Hz), 7.1 (2H, d, J = 8.8Hz), 7.79 - 7.89 (4H, m),
10 12.08 (1H, s).
MS: 420.2 (M+H)+, 442.1 (M+Na)+

Step 4

To a solution of N-[4-(2-{4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}ethyl)-1,3-thiazol-2-
15 yl]acetamide (2.06 g) in acetonitrile (20 ml) was added hydrazine monohydrate (2.38 ml), and the mixture was stirred at 50 °C for 2 hr. Volatiles were evaporated. To the mixture was added chloroform (10 ml), and the insoluble material was removed by filtration to give crude pale yellow
20 foam (1.49 g, 104.8 %). The crude oil was purified by flash column chromatography over NH₂-silica gel with CHCl₃ / MeOH (10:0-10:2) as an eluent to give N-(4-{2-[4-(2-aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (1.1304 g) as a pale yellow solid.
25 ¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.58 (2H, t, J = 7.3Hz), 2.72 (2H, t, J = 7.1Hz), 2.81 - 2.94 (4H, m), 6.73 (1H, s), 7.08 (2H, d, J = 8.4Hz), 7.11 (2H, d, J = 8.4Hz).
MS: 290.2 (M+H)+

Step 5

N-(4-{2-[4-(2-Aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (150 mg), ethyl 2-(methylthio)-4,5-dihydro-1H-imidazole-1-carboxylate (117.1 mg), AcOH (0.6 ml) and EtOH (3 ml) were combined under N₂ atmosphere, and the mixture was
5 refluxed for 24 hr. After cooled to 20 °C, the reaction mixture was diluted with AcOEt. The solution was made basic by aq. sat. NaHCO₃ solution. The resulting precepitate was collected by filtration to give N-[4-(2-{4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide (111 mg) as a white solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.76 (2H, t, J = 7.5Hz), 2.81 - 2.94 (4H, m), 3.37 (2H, t, J = 7.1Hz), 3.12 - 3.82 (4H, m), 6.71 (1H, s), 7.12 (2H, d, J = 8.4Hz), 7.15 (2H, d, J = 8.4Hz), 9.84 (1H, brs).

15 MS: 358.3 (M+H)+

Production Example 28: Synthesis of N-[4-(2-{4-[2-(ethanimidoethylamino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide

N-(4-{2-[4-(2-Aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (100 mg), methyl ethanimidothioate hydroiodide (150.0 mg) and MeOH (2 ml) were combined, and the mixture was
20 stirred for 3 hr at 20 °C. Volatiles were evaporated in vacuo. The residue was purified by flash column chromatography over NH-silica gel with CHCl₃ / MeOH (5:0-5:1) as an eluent to give a white foam. The foam was triturated with IPE to give N-[4-(2-{4-[2-(ethanimidoethylamino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide (97.4 mg) as a white solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 1.83 (3H, s), 2.09 (3H, s),
30 2.72 (2H, t, J = 7.5Hz), 2.8 - 2.93 (4H, m), 3.18 (2H, t, J =

7.5Hz), 6.69 (1H, s), 7.11 (2H, d, J = 8.4Hz), 7.13 (2H, d, J = 8.4Hz).

MS: 331.3 (M+H)+

Production Example 29: Synthesis of N-[4-(2-{4-[2-(4,5-dihydro-1,3-thiazol-2-ylamino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide

N-(4-{2-[4-(2-Aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (100 mg), 2-(methylthio)-4,5-dihydro-1,3-thiazole (92.1 mg), conc. HCl (0.04 ml) and 2-methoxyethanol (1.5 ml) were combined under N₂ atmosphere, and the mixture was stirred at 120 °C for 24 hr. After cooled to 20 °C, the reaction mixture was dissolved in water (0.5 ml), and the solution was adjusted to pH=10 by aq. K₂CO₃, and resulting precipitate was collected by filtration to give N-[4-(2-{4-[2-(4,5-dihydro-1,3-thiazol-2-ylamino)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide (111.47 mg) as a beige solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.73 (2H, t, J = 7.5Hz), 2.82 - 2.93 (4H, m), 3.21 (2H, t, J = 7.1Hz), 3.31 (2H, t, J = 7.5Hz), 3.82 (2H, t, J = 7.3Hz), 6.73 (1H, s), 7.09 (2H, d, J = 8.8Hz), 7.12 (2H, d, J = 8.8Hz).

MS: 375.2 (M+H)+

Production Example 30: Synthesis of N-(4-{2-[4-(2-{[imino(methylamino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide

Step 1

N-(4-{2-[4-(2-Aminoethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (200 mg) was dissolved in acetone (2.8 ml) under N₂ atmosphere, and then isothiocyanic acid benzoyl ester (93.2 μl) was added dropwise to the solution at 0 °C. The reaction mixture was stirred at 20 °C for 1 hr. Water was added to the mixture, and the precipitate was filtered *in vacuo* to give a crude yellow solid (237.9 mg, 76 %). The

WO 2006/011631

PCT/JP2005/014136

crude solid was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (100:0-100:2) as an eluent to give N-([2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)ethyl]amino)carbonothioyl)benzamide (152.8 mg) as a pale yellow solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.81 - 2.96 (6H, m), 3.82 (2H, q, J = 6.7Hz), 6.72 (1H, s), 7.15 (2H, d, J = 8Hz), 7.19 (2H, d, J = 8Hz), 7.51 (2H, t, J = 7.7Hz), 7.63 (1H, t, J = 7.5Hz), 7.91 (2H, d, J = 7.7Hz), 10.93 (1H, t, J = 5.3Hz), 11.34 (1H, s), 12.09 (1H, s).

MS: 453.3 (M+H)⁺, 475.1 (M+Na)⁺

Step 2

To a suspension of N-([2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)ethyl]amino)carbonothioyl)benzamide (140 mg) in EtOH (1.5 ml) was added dropwise aq. 6N NaOH (154.7 μl) at 0 °C. The reaction mixture was stirred for 2 hr at 20 °C, and neutralized with 1N-HCl at 0 °C. The precipitate was collected by filtration to give N-{4-[2-(4-{2-[(aminocarbonothioyl)amino]ethyl}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide (98.6 mg) as a pale yellow solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.11 (3H, s), 2.68 - 2.79 (2H, m), 2.82 - 2.95 (4H, m), 3.12 - 3.65 (2H, m), 6.74 (1H, s), 6.96 (2H, brs), 7.14 (4H, s), 7.46 - 7.71 (1H, m), 12.08 (1H, s).

MS: 349.1 (M+H)⁺, 371.2 (M+Na)⁺

Step 3

To a solution of N-{4-[2-(4-{2-[(aminocarbonothioyl)amino]ethyl}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide (50 mg) in MeOH (0.5 ml) was added iodomethane (10.72 μl), and the mixture was refluxed for 5 hr. Volatiles were evaporated and the residue was solidified with AcOEt. The resulting precipitate was collected by

filtration to give methyl N-[2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)ethyl]imidothiocarbamate hydroiodide (71.2 mg) as a colorless oil.

MS: 363.27 (M+H)⁺ Free

⁵ Step 4

Methyl N-[2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)ethyl]imidothiocarbamate hydroiodide (71.2 mg) and 2M methylamine solution in THF (726 μ l) were combined at 0 °C under N₂ atmosphere. The reaction mixture
¹⁰ was stirred for 24 hr at 20 °C. Volatiles were evaporated. The residue was dissolved in water and MeOH, and the solution was adjusted to pH=8 with aq. saturated NaHCO₃. MeOH was evaporated, and then water and AcOEt were added. The resulting precipitate was collected by filtration to
¹⁵ give N-(4-{2-[4-(2-{[imino(methylamino)methyl]amino}ethyl)-phenyl]ethyl}-1,3-thiazol-2-yl)acetamide (42.8 mg) as a white solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.02 (3H, s), 2.64 - 2.79 (5H, m), 2.79 - 2.92 (4H, m), 3.32 (2H, t, J = 7.7Hz), 6.53
²⁰ (1H, s), 7.13 (4H, s), 8.86 (3H, bs).

MS: 346.3 (M+H)⁺

Production Example 31: Synthesis of 2-[4-(2-{2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]-N-[amino(imino)methyl]acetamide

²⁵ Step 1

To the solution of [4-(carboxymethyl)benzyl](triphenyl)phosphonium bromide (1.76 g) in DMF (30 ml) was added potassium tert-butoxide (1.10 g) at 0 °C, and the mixture was stirred for 30 min at same temperature. To the solution was
³⁰ added N-{4-formyl-5-[4-(methylthio)benzyl]-1,3-thiazol-2-yl}acetamide (1.00 g) (prepared in Step 6 of Production

Example 11), and the mixture was stirred for 3hr at 20 °C. The reaction mixture was poured in ice-0.1N-HCl, and the resulting precipitate was collected by filtration. The obtained powder was dissolved with 1N-NaOH (40 ml) and washed with AcOEt. The aqueous layer was adjusted to pH=3 with conc. hydrochloric acid, and the resulting precipitate was collected by filtration to give a mixture of [4-((E)-2-{2-(acetylamino)-5-[4-(methylthio)benzyl]-1,3-thiazol-4-yl}vinyl)phenyl]acetic acid and [4-((Z)-2-{2-(acetylamino)-5-[4-(methylthio)benzyl]-1,3-thiazol-4-yl}vinyl)phenyl]acetic acid (E:Z=1:2) (1.18 g) as yellow powder.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.07 (3Hx2/3, s), 2.11 (3Hx1/3, s), 2.43 (3Hx2/3, s), 2.43 (3Hx1/3, s), 3.54 (2Hx2/3, s), 3.58 (2Hx1/3, s), 3.89 (2Hx2/3, s), 4.23 (2Hx1/3, s), 6.53 (1Hx2/3, d, J = 12.4Hz), 6.63 (1Hx2/3, d, J = 12.4Hz), 7.08 (2Hx2/3, d, J = 8.4Hz), 7.16 (2Hx2/3, d, J = 8Hz), 7.17 (2Hx2/3, d, J = 8.4Hz), 7.22 (4Hx1/3, s), 7.23 (1Hx1/3, d, J = 15.4Hz), 7.26 (2Hx1/3, d, J = 8.1Hz), 7.26 (2Hx2/3, d, J = 8.1Hz), 7.38 (1Hx1/3, d, J = 15.7Hz), 7.56 (2Hx1/3, d, J = 8Hz), 11.98 (1Hx2/3, s), 12.11 (1Hx1/3, s), 12.41 (1H, brs). MS: 439.0 (M+H)⁺, 461.0 (M+Na)⁺

Step 2

[4-((E)-2-{2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}vinyl)phenyl]acetic acid was prepared from the compounds of Step 1 of Production Example 31 in a manner similar to Step 11 of Production Example 1.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.08 (3Hx2/5, s), 2.12 (3Hx3/5, s), 3.18 (3H, s), 3.54 (2Hx2/5, s), 3.58 (2Hx3/5, s), 4.09 (2Hx2/5, s), 4.42 (2Hx3/5, s), 6.54 (1Hx2/5, d, J = 12.4Hz), 6.64 (1Hx2/5, d, J = 12.4Hz), 7.15 (2Hx2/5, d, J = 8Hz), 7.25 (1Hx3/5, d, J = 14.3Hz), 7.26 (2Hx2/5+2Hx3/5, d, J

= 8Hz), 7.41 (2Hx2/5, d, J = 8.4Hz), 7.42 (1Hx3/5, d, J = 15.7Hz), 7.54 (2Hx3/5, d, J = 8.4Hz), 7.58 (2Hx3/5, d, J = 8Hz), 7.83 (2Hx2/5, d, J = 8.4Hz), 7.87 (2Hx3/5, d, J = 8Hz), 12.04 (1Hx2/5, s), 12.17 (1Hx3/5, s), 12.4 (1H, s).

5 MS: 471.1 (M+H)+, 493.0 (M+Na)+

Step 3

A mixture of [4-((E)-2-{2-(acetylamino)-5-[4-(methanesulfonyl)benzyl]-1,3-thiazol-4-yl}vinyl)phenyl]acetic acid and [4-((Z)-2-{2-(acetylamino)-5-[4-(methanesulfonyl)benzyl]-1,3-thiazol-4-yl}vinyl)phenyl]acetic
10 acid (1.010 g), MeOH (15 ml), THF (60 ml) and then 10 % Pd/C (50 % wet) (1.01 g) were combined under N₂ atmosphere. The mixture was stirred at 20 °C for 12 hr under H₂ atmosphere (4 atm). The reaction mixture was filtered through a celite pad,
15 and to the filtrate was added 10 % Pd/C (1.01 g) under N₂ atmosphere. The mixture was stirred at 20 °C for 12 hr under H₂ atmosphere (4 atm). The reaction mixture was filtered through a celite pad, and the filtrate was concentrated *in vacuo*. The residue was washed with Et₂O and collected by filtration to
20 give [4-(2-{2-(acetylamino)-5-[4-(methanesulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]acetic acid (532.8 mg) as an off-white solid.

¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.08 (3H, s), 2.85 (4H, s), 3.18 (3H, s), 3.52 (2H, s), 4.01 (2H, s), 7.08 (2H, d, J =
25 8Hz), 7.15 (2H, d, J = 8Hz), 7.32 (2H, d, J = 8.4Hz), 7.81 (2H, d, J = 8.4Hz), 12.06 (2H, brs).

MS: 473.2 (M+H)+, 495.1 (M+Na)+

Step 4











To a solution of [4-(2-{2-(acetylamino)-5-[4-(methanesulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]acetic
30 acid (100 mg) in DMF (1 ml) was added 1,1'-carbonyldiimidazole (37.7 mg). The mixture was stirred at 50 °C for 2 hr. To the

mixture was added a mixture of guanidine hydrochloride (101.1 mg) and 28% sodium methoxide solution in MeOH (0.216 ml) at 25 °C. The reaction mixture was stirred at 25 °C for 15 hr, and concentrated *in vacuo*. The residue was dissolved in water, and
5 the solution was adjusted to pH=8 with 1N-HCl, and extracted with AcOEt/MeOH. The organic layer was dried over MgSO₄ and evaporated. The residue was purified by flash column chromatography over silica gel with CHCl₃ / MeOH (20:0-20:1) as an eluent, and triturated with diethyl ether to give 2-[4-(2-
10 {2-(acetylamino)-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-4-yl}ethyl)phenyl]-N-[amino(imino)methyl]acetamide (49.2 mg) as a pale yellow solid.











¹H-NMR (400MHz, DMSO-d₆) δ (ppm): 2.07 (3H, s), 2.83 (4H, s), 3.18 (3H, s), 3.36 (2H, s), 4 (2H, s), 6.57 (2H, brs), 7.03
15 (2H, d, J = 8Hz), 7.12 (2H, d, J = 8Hz), 7.3 (2H, d, J = 8Hz), 7.81 (2H, d, J = 8Hz), 7.82 (2H, brs), 12.03 (1H, brs).

MS: 514.2 (M+H)+

The compounds according to the present invention useful
20 as VAP-1 inhibitors are listed in the following tables.

No.	Structure	No.	Structure
1		6	
2		7	
3		8	
4		9	
5		10	

No.	Structure	No.	Structure
11	Chemical structure 11: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl	16	Chemical structure 16: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl
12	Chemical structure 12: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl HCl	17	Chemical structure 17: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl
13	Chemical structure 13: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl HCl	18	Chemical structure 18: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl
14	Chemical structure 14: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl HCl	19	Chemical structure 19: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl
15	Chemical structure 15: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl HCl	20	Chemical structure 20: A thiazine derivative. It features a 4-methylsulfonylphenyl group attached to a thiazine ring. The thiazine ring also has a hydrazide group (-NH-C(=O)-NH-NH₂) and a benzyl group (-CH₂-C₆H₄-NH-C(=O)-NH-NH₂). HCl

No.	Structure	No.	Structure
21		26	
22	 HCl	27	
23	 HCl	28	
24		29	
25		30	

No.	Structure
31	

Example 1

Inhibitory effect of the present compound on VAP-1 enzyme
 5 (SSAO) activity in human.

VAP-1 enzyme (SSAO) activity in human plasma was determined by a radiochemical-enzyme assay using ^{14}C -benzylamine as an artificial substrate. The enzyme suspension prepared from blood plasma was pre-incubated with a control
 10 compound (Reference Example 1) in 96-well microplate at room temperature for 30 min. The enzyme suspension was then incubated with ^{14}C -benzylamine (2×10^{-5} mol/l final concentration) in a final volume of 50 μl at 37°C for 1 hour. The enzyme reaction was terminated by adding 2 mol/l (50 μl)
 15 citric acid. The oxidized products were directly extracted into a 200 μl toluene scintillator, and its radioactivity was measured by a scintillation spectrometer. Inhibition activity was expressed as IC_{50} ($\mu\text{mol/l}$) value.

Test compounds (i.e., the present compounds) inhibited
 20 the enzyme activity of human plasma SSAO in comparison with the control compound as shown in Table 1.

Table 1. Inhibitory effect (IC₅₀ values, μ M) of test compounds

Compounds	Human plasma SSAO
Reference Example 1 (control)	0.033
Production Example 1	0.016
Production Example 3	0.0045
Production Example 7	0.015
Production Example 9	0.0026
Production Example 12	0.019
Production Example 14	0.014
Production Example 16	0.012
Production Example 19	0.032
Production Example 25	0.0057

5

INDUSTRIAL APPLICABILITY


The present invention provides a compound of the formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof useful as a VAP-1 inhibitor, a pharmaceutical composition, a method for preventing or
10 treating a VAP-1 associated disease, especially macular edema such as diabetic macular edema and non-diabetic macular edema, which method comprises administering to a patient in need thereof a VAP-1 inhibitor in an amount sufficient to treat the patient suffering from the VAP-1
15 associated disease, and the like.

This application is based on a provisional patent application No. 2004904196 filed in Australia, the contents of which are all hereby incorporated by reference.

20

CLAIMS

1. A compound of the formula (I), (II), (III) or (IV):



5 wherein

R^1 is alkylcarbonyl;

X_1 is a bond or lower alkylene;

Y_1 is a bond, lower alkylene, $-\text{CH}_2-\text{CO}-$, $-\text{CH}_2-\text{CH}_2-\text{CO}-$,
 $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{CH}_2-$ or $-\text{NH}-\text{CH}_2-\text{CH}_2-$; and

10 Z_1 is $-\text{NH}_2$, $-\text{NH}(\text{lower alkyl})$ or lower alkyl;


provided that

when X_1 is ethylene, then Y_1 should be C_2-C_6 alkylene,
 $-\text{CH}_2-\text{CO}-$, $-\text{CH}_2-\text{CH}_2-\text{CO}-$, $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{CH}_2-$ or $-\text{NH}-\text{CH}_2-\text{CH}_2-$,

when X_1 is a bond, then Y_1 should be a bond, methylene,
 15 C_3-C_6 alkylene, $-\text{CH}_2-\text{CO}-$, $-\text{CH}_2-\text{CH}_2-\text{CO}-$, $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{CH}_2-$ or
 $-\text{NH}-\text{CH}_2-\text{CH}_2-$, and


when R^1 is acetyl, X_1 is ethylene, Y_1 is ethylene and Z_1 is
 $-\text{NH}_2$, then Y_1 should be attached to *ortho* or *meta* position of
 the phenyl group;

20




wherein


R^1 is alkylcarbonyl;



25 wherein R^a is (lower alkyl)sulfonyl, aminosulfonyl or
 di(lower alkyl)aminosulfonyl,



wherein R^b is mono- or di-(lower alkyl)amino,



wherein R^c is lower alkyl and R^d is (lower alkyl)sulfonyl,
 5 di(lower alkyl)aminocarbonyl, alkylcarbonyl or nitro, or
 -CH=CH-CO-di(lower alkyl)amino;

X_2 is a bond or lower alkylene;


Y_2 is a bond, lower alkylene, -CH₂-CO- or -NH-CO-CH₂-; and

Z_2 is -NH₂;

10 provided that


when R^1 is acetyl, X_2 is ethylene, Y_2 is a bond and Z_2 is
 -NH₂, then R^2 should not be 3-(methanesulfonyl)benzyl,
 4-(methanesulfonyl)benzyl, 4-(ethanesulfonyl)benzyl and
 2-(dimethylaminocarbonyl)pyrrolidin-1-ylmethyl;

15




wherein

R^1 is alkylcarbonyl;



20 X_3 is lower alkylene; and

Y_3 is lower alkylene;



wherein

25 R^1 is alkylcarbonyl; and

X₄ is lower alkylene;
or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R¹ is acetyl, or a
5 pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein Z₁ is -NH₂, or a
pharmaceutically acceptable salt thereof.

10 4. The compound of claim 1, wherein the compound is
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-
(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-
thiazol-2-yl}acetamide,
15 2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-
[amino(imino)methyl]acetamide,
(3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-
pyrrolidinecarboxamide,
20 (3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-
pyrrolidinecarboxamide,
N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-
25 (methylsulfonyl)benzamide, or
N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-
nitrobenzamide,
or a pharmaceutically acceptable salt thereof.

30

5. The compound of claim 1 or a pharmaceutically acceptable
salt thereof for use as a medicament.

6. A pharmaceutical composition, which comprises, as an active ingredient, the compound of claim 1 or a pharmaceutically acceptable salt thereof.

5 7. A use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament as a VAP-1 inhibitor.

8. The use of claim 7, wherein the compound is

10 N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-thiazol-2-yl}acetamide,

2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-

15 [amino(imino)methyl]acetamide,

(3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide,

20 (3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-pyrrolidinecarboxamide,

N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-(methylsulfonyl)benzamide, or

25 N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-nitrobenzamide.

9. A use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament for the prophylaxis or treatment of a VAP-1 associated disease.

10. The use of claim 9, wherein said VAP-1 associated disease

is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uremia, 5 pain associated with gout and arthritis, retinopathy (in diabetes patients), an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjögren's syndrome, Behçet's syndrome, relapsing polychondritis, 10 systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, 15 mixed connective tissue disease, and juvenile rheumatoid arthritis), a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and 20 recurrent aphthous stomatitis], a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke), a pulmonary inflammatory disease or condition (asthma, adult respiratory distress 25 syndrome, and chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris), a disease related to carbohydrate metabolism (diabetes and 30 complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy),

foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity), a vascular disease [atheromatous atherosclerosis, 5 nonatheromatous atherosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, 10 diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM)) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)], macular edema (diabetic and non-diabetic 15 macular edema), hepatitis and transplantation.

11. The use of claim 10, wherein said VAP-1 associated disease is macular edema.

20 12. The use of claim 11, wherein said macular edema is diabetic macular edema.

13. The use of claim 11, wherein said macular edema is non-diabetic macular edema.

25

14. A VAP-1 inhibitor, which comprises the compound of claim 1 or a pharmaceutically acceptable salt thereof.

15. A method for preventing or treating macular edema, which 30 method comprises administering to a subject in need thereof a VAP-1 inhibitor in an amount sufficient to treat said subject for macular edema.

16. The method of claim 15, wherein the VAP-1 inhibitor is
 N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-
 (aminosulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,
 N-{4-[4-(4-{[amino(imino)methyl]amino}butyl)phenyl]-1,3-
 5 thiazol-2-yl}acetamide,
 2-(4-{2-[2-(acetylamino)-1,3-thiazol-4-yl]ethyl}phenyl)-N-
 [amino(imino)methyl]acetamide,
 (3R)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-
 10 pyrrolidinecarboxamide,
 (3S)-1-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N,N-dimethyl-3-
 pyrrolidinecarboxamide,
 N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 15 phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-
 (methylsulfonyl)benzamide, or
 N-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}-
 phenyl)ethyl]-1,3-thiazol-5-yl}methyl)-N-methyl-4-
 nitrobenzamide,
 20 or a pharmaceutically acceptable salt thereof.

17. A method for preventing or treating a VAP-1 associated
 disease, which method comprises administering an effective
 amount of the compound of claim 1 or a pharmaceutically
 25 acceptable salt thereof to a mammal.

18. The method of claim 17, wherein said VAP-1 associated
 disease is selected from the group consisting of cirrhosis,
 essential stabilized hypertension, diabetes, arthrosis,
 30 endothelium damage (in diabetes, atherosclerosis and
 hypertension), a cardiovascular disorder associated with
 diabetes and uremia, pain associated with gout and
 arthritis, retinopathy (in diabetes patients), an

(connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjögren's syndrome, Behçet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis), a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon), fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis), and recurrent aphthous stomatitis], a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischemia-reperfusion injury associated with ischemic stroke), a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, and chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allergic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, and pityriasis rubra pilaris), a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies, retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity), a vascular disease [atheromatous atherosclerosis,

nonatheromatous atherosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, and thromboangiitis obliterans (Buerger's disease)], chronic
5 arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM)) and vascular complication (heart attack, angina, strokes, amputations,
10 blindness and renal failure)], macular edema (diabetic and non-diabetic macular edema), hepatitis and transplantation.

19. The method of claim 18, wherein said VAP-1 associated disease is macular edema.

15

20. The method of claim 19, wherein said macular edema is diabetic macular edema.

21. The method of claim 19, wherein said macular edema is
20 non-diabetic macular edema.

